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SUMMARY 
Polyhydroxyalkanoates (PHA) constitute the carbon and energy storage material of 
certain bacterial species under excess of carbon and nutrient limitation conditions. These 
polymers are considered a good choice to replace oil-based plastics, especially for value 
added applications in the industrial and medical fields, since they are non-toxic, biocompatible 
and biodegradable materials. They play an important role in the development of novel 
generation biomaterials with exceptional appealing biomedical applications that include their 
use as surgical sutures, scaffolds or drug carriers. The capacity to incorporate novel 
functionalities into PHA confers tremendous versatility to these polymers. The complex 
structure of the PHA granule can be exploited as a toolbox to display molecules on their surface 
carrying out specific functions. In this sense, many granule-associated proteins (GAPs) have 
been employed as anchoring tags to obtain functionalized PHA beads for various applications 
such as high-affinity bioseparation, enzyme immobilization, diagnostics or cell targeting. In 
addition, the ability to edit and redirect the cell system through metabolic and genetic 
engineering tools enables the construction of platforms to produce a huge range of polymers 
varying their monomer contents and thus affecting thermal and mechanical properties of the 
material. This approach can be added to the possibility of incorporating functional groups on 
the lateral chains of the monomers to generate novel functionalities. The combination and 
optimization of the functionalization strategies from a multidisciplinary approach is the basis to 
expand the PHAs potentialities for target applications.  
This Thesis tries to explore and optimize the described tools for the functionalization of 
PHA materials following in vivo and in vitro techniques to further increase the applicability of 
these polymers. This has been achieved by following a multidisciplinary approach.  
The first two chapters explore the structural aspects of the binding of phasin PhaF from 
Pseudomonas putida KT2440 to different hydrophobic supports by applying various 
methodologies. Langmuir techniques have demonstrated the surfactant activity of phasin PhaF 
and its N-terminal domain, BioF, at different hydrophobic-hydrophilic interfaces. Furthermore, 
both proteins were able to interact with phospholipids suggesting a non-specific binding of the 
protein to hydrophobic supports. The results obtained increase the potential to apply phasins 
in combination with other hydrophobic materials. Moreover, the surface-active properties of 
these proteins make them interesting to be exploited as biosurfactants. Protein structural 
models provide a good way to predict the hydrophobicity and the hydrophobic moment of an 
amphipathic protein, which has enabled the design of various structures based on BioF that 
preserve their affinity for the PHA granule. This affinity was maintained in the absence of other 
GAPs on the surface of the granule. Based on one of these structures, a novel anchoring tag 
Summary 
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was designed. The tag developed showed comparable functionalization efficiency and stability 
on the surface of the PHA granule to the complete BioF. 
Nanotechnology has emerged as a promising research field especially for biomedical 
purposes. This Thesis explores the potential to apply PHA nanoparticles to transport drugs to 
the lungs. On the one hand, a study of the potential negative effects of naked PHA particles 
on the pulmonary surfactant biophysical properties was carried out. Pulmonary surfactant is 
one of the first barriers the nanoparticles will found in the alveoli. Various techniques, such as 
the Surfactant Adsorption Test (SAT) and the Langmuir plate, demonstrated negligible effects 
on the adsorption and spreading capacity of pulmonary surfactant in combination with 
nanoparticles. On the other hand, the possibility to incorporate pulmonary surfactant proteins 
on the surface of the PHA beads was explored. The hydrophobicity of these proteins would 
facilitate their immobilization on a hydrophobic support like PHAs. The production of PHA 
granules and recombinant forms of the pulmonary surfactant protein SP-B at the same time 
resulted in the functionalization of PHA nanoparticles for their potential use in lung therapy.  
In the last section, the structural versatility of PHAs has been studied to obtain novel 
properties and functionalities. Various mutants of the β-oxidation pathway were demonstrated 
to affect the monomer contents and thus the thermal properties of the polymer. The use of 
different fatty acids as substrates conducted to a plethora of polymers. An increase of 
functional groups such as double bonds was observed when feeding a slowdown β-oxidation 
mutant with unsaturated precursors. Double bonds allow to incorporate functional groups into 
the polymer. As a proof of concept, a fluorescent group was covalently attached to a polymer 
containing double bonds. Succesful fluorescent nanoparticles were obtained with this 
functionalized polymer, what may expand the applicability of this polymer. 
The multidisciplinary approach applied during this research has proven to be a good 
strategy to improve the exploitation of the protein network covering the PHA granule and the 
structural versatility of the PHA family. The results achieved open novel potential applications 
in various fields that would be interesting to explore in the future.  
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RESUMEN 
Los polihidroxialcanoatos (PHA) constituyen el material de almacenamiento de carbono 
y energía de ciertas especies bacterianas en condiciones de exceso de carbono y limitación 
de nutrientes. Estos polímeros se consideran una alternativa interesante para reemplazar los 
plásticos de origen petroquímico, especialmente para aplicaciones de valor añadido en los 
campos industrial y médico, ya que son materiales no tóxicos, biocompatibles y 
biodegradables. Desempeñan un papel importante en el desarrollo de biomateriales de nueva 
generación con aplicaciones biomédicas excepcionales que incluyen su uso como suturas 
quirúrgicas, andamios o transportadores de fármacos. La capacidad de incorporar nuevas 
funcionalidades a los PHA confiere una gran versatilidad a estos polímeros. La compleja 
estructura del gránulo de PHA se puede explotar como una caja de herramientas para exponer 
moléculas en su superficie que lleven a cabo funciones específicas. En este sentido, se han 
empleado numerosas proteínas asociadas a los gránulos (GAPs) como tags de afinidad para 
obtener partículas de PHA funcionalizadas con diversas aplicaciones, como bioseparación, 
inmovilización de enzimas, diagnóstico o transporte dirigido. Además, la capacidad de editar 
y redirigir el sistema celular a través de herramientas de ingeniería metabólica y genética 
permite la construcción de plataformas a partir de las cuales se pueden producir una amplia 
gama de polímeros que varían su contenido monomérico y, por lo tanto, sus propiedades 
térmicas y mecánicas. Este enfoque se puede añadir a la posibilidad de incorporar grupos 
funcionales en las cadenas laterales de los monómeros para generar nuevas funcionalidades. 
La combinación y optimización de las estrategias de funcionalización desde un enfoque 
multidisciplinar es la base para expandir las potencialidades de los PHA en aplicaciones 
específicas. 
La presente Tesis trata de explorar y optimizar las herramientas descritas para la 
funcionalización de materiales de PHA siguiendo técnicas in vivo e in vitro y mejorar la 
aplicabilidad de estos polímeros. Esto se ha logrado siguiendo un enfoque multidisciplinar. 
Los dos primeros capítulos exploran los aspectos estructurales de la unión de la fasina 
PhaF de Pseudomonas putida KT2440 a diferentes soportes hidrofóbicos aplicando varias 
metodologías. A través del uso de la balanza de Langmuir se ha demostrado la actividad 
surfactante de la fasina PhaF y su dominio N-terminal, BioF, en diferentes interfases 
hidrofóbicas-hidrofílicas. Además, se comprobó que ambas proteínas interaccionan con 
fosfolípidos, lo que sugiere una unión no específica de la proteína a soportes hidrófobos. Los 
resultados obtenidos incrementan el potencial para aplicar fasinas en combinación con otros 
materiales hidrofóbicos. Añadido a esto, las propiedades interfaciales de estas proteínas las 
hacen interesantes para su uso como biosurfactantes. Por otra parte, los modelos 
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estructurales de proteínas constituyen una buena herramienta para predecir la hidrofobicidad 
y el momento hidrofóbico de una proteína anfipática, lo que ha permitido el diseño de varias 
estructuras basadas en el módulo BioF que conservan su afinidad por el gránulo de PHA. Esta 
afinidad se mantuvo en ausencia de otras GAPs en la superficie del gránulo. Sobre la base 
de una de estas estructuras se diseñó un nuevo tag de afinidad. El tag desarrollado mostró 
ser eficaz para la funcionalización de gránulos de PHA, así como una gran estabilidad en la 
superficie de los mismos, de forma similar al BioF completo. 
La Nanotecnología se ha convertido en un campo de investigación prometedor, 
especialmente con fines biomédicos. Esta Tesis explora el potencial de aplicar nanopartículas 
de PHA para transportar fármacos a los pulmones. Por un lado, se llevó a cabo un estudio de 
los posibles efectos negativos de las partículas de PHA desnudas en las propiedades 
biofísicas del surfactante pulmonar, ya que este complejo de lípidos y proteínas es una de las 
primeras barreras que las nanopartículas encontrarán en los alvéolos. Varias técnicas, como 
la Prueba de Adsorción de Surfactante (SAT) y la balanza de Langmuir, demostraron efectos 
insignificantes en la capacidad de adsorción y propagación del surfactante pulmonar en 
combinación con nanopartículas. Por otro lado, se exploró la posibilidad de incorporar 
proteínas del surfactante pulmonar en la superficie de partículas o gránulos de PHA. La 
hidrofobicidad de estas proteínas facilitaría su inmovilización en un soporte hidrofóbico como 
el PHA. La producción de gránulos de PHA y de formas recombinantes de la proteína del 
surfactante pulmonar SP-B al mismo tiempo da como resultado la funcionalización de las 
nanopartículas de PHA para su uso potencial en terapia pulmonar. 
En la última sección de la Tesis, se ha estudiado la versatilidad estructural de los PHA 
para obtener nuevas propiedades y funcionalidades. Se demostró que varios mutantes en la 
β-oxidación afectan el contenido de monómeros y, por lo tanto, las propiedades térmicas del 
polímero. El uso de diferentes ácidos grasos como sustratos condujo a una gran cantidad de 
polímeros. Se observó un aumento de los grupos funcionales, como los dobles enlaces, 
cuando se alimenta un mutante de β-oxidación con un precursor insaturado. Los dobles 
enlaces permiten incorporar grupos funcionales en el polímero. Como prueba de concepto, se 
unió covalentemente un grupo fluorescente a un polímero con dobles enlaces. Se obtuvieron 
así con éxito nanopartículas fluorescentes de este polímero funcionalizado, lo que puede 
ampliar la aplicabilidad del mismo. 
El enfoque multidisciplinar aplicado durante esta Tesis ha demostrado ser una buena 
estrategia para mejorar la utilización de la red de proteínas que cubre el gránulo de PHA y la 
versatilidad estructural de la familia de PHA. Los resultados obtenidos aquí abren nuevas 
aplicaciones potenciales en varios campos que será interesante explorar en el futuro. 
Introduction 
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1. Bioplastics as alternative materials in a circular economy 
The use of petroleum-derived plastics is widely extended in our societies for many 
applications, ranging from the industrial to the medical fields. Their structure can be chemically 
manipulated to obtain a wide variety of strengths and shapes. They have versatile 
characteristics concerning resistance, elasticity and durability that make them suitable 
materials for many applications such as packaging, furniture, films, fibers and many others. 
The plastic consumption worldwide is calculated in about 335 million tonnes per year (Plastics 
Europe, 2018). 
Unfortunately, large-scale consumption of petroleum-based plastics has contributed to a 
dramatic environmental challenge. The production of plastics derived from petroleum has a 
direct impact on atmospheric greenhouse gas emissions and, therefore, on global warming 
and climate change. In addition, they constitute a serious pollution problem associated to their 
non-biodegradable durability. Around 5-13 million tonnes of plastic per year reach the marine 
environment (Geyer et al., 2017) Their massive accumulation in landfills and oceans results in 
thousands of animal deaths per year. The Intergovernmental Panel on Climate Change 
trajectory to 2050 requires for stabilization of atmospheric greenhouse gas (GHG) 
concentrations at 450 ppm CO2 what implies a reduction of 80 % of the emissions compared 
to the 1990 level (Prieto, 2016). In this context, bio-based plastics have emerged as an 
alternative to reduce our dependence of plastic from petroleum origin and to contribute to 
sustainability in a circular economy. Among them, two main groups of bioplastics can be 
distinguished. On the one hand, bioplastics based on renewable sources including some 
biodegradable polymers like polyhydroxyalkanoates (PHA) or polylactic acid (PLA). On the 
other hand, the drop-in bio-based polymers that share identical chemical properties with their 
petrochemical counterparts but containing a component of biological origin such as 
polyethylene terephthalate (PET) or polyethylene (PE). These polymers are non-
biodegradable, but they can be obtained from renewable materials. The demand of bio-based 
polymers will grow from 1.7 million tonnes in 2014 to 7.8 million tonnes in 2019, especially the 
drop-in bio-based polymers like PET and PE. The market of PHA shows the second fastest 
growth rate and is projected to reach around100,000 tonnes by 2020 (Prieto, 2016). 
 
2. Polyhydroxyalkanoates: an overview 
PHA are biopolymers synthetized by certain microorganisms as energy storage in carbon 
excess and nutrient limitation conditions (Figure 1) (Kniewel et al., 2017). They are 
accumulated as possibly phospholipid-coated inclusions surrounded by a layer of proteins 
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involved in PHA metabolism (Jendrossek and Pfeiffer, 2014). The accumulation of PHA is a 
complex process that involves several central metabolic pathways and is extensively regulated 
at the enzymatic, transcriptional and translational levels. Since the discovery of the poly(3-
hydroxybutyrate) (P(3HB)) in Bacillus megaterium by Lemoigne in 1926  (Lemoigne, 1926), a 
wide range of different PHA and producer microorganisms have been described (Koller et al., 
2017).  
 
Figure 1. Transmission electron microscopy (TEM) image of Pseudomonas putida KT2440 
growing under PHA producing conditions. PHA granules are accumulated inside the cytoplasm as 
energy storage hydrophobic inclusions under carbon excess and nutrient limitation conditions.  
PHA production is widespread in nature. Among bacteria, more than 90 of Gram-positive 
and Gram-negative genera that produce PHA under both aerobic and anaerobic conditions 
have been described (Kniewel et al., 2017). PHA producers colonize a huge range of habitats 
such as marine microbial mats, rhizosphere or anthropogenic generated ecosystems like 
wastewater treatment plants (Koller et al., 2017). This wide distribution in such diverse 
environments suggests some advantages for the producer microorganisms (Obruca et al., 
2018). In addition to the classical function associated to the storage of carbon and energy, 
PHA have also been demonstrated to play other physiological roles that enhance the 
resistance to stress and fitness of microorganisms under adverse conditions such as UV 
radiation, high temperature, osmotic shock or exposure to solvents and other chemical 
compounds (Kadouri et al., 2005). They have been related to the interaction established 
among microorganisms during biofilm formation (Pham et al., 2004; Campisano et al., 2008) 
and in plant-microorganism symbiotic relationships (Encarnación et al., 2002; Lodwig et al., 
2005). Additionally, PHA have been proven to play an essential role in controlling the carbon 
and energy spillage in some bacterial species (Escapa et al., 2012). 
2.1. PHA structure and properties 
PHA consist of thermoplastic linear polyesters of several (R)-3-hydroxyacid ((R)-HA) 
monomer units connected by an ester bond. Despite the most usual substituent groups found 
in PHA monomers are aliphatic chains, an enormous variability can be achieved by controlling 
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the metabolism involved in PHA accumulation (Figure 2). Around 150 different monomer 
constituents have been described including unsaturated, aliphatic and aromatic groups among 
others in the lateral chain (Zinn et al., 2001). PHA are usually classified according to their 
monomer size as short-chain-length PHA (scl-PHA), consisting of 3-5 carbon monomers and 
medium-chain-length PHA (mcl-PHA), which contain 6-14 carbon monomers. Differences are 
mainly due to enzyme specificity of the PHA synthase, the key enzyme involved in PHA 
biosynthesis, which can accept precursors of certain carbon-length, as well as the substrate 
employed and the metabolic and regulatory networks in each species (Prieto et al., 2016). PHA 
may be composed by only one type of monomer (homopolymers) or by various types of 
monomers, called copolymers or heteropolymers (Olivera et al., 2010). Depending on the 
monomer composition and the length of the side chain, different PHA hydrophobicity, melting 
point, glass transition temperature and degree of crystallinity properties are obtained, with a 
wide diversity of mechanical properties varying from rigid and crystalline to flexible, amorphous 
or elastic. Scl-PHA tend to be stiff and brittle with a high degree of crystallinity (60-80 %), while 
mcl-PHA are elastic with low crystallinity (25 %), low tensile strength, high elongation to break, 
low melting point and glass transition temperature below room temperature (Anjum et al., 
2016). Nevertheless, controllable thermal and mechanical properties may be achieved by 
modifying the structure and monomer composition of the final polymer through different 
strategies that will be deeply discussed in Section 6 of the Introduction. 
 
Figure 2. PHA monomer chemical structure and potential functional groups of the lateral chain. 
Classification is usually based on the length of the side chain and has been divided into short-length 
PHA (scl-PHA) and medium-length PHA (mcl-PHA) depending on the number of carbons. An enormous 
variability of the monomer lateral chain can be incorporated by applying metabolic and genetic 
engineering strategies.  
 
2.2. PHA applications and functionalization  
From an industrial point of view, PHA show unique combination of biodegradability, 
biocompatibility and non-toxicity properties that make them excellent candidates to be used as 
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environmentally friendly plastics for packaging purposes and therapeutic applications (Table 
1) (Zhang et al., 2018). Many companies commercialize scl-PHA under different names like 
TephaFLEX®, Biocycle® or Mirel®. Most of them are produced and commercialized as raw 
materials in the form of pellets, resins and powders that can be moulded by injection, extrusion 
or blowing. However, some companies offer final products for direct uses such as packaging, 
bags, bottles, surgical films and sutures among others (Dietrich et al., 2017). The most widely 
employed strain for the production of scl-PHA is Cupriavidus necator due to high cell density 
fermentation (100-200 g/l) and PHA content (75-80 %), simple growth and well-known 
metabolism (Możejko-Ciesielska and Kiewisz, 2016). The commercial production of mcl-PHA 
constitutes a promising market since these polymers are more elastic, hydrophobic and 
amorphous than scl-PHA, what favours their processing and use in flexible packaging 
applications such as food coatings and adhesives. NodaxTM and AirCarbonTM constitute 
examples of mcl-PHA commercialized as raw materials. Pseudomonas species are commonly 
used for production of mcl-PHA. A bacterial model like P. putida KT2440 has emerged as an 
outstanding candidate for the development of improved PHA producing phenotypes since it is 
a non-pathogen considered Generally Recognized As Safe (GRAS) with broad metabolic 
versatility, resistance to stress and genetic plasticity (Prieto et al., 2016). Moreover, several 
recombinant Escherichia coli strains with the ability to produce efficiently both scl-PHA and 
mcl-PHA have been designed (Chen et al., 2016). Despite the actual limited market of PHA, 
its demand is expected to grow by 2020 due to the environmental oil-based plastics associated 
problems (Możejko-Ciesielska and Kiewisz, 2016). 
In addition, PHA have gained much attention due to the huge structural versatility that 
can be obtained by bacterial fermentation and post biosynthetic modifications (Tortajada et al., 
2013; Prieto et al., 2016). The availability of broad metabolic engineering and synthetic biology 
tools as well as the use of a variety of carbon sources make feasible to produce PHA with 
unique properties and functionalities in a cost-effective way. Different strategies can be 
exploited to create a plethora of PHA that may expand their applicability. One approach takes 
advantage of the complex architecture of PHA bacterial inclusions. These structures are 
coated by a layer of proteins that can be exploited as a toolbox to display fusion peptides with 
specific functions on their surface (Dinjaski and Prieto, 2015). Other approach consists on the 
use of metabolic engineering strategies to control the structure and final properties of PHA. 
For instance, functionalized groups can be incorporated into the polymer leading to the 
potential of incorporating chemical modifications that multiply the possibilities of these 
polymers (Tortajada et al., 2013). In this research, both strategies have been followed to 
expand the structural diversity and functionalization of PHA and thus their possible 
applications. 
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Table 1. Examples of therapeutic applications of PHA. 
Application  Polymer References 
Bone implants P(3HB) (Shishatskaya et al., 
2014; Meischel et al., 
2016) 
 P(3HB-co-3HHx) (Zhou et al., 2010) 
Bone scaffolds P(3HB-co-3HHx) (Wang et al., 2004; 
Yang et al., 2004; 
Berger et al., 2015) 
 P(3HB)/poly(ε-
caprolactone) (PCL)/58S 
bioactive glass 
(Ding et al., 2016) 
 P(3HB) (Rentsch et al., 2010) 
 nano-HAp/P(3HB) fibers 
and protein hydrogels 
(Sadat-Shojai et al., 
2016) 
 P(3HB)/gelatin (GEL) 
P(3HB)/GEL/nHAs 
(Ramier et al., 2014) 
 P(3HB-co-3HV) (Ribeiro-Samy et al., 
2013) 
Tendon, bone, cartilage 
scaffolds 
P(3HB-co-3HHx)/collagen (Lomas et al., 2013) 
Cartilage scaffolds P(3HB-co-3HHx) (Wang et al., 2008) 
Tendon scaffolds P(3HB-co-3HHx) (Webb et al., 2013) 
Artificial blood vessels P(3HB-co-4HB) (Cheng et al., 2008) 
Heart valves P(3HO-co-3HHx) (Sodian et al., 2000) 
 P(3HB-co-3HHx) (Qu et al., 2005) 
Myocardial patch P(3HB-co-3HV) (Kenar et al., 2010) 
Nerve conduits P(3HB) (Young et al., 2002; 
Novikova et al., 2008; 
Xu et al., 2010) 
 P(3HB-co-3HHx) (Bian et al., 2009; Xu et 
al., 2010) 
 P(3HB-co-4HB) (Xu et al., 2010) 
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Application  Polymer References 
Subcutaneous patches Unsaturated mcl-PHA (Hazer et al., 2009; 
Hazer and Hazer, 2011) 
Surgical sutures P(3HB-co-3HHx)/ P(3HB-
co-3HV) 
(He et al., 2014) 
 P(3HB)/ P(3HB-co-3HV) (Volova et al., 2003; 
Shishatskaya et al., 
2004) 
Antimicrobials PHACOS (Dinjaski et al., 2014) 
Drug delivery P(3HB) (Kassab et al., 1997; 
Yao et al., 2008; Xiong 
et al., 2010; Lee et al., 
2011; Murueva et al., 
2014) 
 P(3HB-co-3HHx) (Bayram et al., 2008; 
Xiong et al., 2010; 
Kılıçay et al., 2011; Lu 
et al., 2011; Peng et al., 
2012; Zhang et al., 
2012; Heathman et al., 
2014; Wu et al., 2014) 
 PEGylated-P(3HB) (Chaturvedi et al., 2015) 
 P(4HB)-mPEG (Shah et al., 2014) 
 mP(3HB-co-4HB)-g-bPEI (Zhou et al., 2012) 
Drug candidates 
(therapeutic agents 
against Alzheimer, 
Parkinson, osteoporosis, 
adjuvant cancer) 
PHA monomers (O’Connor et al., 2013; 
Zhang et al., 2013; Cao 
et al., 2014) 
See the Abbreviation section for full names. Blending is represented as a division sign. 
 
3. PHA granule structure 
Prokaryotic microorganisms store PHA as intracellular spherical inclusions that 
traditionally have been proposed to be coated by a layer of proteins and phospholipids (Figure 
3) (Jendrossek and Pfeiffer, 2014). However, the presence of phospholipids is still under 
discussion (Pötter and Steinbüchel, 2006; Jendrossek and Pfeiffer, 2014). Previous results 
suggested the presence of a layer of phospholipids on PHA granules based on the detection 
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of these molecules in isolated granules (Griebel et al., 1968; Steinbuchel et al., 1995) and 
electron microscopy images (Horowitz and Sanders, 1994; Mayer and Hoppert, 1997). The 
thickness of that supposed layer was determined and fits with the value expected for a 
phospholipid monolayer (~4 nm) with proteins embedded. Conversely, recent results suggest 
the absence of these molecules on the surface of PHA granules based on electron 
cryotomography (Beeby et al., 2012) and localization of fluorescent proteins fusioned to a 
phospholipid binding domain (Bresan et al., 2016). In such case, the authors suggested that 
the detection of phospholipids may be an isolation artefact.  
 
 
Figure 3. PHA production and granule structure. A) TEM image of P. putida KT2440 growing under 
PHA producing conditions. Granules are accumulated as spherical hydrophobic inclusions inside the 
cell. B) Schematic representation of a PHA granule from P. putida KT2440. The PHA granule is 
surrounded by a layer of granule associated proteins (GAPs). Among them, PHA synthase, PHA 
depolymerase, phasins PhaF and PhaI, and the ACS1 synthetase can be found. The presence of 
phospholipids is still uncertain. 
 
On the contrary, the presence of proteins on the surface of PHA granules is widely 
accepted. The so-called granule associated proteins (GAPs) play structural, biosynthetic, 
catabolic and regulatory functions which has led to consider PHA granules as complex 
subcellular structures designated carbonosomes (Jendrossek, 2009). These include PHA 
synthases, depolymerases and a group of low weight molecular proteins called phasins. Other 
proteins such as regulators, hydrolases or reductases can also be found on the surface of the 
granule (Jendrossek and Pfeiffer, 2014).  
1 µm
Phospholipids
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Acyl-CoA synthetase
Phasin PhaF
Phasin PhaI
PHA depolymerase
Other proteins
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3.1. PHA synthases and depolymerases 
PHA synthase (PhaC) is the key enzyme of PHA synthesis since it catalyses the 
conversion of 3-hydroxyacyl-CoA substrates into PHA and is covalently attached to the PHA 
chain in formation (Zou et al., 2017). PHA synthases are divided into four classes based on 
their primary sequence, subunit composition and substrate specificity (Rehm, 2003). Class I 
synthase consists of a single subunit (PhaC) that forms a homodimer with specificity for short-
chain length monomers (C3-C5). Similar to class I PHA synthases, class II contains one 
subunit, PhaC1 or PhaC2, which favours the incorporation of medium-chain-length monomers 
(C6-C12). The others, class III and class IV, form heterodimers that require two subunits for 
full activity. Both classes of PHA synthases show affinity for scl-PHA (Chek et al., 2017; Zou 
et al., 2017).  
PHA depolymerases are the enzymes that catalyse the depolymerization of PHA during 
starvation. They are classified as intracellular and extracellular depolymerases depending on 
their localization on the surface of PHA granules or outside the cell, respectively (Knoll et al., 
2009).  
3.2. Phasins 
Phasins are the most abundant group of proteins that coat PHA hydrophobic inclusions 
(Mezzina and Pettinari, 2016). These multifaceted proteins have been proven to play an 
important role in PHA biosynthesis and PHA granule biogenesis (Pötter and Steinbüchel, 2005; 
Dinjaski and Prieto, 2013), participating in the PHA regulatory machinery (Wieczorek et al., 
1995; Handrick et al., 2004; Hauf et al., 2015), influencing PHA granules localization and 
segregation (Galán et al., 2011; Bresan and Jendrossek, 2017) and affecting the number and 
size of granules inside the cell. They have been postulated as a new family of surfactant 
proteins with a key structural role in generating and stabilizing the interface between the 
hydrophilic cytoplasm and the hydrophobic core of PHA granules, preventing them from 
coalescence and protecting against damage of cell components due to interactions with the 
polymer (Wei et al., 2011; Sunde et al., 2017).  
Phasins are widely distributed among PHA producer microorganisms and constitute a 
heterogeneous group with very low degree of conservation in their primary structures (Mezzina 
and Pettinari, 2016). They are amphipathic proteins that contain a hydrophobic face associated 
with the PHA granule and a hydrophilic one exposed to the cytoplasm. According to the Pfam 
database (https://pfam.xfam.org/), phasins can be classified into four families based on their 
phylogenetic origin and the type of PHA produced in such strains. The first family (PF09361) 
constitutes the largest one, containing phasins belonging to α-, β-, and γ-Proteobacteria. This 
group includes the well studied PhaP1 from C. necator (PhaPRe). The second (PF09602) and 
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third (PF09650) families include phasins found in Bacillus species and a group of 
uncharacterized proteins from Proteobacteria, respectively. The fourth (PF05597) includes 
phasins from Pseudomonas species (Maestro and Sanz, 2017).  
3.2.1. Phasin PhaF 
P. putida strains contain phasin PhaI (15 kDa) and phasin PhaF (26 kDa) (Prieto et al., 
1999). Phasin PhaF has been described as an amphipathic intrinsically disordered protein 
containing two different modules connected by a leucine zipper domain responsible of the 
oligomerization (Figure 4) (Tarazona et al., 2019). The N-terminal module consists of an 
elongated α-helix that binds to the PHA granule, partially unfolded in the absence of a 
hydrophobic support (Maestro et al., 2013). The C-terminal domain of the protein is predicted 
to contain a superhelical structure with basic residues that interact with the nucleoid (Galán et 
al., 2011). The N-terminal and leucine zipper domains of PhaF have been included into the 
BioF module and shares sequence similarity with phasin PhaI (Moldes et al., 2004). This 
module has been demonstrated to bind not only to emerging native mcl-PHA granules (Moldes 
et al., 2004; Dinjaski and Prieto, 2013) but also to P(3HB) in vitro (Bello-Gil et al., 2018a) and 
other hydrophobic-hydrophilic interfaces such as oleate or chromatographic resins (Maestro 
et al., 2013).  
Phasin PhaF plays a critical role in the localization of the PHA granules and their 
segregation between daughter cells during division (Galán et al., 2011). The lack of this protein 
has been demonstrated to reduce the cellular PHA accumulation and to increase the 
heterogeneity of the population in terms of number of granules (Dinjaski and Prieto, 2013). 
 
Figure 4. Structural model of phasin PhaF monomer unit. PhaF monomeric unit interacting with DNA 
through the C-terminal domain. Leucine zipper region is shown in blue. The N-terminal consists in an 
amphipathic alpha-helix that binds to the PHA granule while the C-terminal domain interacts with DNA 
through basic residues (Maestro et al., 2013). 
N-terminal C-terminal
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4. GAPs applications 
4.1. GAPs engineering for PHA functionalization 
The available knowledge about the structure and function of GAPs increase the potential 
to rationally engineer these proteins by fusing or inserting functional proteins while conserving 
their affinity for PHA (Parlane et al., 2017). PHA synthases, depolymerases and phasins have 
served as anchoring tags to immobilize value added proteins on the surface of PHA materials 
obtaining functionalized supports for a variety of applications that include protein purification, 
enzyme immobilization or cell targeting among others (Table 2).  
Depending on the target application, functionalization with GAPs fusions is achieved 
either in vivo (simultaneously to the PHA production in the bacterial cytoplasm) or in vitro 
(utilizing endotoxin free PHA purified after the biotechnological production) (Figure 5) (Dinjaski 
and Prieto, 2015).  
 
 
Figure 5. Strategies for functionalization of PHA nanoparticles using GAPs as affinity tags. A) In 
vivo simultaneous production of PHA and GAPs fusion protein. In the picture, a monomeric unit of the 
N-terminal domain of phasin PhaF, BioF, is shown as an example of affinity tag. B) Production of PHA 
nanoparticles and in vitro functionalization using previously produced and purified GAPs fusion proteins. 
 
The first strategy takes advantage directly of the particle-like PHA granules within the 
bacterial cell, obtaining GAPs fusions that are immobilized onto the surface simultaneously 
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with the production of PHA. The second approach requires PHA extraction, followed by PHA 
nanoparticles or film formation and in vitro immobilization of the GAPs fusions. This strategy is 
preferred for biomedical purposes that require endotoxin-free PHA materials. However, other 
applications like protein delivery to natural environments or enzyme immobilization for 
industrial purposes may benefit from the direct use of PHA granules since they do not require 
such purity conditions. 
Among GAPs, phasins constitute an attractive tool for tuning PHA materials because of 
the structural diversity. Moldes and collaborators (2004) first described the use of a phasin for 
enzyme immobilization by fusion of the N-terminal domain of PhaF, BioF, to the LacZ and C-
Lyt proteins. During these years, several works have developed strategies that take advantage 
of phasins as PHA functionalized tags (Figure 6). 
 
 
Figure 6. Examples of functional proteins fused to phasins on PHA nanoparticles and their 
applications. Laccase-like multicopper oxidase (CueO), human lipopolysaccharide binding protein 
(hLBP), mouse interleukin-2 (IL-2), myelin oligodendrocyte glycoprotein (MOG), antimicrobial peptide 
tachyplesin I (Tac), human epidermal growth factor (hEGF), recombinant human α1-acid glycoprotein 
(rhAGP), β-galactosidase (β-gal), recombinant human tissue plasminogen activator (rPA), insecticidal 
crystal protein (Cry1Ab). 
 
The BioF has been exploited as a tag to immobilize Cry1Ab insecticide specific toxin 
protein on PHA granules for their direct use as an insecticide (Moldes et al., 2006) or β-
galactosidase and C-LytA proteins for industrial purposes (Bello-Gil et al., 2018a). This domain 
Diagnosis
Protein purification Drug targeting
Enzyme
immobilization
Antimicrobials
Endotoxin removal
Phasin
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has also been employed to decolorize wastewaters dye through the immobilization of CueO 
laccase-like multicopper oxidase on P(3HB) beads (Bello-Gil et al., 2018b). PhaP from C. 
necator and Aeromonas hydrophila have been used as tags for intein-mediated protein 
purification through the incorporation of a self-cleaving intein site between both proteins (Banki 
et al., 2005; Wang et al., 2008; Geng et al., 2010). PhaP fusion to antigens has been applied 
in fluorescence activated cell sorting (FACS) based diagnostics for the detection of antibodies 
which are then fluorescently labeled using secondary antibodies (Bäckström et al., 2007; 
Atwood and Rehm, 2009). The immobilization of ligands and receptors (such as the cell 
adhesion motif (RGD), the growth factor receptor (EGFR), the recombinant human α1-acid 
glycoprotein (hAGP) or the recombinant human epidermal growth factor (hEGF)) on PHA 
materials using phasin PhaP as a tag have been employed for cell targeting and drug delivery 
(Yao et al., 2008; Dong et al., 2010; You et al., 2011; Xie et al., 2013; Fan et al., 2018). Anti-
infective poly(3- hydroxybutyrate-co-3-hydroxyvalerate) (P(3HB-co-3HV)) biomaterials have 
been developed by displaying the tachyplesin I fusion to PhaP (Xue et al., 2018).  
In addition, PHA synthases from Pseudomonas aeruginosa, P. putida or C. necator  have 
been widely employed as tags through the incorporation of functional proteins into dispensable 
regions of both the N-terminal and C-terminal domains (Parlane et al., 2017). These devices 
have been applied with several purposes. For instance, PhaC has been employed to purify 
proteins like the human tumor necrosis factor alpha (TNFα) or the human granulocyte 
macrophage colony-stimulating factor (GM-CSF) by incorporating an intein site (Du and Rehm, 
2017). The immobilization of the organophosphohydrolase from Agrobacterium radiobacter on 
the surface of P(3HB) granules has been applied as a strategy to clean-up polluted 
environments (Blatchford et al., 2012). The immobilization of the IgG binding ZZ domain of 
protein A from Staphylococcus aureus has been developed as a bioseparation system to purify 
antibodies (Lewis and Rehm, 2009). Many works have also explored the use of PHA granules 
for diagnostics and as vaccines by fusion of the Pneumococcal surface antigen A (PsaA) 
(González-Miro et al., 2017) or the Hepatitis C Core (HCc) antigen (Martínez-Donato et al., 
2016). A summary of most of the applications developed using PhaC synthase as a tag is 
shown in Table 2. 
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Table 2. Summary of applications of granule associated proteins (GAPs) as tags. 
Application Support Description GAP Bacterial 
strain 
Refs. 
Protein 
purification 
P(3HB) Intein-mediated 
purification of maltose 
binding protein (MBP), β-
galactosidase (β-gal), 
chloramphenicol 
acetyltransferase (CAT), 
NusA 
PhaP  E. coli (Banki et al., 
2005) 
 P(3HB) Thrombin mediated 
purification of 
recombinant human 
tissue plasminogen 
activator (rPA) 
PhaP  E. coli (Geng et al., 
2010) 
 P(3HB-
co-3HHx) 
Intein mediated 
purification enhanced 
green fluorescent protein 
(EGFP), β-gal and MBP 
PhaP  In vitro (Z. Wang et 
al., 2008) 
 mcl-PHA β-gal PhaF  P. putida (Moldes et 
al., 2004) 
 P(3HB) Intein mediated 
purification of GFP, 
tuberculosis vaccine 
Rv1626, Immunoglobulin 
G (IgG) binding ZZ 
domain of protein A from 
S. aureus, human tumor 
necrosis factor alpha 
(TNFα), human 
granulocyte colony-
stimulating factor (G-
CSF), and human 
interferon alpha 2b 
(IFNα2b). 
PhaC  E. coli (Du and 
Rehm, 2017) 
 P(3HB) Sortase mediated 
purification of TNFα and 
IFNα2b 
PhaC  E. coli (Du and 
Rehm, 2018) 
 P(3HB) Enterokinase mediated 
purification of anti-β-
galactosidase single-
chain variable fragment 
(scFv) 
PhaC  E. coli (Grage et al., 
2011) 
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Application Support Description GAP Bacterial 
strain 
Refs. 
 P(3HB) Sortase mediated 
purification of GFP and 
MBP 
PhaC  E. coli (Hay et al., 
2015) 
Enzymes 
immobilization 
P(3HB) Choline-binding module 
(C-LytA) and β-gal 
PhaF  In vitro (Bello-Gil et 
al., 2018a) 
 P(3HB) Laccase-like multicopper 
oxidase (CueO) from E. 
coli for dye removal 
PhaF  In vitro (Bello-Gil et 
al., 2018b) 
 mcl-PHA Cry1Ab insect-specific 
toxin 
PhaF  P. putida (Moldes et 
al., 2006) 
 P(3HB) Human 
lipopolysaccharide 
binding protein (hLBP) for 
endotoxin removal 
PhaP  In vitro (J. Li et al., 
2011) 
 P(3HB) Organophosphohydrolase 
(OpdA) from 
Agrobacterium 
radiobacter for clean-up of 
polluted environments 
PhaC  E. coli (Blatchford et 
al., 2012) 
 P(3HB) α-Amylase (BLA) from 
Bacillus licheniformis 
PhaC  E. coli (Rasiah and 
Rehm, 2009) 
 P(3HB) β-gal PhaC1  P. aeruginosa (Peters and 
Rehm, 2006) 
 mcl-PHA MBP PhaZ  In vitro (Ihssen et al., 
2009) 
 P(3HB) EGFP and Red 
Fluorescent Protein (RFP) 
PhaZ  In vitro (Lee et al., 
2005) 
Bioseparation P(3HB) IgG binding ZZ domain of 
protein A from S. aureus 
PhaC  E. coli (Brockelbank 
et al., 2006; 
Lewis and 
Rehm, 2009) 
 P(3HB) VHH domains from camelid 
antibodies, designed 
ankyrin repeat proteins 
(DARPins), and OB-folds 
(OBodies) 
PhaC  E. coli (Hay et al., 
2015) 
 P(3HB) IgG binding ZZ domain of 
S. aureus protein A 
PhaC  Lactococcus 
lactis 
(Mifune et 
al., 2009) 
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Application Support Description GAP Bacterial 
strain 
Refs. 
 P(3HB) Streptavidin PhaC  E. coli (Peters and 
Rehm, 2008) 
Bioimaging P(3HB) Gold-binding peptide 
GBP1 and the antibody 
(IgG) binding ZZ domain 
PhaC  E. coli (Jahns et al., 
2008) 
Diagnostics P(3HB) FACS-based detection of 
myelin oligodendrocyte 
glycoprotein (MOG) and 
mouse interleukin-2 (IL2) 
anti-sera 
PhaP  E. coli (Bäckström 
et al., 2007; 
Atwood and 
Rehm, 2009) 
 P(3HB) 6-kDa Early secretory 
antigenic target (ESAT6), 
10-kDa culture filtrate 
protein (CFP10), and 
Rv3615c tuberculosis 
(TB) antigens 
PhaC  E. coli (Chen et al., 
2014; 
Parlane et 
al., 2016) 
 P(3HB) Anti-β-galactosidase 
single chain antibody 
variable fragment (scFv) 
PhaC  E. coli (Grage and 
Rehm, 2008) 
Vaccines P(3HB) Antigen 85A (Ag85A) and 
ESAT-6 TB antigens 
PhaC  E. coli (Parlane et 
al., 2009) 
 P(3HB) Pneumococcal surface 
antigen A (PsaA) 
PhaC  E. coli (González-
Miro et al., 
2017) 
 mcl-PHA Surface epitopes of outer 
membrane vaccine 
candidates AlgE, OprF, 
and OprI agains P. 
aeruginosa 
PhaC  P. aeruginosa (Lee et al., 
2017) 
  
P(3HB) 
 
Hepatitis C Core (HCc) 
antigen 
 
PhaC  
 
E. coli 
L. lactis 
E. coli 
 
(Parlane et 
al., 2011; 
Martínez-
Donato et al., 
2016) 
 P(3HB) Rv1626 and the 
immunostimulatory 
proteins/peptides TB 
antigens 
PhaC  E. coli (Rubio‐
Reyes et al., 
2017) 
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Application Support Description GAP Bacterial 
strain 
Refs. 
Antimicrobials P(3HB-
co-3HV) 
Antimicrobial peptide 
tachyplesin I (Tac) 
PhaP  In vitro (Xue et al., 
2018) 
Cell targeting P(3HB-
co-3HHx), 
P(3HB-
co-3HV) 
Cell adhesion motif (RGD) 
for fibroblasts attachment 
PhaP  In vitro (Dong et al., 
2010) 
 P(3HB-
co-3HHx) 
Growth factor receptor 
(EGFR)-targeting peptide 
(ETP) for tumor targeting 
PhaP  In vitro (Fan et al., 
2018) 
 P(3HB-
co-3HHx) 
RGD for chondrogenic 
differentiation 
PhaP  In vitro (You et al., 
2011) 
 P(3HB-
co-3HHx) 
P(3HB-
co-3HV-
co-3HHx) 
RGD, IKVAV for cell 
proliferation and neural 
differentiation 
PhaP  In vitro (Xie et al., 
2013) 
Drug delivery P(3HB-
co-3HHx) 
Recombinant human α1-
acid glycoprotein (rhAGP) 
or recombinant human 
epidermal growth factor 
(rhEGF) 
PhaP  In vitro (Yao et al., 
2008) 
 P(3HB) Tumor ligand RGD4C PhaC  In vitro (Lee et al., 
2011) 
PhaP (PhaP phasin), PhaF (PhaF phasin), PhaC (PhaC synthase), PhaZ (PhaZ depolymerase). 
See the Abbreviation section for full names.  
 
4.2. Other applications of Phasins 
The amphiphilic character of phasins makes them suitable for their use as biosurfactants. 
For instance, phasin PhaPAh from Aeromonas hydrophila 4AK4 has been demonstrated to 
exhibit a strong ability to form emulsions with lubricating oil, diesel or soybean oil and high 
thermal stability (Wei et al., 2011). Furthermore, the chaperone-like activity of some phasins 
such as PhaPAz from Azotobacter sp. FA-8 could be exploited to enhance the production of 
heterologous proteins (Mezzina et al., 2015). 
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5. Metabolic and regulatory networks involved in PHA synthesis 
The PHA metabolism involves complex metabolic and regulatory networks that vary 
depending on the microorganism and the type of PHA produced. The specific metabolism of 
PHA is encoded by the pha gene cluster and constitutes a dynamic cycle in which synthesis 
and degradation occurs simultaneously, favouring the flux to one or another direction 
according to cellular needs. Moreover, PHA accumulation is connected to other central carbon 
metabolic routes that provide precursors to the PHA synthase. 
5.1. Scl-PHA metabolism 
Among scl-PHA, the most widely described biosynthesis route has been the P(3HB) 
production that comprises three reaction steps catalysed by acetyl-CoA acetyltransferase (β-
ketothiolase or PhaA), acetoactyl-CoA reductase (PhaB), and PHA synthase (PhaC). The 
three enzymes are encoded in the phb gene cluster. This pathway has been extensively 
studied in the model bacterium C. necator. PhaA catalyzes the condensation of two acetyl-
CoA molecules into acetoacetyl-CoA that is stereoselectively reduced to (R)-3-hydroxybutyryl-
CoA by PhaB. The last step involves the polymerization of (R)-3-hydroxybutyryl-CoA into the 
growing chain of P(3HB) by PhaC synthase releasing CoA (Figure 7) (Sagong et al., 2018).  
 
Figure 7. Scl-PHA biosynthesis. A) TEM image of C. necator growing under P(3HB) producing 
conditions. B) Scl-PHA such as P(3HB) is produced in three steps from acetyl-CoA. Three enzymes are 
responsible of this pathway: the β-ketothiolase (PhaA), NADPH-dependent acetoacetyl-CoA reductase 
(PhaB) and PHB synthase (PhaC). 
Acetyl-CoA
PhaA
PhaB
PhaC
Scl-PHA
Acetoacetyl-CoA
(R)-3-hydroxybutyryl-
CoA
A
B
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5.2. Mcl-PHA metabolism 
In Pseudomonas spp., the process of PHA synthesis and degradation works as a 
continuous cycle in which the PHA synthases and depolymerases are simultaneously active. 
Other enzymes like the acyl synthetase ACS1 have an important role in the process by 
converting the (R)-HA released by the PHA depolymerase into active (R)-HA-CoA that can be 
catabolized via the β-oxidation pathway or re-incorporated into the PHA granule by the PHA 
synthase (de Eugenio et al., 2010a). The PHA cycle is a highly controlled process (Prieto et 
al., 2016). PHA accumulation is extensively regulated at the enzymatic level, by cofactor 
inhibition and availability of metabolites (Escapa et al., 2012), at transcriptional level, by 
specific and global transcriptional regulatory factors (de Eugenio et al., 2010a; de Eugenio et 
al., 2010b) and at translational level by global post-transcriptional regulators (Fonseca et al., 
2014; La Rosa et al., 2014). Thereby, the PHA turnover is connected to the central carbon 
metabolism through the β-oxidation and the de novo fatty acid synthesis (direct PHA precursor 
routes) and non-related pathways like the TCA cycle (indirect PHA precursor routes) linked by 
the acetyl-CoA metabolite (Figure 8).  
 
 
Figure 8. Metabolic and regulatory network of PHA metabolism in P. putida KT2440. The PHA 
cycle (green) constitutes a dynamic route where 3-hydroxyacids are released from PHA granules by 
PhaZ depolymerase and activated to 3-hydroxyacyl-CoAs by ACS1 acyl synthetase. The PHA metabolic 
machinery is related with the fatty acid metabolism, called the “direct PHA precursor routes” (red), and 
other carbon metabolic pathways, the “indirect precursor routes” (blue), interconnected among them by 
the acetyl-CoA metabolite (Prieto et al., 2016). 
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In P. putida KT2440, the pha cluster is organized in two operons, phaC1ZC2D and phaIF, 
under the regulation of the transcriptional activator PhaD in response to β-oxidation 
intermediates (Figure 9) (de Eugenio et al., 2010b). The first encodes two Class II synthases 
(phaC1 and phaC2), a PHA depolymerase (phaZ) and the regulator (phaD) while the second 
encodes the phasins (phaF and phaI), the most abundant amphipathic proteins covering the 
PHA granule. Despite other promoter regions could be detected (PZ, PC2 and PF), quantitative 
PCR experiments demonstrated that the PC1 and PI promoters are the ones that drive the 
transcription of phaC1ZC2D and phaIF operons. The substrates of the PHA synthases are the 
(R)-3-hydroxyacyl-CoA of different lengths obtained through beta-oxidation and the de novo 
synthesis of fatty acids depending on the carbon source used (see below).  
 
 
Figure 9. Pha gene cluster organization in P. putida KT2440. The cluster contains two synthases 
(phaC1 and phaC2), a PHA depolymerase (phaZ) and two phasins encoded by phaF and phaI genes. 
The phaD gene encodes a transcriptional regulator that has been demonstrated to activate PC1 and PI 
promoters. 
 
Structurally related substrates like fatty acids can be incorporated into PHA directly as 
β-oxidation intermediates without complete oxidation to acetyl-CoA yielding monomer chains 
of equal or shorter length than those of the carbon source. The fatty acids are activated into 
acyl-CoA through the acyl-CoA synthetase (FadD). An acyl-CoA dehydrogenase (FadF) with 
the electron-transferring protein assistance (FadE) catalyses the formation of a double bond 
yielding enoyl-CoA. A tetrameric complex formed (FadBA) carries out the next steps of 
hydration, oxidation and thiolysis. This complex codifies five enzymatic reactions (enoyl-CoA 
hydratase, 3-hydroxyacyl-CoA dehidrogenase, cis-Δ3-trans-Δ2-enoyl-CoA isomerase, 3-
hydroxyacyl-CoA epimerase, and 3-ketoacyl-CoA thiolase) and is responsible of the removal 
of two carbon units of the acyl-chain (Figure 10). The FadBA complex is encoded by two set 
of genes in P. putida KT2440, fadB and fadA (PP_2136 and PP_2137) and fadBx and fadAx 
(PP_2214 and PP_2215). The first set seem to play a more important role since their lack 
causes a defective β-oxidation pathway yielding polymers with longer chain monomers 
(Ouyang et al., 2007). Various isoenzymes have been proposed to carry out some of the steps 
performed by the FadBA complex (Olivera et al., 2001a). The intermediates of the β-oxidation 
1 kb
phaC1 phaZ phaC2 phaD
PC1
PF
PI
PZ PC2
phaF phal
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enoyl-CoA, (S)-3-hydroxyacyl-CoA and (R)-3-ketoacyl-CoA, can be converted into (R)-3-
hydroxyacyl-CoA PHA synthase substrates through a stereospecific trans-enoyl-CoA 
hydratase (PhaJ), an epimerase (FadB), and a specific ketoacyl-CoA reductase (FabG), 
respectively (Kniewel et al., 2017). 
 
 
Figure 10. Direct metabolic pathways involved in PHA biosynthesis in P. putida KT2440. The 
substrates of the PHA synthase come from the central carbon metabolism: β-oxidation and synthesis 
de novo depending on the feeding carbon source. FadD: acyl-CoA synthetase; FadE: acyl-CoA 
dehydrogenase; FadBA: tetrameric complex that perform several reactions (enoyl-CoA hydratase, 3-
hydroxyacyl-CoA dehydrogenase, cis-Δ3-trans-Δ2-enoyl-CoA isomerase, 3-hydroxyacyl-CoA 
epimerase, and 3-ketoacyl-CoA thiolase); PhaJ: trans-enoyl-CoA hydratase; PhaG: 3-hydroxyacyl- acyl 
carrier protein (ACP)- CoA transferase; PhaC1: PHA synthase; PhaZ: PHA depolymerase; Acs1: Acyl 
synthetase; FabG: ketoacyl-ACP reductase; FabB/F: 3-ketoacyl-ACP synthase; FabA/Z: 3-hydroxyacyl-
ACP dehydratase; FabI: enoyl-ACP reductase; FabD: malonyl-CoA-ACP transacylase. 
 
Non-related substrates such as carbohydrates can act as indirect precursors of PHA 
through their complete oxidation to acetyl-CoA and be channelled towards the de novo 
synthesis pathway (Figure 10). This process involves the transformation of acetyl-CoA into 
malonyl-CoA, which is activated into malonyl-ACP through a malonyl-CoA:ACP transacylase 
(FabD). Malonyl and acyl-ACP derivatives are condensed by ketocyl-ACP synthetase, reduced 
(losing a ketone group), dehydrated and saturated to the corresponding (R)-3-hydroxyacyl-
ACP that may be elongated by successive two-carbon units (FabA/Z). Hydroxyacyl-ACP 
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R-3-
Hydroxyacyl-
ACP
De novo fatty
acid synthesis
PhaG
PhaC1
Non-Fatty acid
precursors
FadB
Malonyl-CoA
3-ketoacyl-
ACP
Acetyl-CoA
Acyl-ACP
Enoyl-ACP
FabG
FabD
FabA/Z
R-3-Hydroxyacyl-
CoA
PHA cycle
Fatty acids
FadD
PhaJ
PhaZ
Malonyl-ACP
FabB/F
R-3-
Hydroxycarboxilic 
acid
Acs1
Acyl-CoA
trans 2-
enoyl-CoA
S-3-
Hydroxyacyl-
CoA
3-Ketoacyl-
CoA
FadA
FadB FadB
FadE
β-Oxidation
Cycle
FabG
FabI
Introduction 
 
 
39 
IN
T
R
O
D
U
C
T
IO
N
 
intermediates can be transformed into (R)-3-hydroxyacyl-CoAs by the transacylase PhaG 
(Rehm et al., 1998). Recent works suggest that PhaG functions as a 3-hydroxyacyl-ACP 
thioesterase to produce 3-hydroxy fatty acids (Wang et al., 2012). Consequently, at least one 
3-hydroxyacyl-CoA ligase should be necessary to provide (R)-3-hydroxyacyl-CoA and they 
propose the PP_0763 gene in P. putida. 
 
6. Metabolic and genetic engineering strategies to expand the PHA family for 
targeting applications 
The infinity of PHA combinations that can be obtained based on the variety of the lateral 
chains of monomers, their arrangements and the different monomer types that compose the 
polymer expand their potentialities as industrial and medical materials since the 
physicochemical properties are determined by the structure and monomeric composition of the 
final polymer (Figure 11) (Albuquerque and Malafaia, 2018). The potential to edit and redirect 
the cell system using metabolic and genetic engineering tools as well as the use of different 
fermentation strategies and carbon sources lead to create PHAs rationally designed for 
targeting applications (Prieto et al., 2016).  
 
 
Figure 11. PHA diversity based on monomer size, functional substituents of the lateral chain and 
structure of the polymer (modified from Dinjaski and Prieto, 2015). 
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6.1. Manipulating the metabolism to increase PHA structural diversity 
It has become possible to obtain PHA homopolymers, random, and block copolymers or 
functional and graft PHA polymers by controlling the carbon flow through the manipulation of 
the bacterial PHA synthesis metabolism (Chen and Hajnal, 2015; Chen et al., 2016).  
In a strain like P. putida KT2442, the manipulation of various genes involved in the β-
oxidation pathway led to several types of PHA random copolymers with adjustable monomer 
content, PHA homopolymers, scl- and mcl-PHA random copolymers, PHA block copolymers 
and functional PHA (Meng et al., 2014). Here we describe only some examples of the 
application of metabolic engineering tools to increase the diversity of PHA. 
The deletion of the two sets of fadBA genes as well as other key genes of the central 
carbon metabolism related with the PHA cycle, like phaG, led to the production of poly(3-
hydroxyhexanoate) (P(3HHx)), poly(3-hydroxyheptanoate) (P(3HHp)), poly(3-
hydroxydecanoate) (P(3HD)) and poly(3-hydroxydodecanoate) (P(3HDD)) homopolymers 
when growing in the corresponding fatty acids (Liu et al., 2011; Wang et al., 2011). In addition, 
the weakening of β-oxidation pathway through the knocking out of fadA and fadB genes 
conducted to an increase of the final PHA content and a higher proportion of long-chain length 
monomers (Liu and Chen, 2007; Ouyang et al., 2007; Escapa et al., 2011). The introduction 
of the genes from other microorganisms like Aeromonas caviae, which codifies a PHA 
synthase able to polymerize both scl and mcl monomers, in a weakened β-oxidation P. putida 
KT2442 strain results in the production of P(3HB)-b-P(3HV-co-3HHp) block copolymer 
consisting of P(3HB) as one block and 3-hydroxyvalerate (3HV) and 3-hydroxyheptanoate 
(3HHp) copolymer as another block (Li et al., 2011). A diblock copolymer of P(3HB)-b-P(3HHx) 
was also generated in the same strain (Tripathi et al., 2012). Adjustable monomer composition 
was achieved in this strain obtaining random copolymers of P(3HB-co-3HHx), P(3HHx-co-
3HD) and block copolymer PHHx-b-P(3HD-co-3HDD) by feeding the strain with a predefined 
ratio of fatty acids (Tripathi et al., 2013). Other example of block copolymers was achieved by 
the introduction of phbC and orfZ genes of C. necator in the weakened β-oxidation P. putida 
KT2442 strain obtaining P(3HB)-b-P(4HB) (Hu et al., 2011).  
Furthermore, the ability of some bacteria to incorporate (R)-HA-CoA bearing functional 
groups from related substrates lead to an enormous monomeric structural diversification both 
by biosynthetic and post-biosynthetic chemical modifications (Olivera et al., 2010). PHA 
containing double or triple bonds (Y.B. Kim et al., 1995; Ashby and Foglia, 1998; Ballistreri et 
al., 2001), monohalogenated (Kim et al., 1996; Takagi et al., 2004), aromatic (Song and Yoon, 
1996; Kim et al., 2000; Kim et al., 1999; Olivera et al., 2001b; Tobin and O’Connor, 2005; Ward 
and O’Connor, 2005), thioether (Ewering et al., 2002) , thioester (Escapa et al., 2011), cyano 
Introduction 
 
 
41 
IN
T
R
O
D
U
C
T
IO
N
 
or nitro (O. Kim et al., 1995) side groups among others have been obtained using related 
carbon sources. These functional structures not only vary the properties of the final polymer 
through the modification of its thermal and mechanical characteristics but also allow the 
production of tailor-designed PHA through the introduction of post-biosynthetic chemical 
modifications (Olivera et al., 2010). Post-functionalization strategies comprise cross-linking 
and polymer binding, halogenation, epoxidation, hydroxylation, carboxylation or glycosylation 
(Raza et al., 2018). 
6.2. Effects of PHA composition in properties and applications of the final 
material 
6.2.1. Polymer physical, thermal and mechanical properties 
Firstly, some important physical, thermal and mechanical concepts are explained to 
better understand the importance of the polymer structure on material properties.  
The molecular weight of a polymer is related to the degree of polymerization and the 
molecular weight of the unit that is repeating. Since the type and number of molecules that 
compose the polymer may vary, an average of the individual molecular weights is employed 
to calculate this value. The following concepts related with physical properties are usually 
determined in polymer characterization: 
• The number average molecular weight (Mn) is the total weight of the polymer molecules 
divided by the total number of polymer molecules. 
• The weight-average molecular weight (Mw) includes the weight fraction contribution of 
each type of molecule to the total polymer weight. The more massive the molecule, the 
more the molecule contributes to the total weight. 
• The polydispersity index (PDI) is the ratio between the weight-average molecular 
weight and the number-average molecular weight.  
The second group of properties that are usually provided as part of polymer 
characterization are the thermal ones. In this sense, it should be distinguished between the 
amorphous and crystalline regions of a polymer. In the amorphous region, the molecules of 
the polymer are in frozen state at low temperatures. This means that the molecules can vibrate 
slightly. In this state, commonly referred as glassy state, the polymer tends to be brittle and 
rigid, analogous to a glass. If the polymer is heated, the molecules start to move around, and 
the polymer becomes flexible similar to rubber, leading to the rubbery state. Two main values 
can be obtained: 
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• The glass transition temperature (Tg) is the transition from the glassy state to the 
rubbery state of the amorphous region of the polymer. This value is affected by several 
factors such as the molecular weight or the measurement method.   
• The melting point (Tm) is related with the crystalline region of the polymer. A semi-
crystalline polymer has both transition temperatures since it contains an amorphous 
and a crystalline phase. In these polymers, the melting point is the transition from the 
ordered phase to the disordered phase.  
All polymers present a Tg value whereas the Tm is a characteristic of semi-crystalline polymers. 
The Tm usually increases in the presence of double bonds, aromatic or large side groups 
because the flexibility of the chain is affected by the presence of such groups (Kantesh et al., 
2015). 
The understanding of the mechanical properties of a polymer is important to evaluate 
the elasticity and potential applications of the material. The following properties are usually 
determined in polymer characterization:  
• The tensile strength (σt), is the maximum force or tensile stress required to break the 
polymer due to the stretching of the polymer. Among the factors affecting the tensile 
strength are molecular weight, cross-linking and crystallinity. 
• The Percent Elongation to Break (εb) measures the ductility. It is calculated as the 
percentage change in the length of the material before break (tensile strain) measured 
in percentage. The values of thermoplastics are over 100 %. 
• The Young’s Modulus (E) is a measure of the stiffness of the material and is calculated 
as the ratio of the tensile stress (σt) to the tensile strain (ε). 
6.2.2. PHA versatility as a tool to vary polymer properties and expand the range of 
applications  
As previously exposed, the physical, thermal and mechanical properties of the PHA will 
vary as a function of the monomer composition and the molecular structure of the polymer. 
Some of these properties are summarized in Table 3 for various PHA and will determine the 
target applications of the material. 
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Table 3. Thermal and mechanical properties of some representative polymers from the PHA 
family. 
PHA Copolymer 
content 
E 
MPa 
σt 
MPa 
εb 
% 
Tm 
ºC 
Tg 
ºC 
Reference 
P(3HB) 100 % 3500-
4000 
40 3-8 173-180 5-9 (Sudesh et 
al., 2000; 
Anjum et al., 
2016) 
P(4HB) 100 % 70 50 1000 60 -51 (Martin and 
Williams, 
2003) 
P(3HB-co-
3HV) 
(97:3 %) 
(91:9 %) 
(86:14 %) 
(80-20 %) 
(75-25 %) 
2900 
1900 
1500 
1200 
700 
38 
37 
35 
32 
30 
- 
- 
- 
- 
- 
170 
162 
150 
145 
137 
- 
- 
- 
-1 
- 
(Anjum et al., 
2016) 
P(3HB-co-
4HB) 
(97:3 %) 
(90:10 %) 
(84:16 %) 
(36:64 %) 
(10:90 %) 
- 
- 
- 
30 
100 
28 
24 
26 
17 
65 
45 
252 
444 
591 
1080 
166 
159 
130 
50 
50 
- 
- 
-7 
-35 
-42 
(Saito and 
Doi, 1994) 
P(3HB-co-
3HHx) 
(88-12 %) 
(90-10 %) 
(86-14 %) 
(83-17 %) 
(69-31 %) 
38.5 
- 
- 
- 
- 
11.3 
21 
23 
20 
6 
67.3 
400 
760 
<800 
<800 
151 
129 
123 
119 
73 
-1 
- 
- 
- 
- 
(Liu and 
Chen, 2007) 
P(3HHx-
co-3HO) 
(12-88 %) - 9 380 61 -31 (Valappil et 
al., 2006) 
P(3HD) 100 % 19.86 11.96 312.86 72.2 -37.21 (Liu et al., 
2011) 
P(3HD-co-
3HDD) 
(15.74-84.26 %) 103.13 5.24 88.30 77.62 -32.49 (Liu et al., 
2011) 
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PHA Copolymer 
content 
E 
MPa 
σt 
MPa 
εb 
% 
Tm 
ºC 
Tg 
ºC 
Reference 
P(3HHx-
co-HO-co-
HD-co-
HDD-co-
HTD) 
(2.9-18.7-27.4-
19.6-31 %) 
31.73 7.57 275.1 58.1 -40 (Liu and 
Chen, 2007) 
(2.8-17.9-24.8-
18.6-36 %) 
39.41 2.97 117.5 59.5 -42 
(2-14-23.6-17.4-
43 %) 
74.58 4.75 107 65.9 -40  
(2.2-11.1-21.6-
16.1-49%) 
34 3.15 107.7 66.8 -40 
DSC Thermal properties: Tm, melting temperature; Tg, glass transition temperature. E, Young’s modulus; 
σt, tensile strength; εb, elongation at break. The script symbol (-) indicates the lack of data for these 
parameters. See the Abbreviation section for full names.  
 
Among scl-PHA, P(3HB) homopolymer and copolyester of P(3HB-co-3HV) are the most 
comprehensively studied PHA. They have been widely applied in the biomedical field as 
cardiovascular products, drug delivery systems, wound management and orthopaedics 
(Khosravi-Darani and Bucci, 2015; Możejko-Ciesielska and Kiewisz, 2016). However, scl-PHA 
are highly crystalline, brittle and stiff so they are not suitable for soft tissue regeneration such 
as in vascular applications, nerve and skin regeneration or as matrices for controlled drug 
delivery (Rai et al., 2011). Mcl-PHA are considered promising candidates as thermoplastic 
elastomers for packaging and some medical applications due to their high elasticity, 
hydrophobicity, low oxygen permeability, water resistance and biodegradability (Rai et al., 
2011; Tortajada et al., 2013). These polymers have been applied as coatings and in medical 
temporary implants such as scaffolding for the regeneration of arteries and nerve axons 
(Hazer, 2010). Nevertheless, conventional mcl-PHA have relatively low mechanical strength 
(σt) and processing temperature (Tm) what difficult their employ in certain uses (Rai et al., 
2011). Therefore, physical and mechanical properties of microbial polyesters need to be 
diversified and improved to expand their potential applications (Hazer et al., 2012). 
In the previous section, several examples of the plethora of PHA that can be obtained 
applying metabolic and genetic engineering tools and choosing the appropriate producer strain 
as well as the carbon source and fermentation conditions have been exposed (Hazer and 
Steinbüchel, 2007). Some of these polymers showed enhanced thermal and mechanical 
properties. For instance, homopolymers obtained through weakened β-oxidation mutants 
show improvements in tensile strength, elongation at break and Young’s modulus (Liu et al., 
2011). Mcl-PHA copolymers with higher percentage of long-chain length monomers like C12 
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and C14 significantly improved thermal and mechanical properties (Ma et al., 2009; Liu et al., 
2011). These polymers showed higher crystallinity, but they behave as thermoplastic 
elastomers with good tensile strength and desirable elongation at break. They contain an 
increased Young’s modulus that has been demonstrated to improve the processing and 
molding of the polymer (Ouyang et al., 2007; Liu et al., 2011). P(3HB-co-3HHx) is one of the 
most promising copolymers since an increment of the flexibility and high biocompatibility 
properties has been observed, making it appropriate for biomedical applications such as tissue 
engineering (Doi et al., 1995; Tripathi et al., 2013). In addition, the P(3HB-co-4HB) copolymer 
constitutes a very interesting polymer since its crystallinity and degradability properties can be 
modified by adjusting the 4HB content (Vigneswari et al., 2009). This monomer has been 
reported to increase the elongation to break up to 1000 % what increases its applicability in 
the medical fields (Martin and Williams, 2003). 
Chemical modifications of functionalized PHA can be used to create multifunctional 
materials with advanced properties (Table 4) (Raza et al., 2018). For instance, epoxidation of 
unsaturated linseed-oil-based PHA conducts to an increase in tensile strength and Young’s 
modulus (Ashby et al., 2000). Crosslinking of poly(3-hydroxybutyrate-co-3-hydroxy-10-
undecenoate) (P(3HB-co-3HU)) with thiolene leads to an increase in tensile strength with 
better properties for soft tissue replacement as well as a decrease of toxicity (Levine et al., 
2015). Carboxylation of P(3HO-co-3HU) enhance hydrophilicity of the polymer (Lee and Park, 
2000). Chlorination of P(3HO) increases glass transition and melting temperature while the 
same procedure on P(3HB) conducts to a decrease in melting temperature and increase in 
glass transition temperature (Arkin and Hazer, 2002). Grafting P(4HB) with polyvinyl alcohol 
(PVA) decreases crystallinity and enhances biodegradability of the final polymer (Torres et al., 
2015). Thiolation of poly(3-hydroxyoctanoate-co-3-hydroxyundec-10-enoate) (P(3HO-co-
3HU)) with Jeffamine® leads to obtain water-soluble copolymers with thermoresponsive 
behaviour (Fer et al., 2012).  
Another strategy to modify PHA properties consists on blending PHA with other polymers 
to obtain controllable thermal and mechanical properties and/or reduce costs.  Several 
examples of blending PHA with natural raw materials and synthetic biodegradable polymers 
have been proven with interesting results (Li et al., 2016). For instance, P(3HB) blended with 
lignin showed reduced crystallization and slower degradation ratios (Mousavioun et al., 2012, 
2013). Blending different types of PHA improve thermal and mechanical properties facilitating 
their applications. As an example, Yang and collaborators observed an improvement of the 
biocompatibility, referring to lower cytotoxicity to the tested cells, when films of P(3HB)/P(3HB-
co-3HHx) were employed instead of P(3HB) (Yang et al., 2002). This is explained by the 
degree of crystallization, which is reduced when the P(3HB-co-3HHx) is present (Kai et al., 
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2003). Increased Young’s modulus, tensile strength, thermal stability and tailorable 
biogregradability as well as improved biocompatibility with HMEC-1 cells, a vascular 
endothelial cell line, were obtained using P(3HB)/P(3HO-co-3HHx) blends comparing with 
P(3HO-co-3HHx) films (Basnett et al., 2013). P(3HB-co-3HV) blended with a synthetic polymer 
like PLA improve thermal stability and significant ductile plastic deformation (Gerard and 
Budtova, 2012). Blending mcl-PHA with PLA form excellent complementary materials, 
obtaining improved elongation at break, lower crystallization and higher biocompatibility 
(Takagi et al., 2004). In addition, the P(3HB-co-3HHx) blending with polycaprolactone (PCL)  
improve degradation, mechanical and biocompatibibility properties (Lim et al., 2013).  
 
Table 4. Chemical modifications of various PHA polymer types. 
Modification PHA type Functional group Properties improved Reference 
Epoxidation P(3HO-co-
3HU) 
Epoxide Decrease in melting 
temperature and increase 
in glass transition 
temperature 
(Park et al., 
1998a, 1998b) 
Epoxidation Unsaturated 
linseed oil 
based PHA 
Epoxide Increase in tensile 
strength and Young’s 
modulus 
(Ashby et al., 
2000) 
Epoxidation/ 
crosslinking 
P(3HO-co-
3HHx) 
P(3HO-co-
3HU) 
Peroxide Decrease in tensile 
modulus and very low 
tensile strength and tear 
resistance 
(Gagnon et al., 
1994) 
Epoxidation/ 
crosslinking 
P(3HO-co-
3HU) 
Succinic 
anyhydride 
Increase in glass 
transition temperature and 
gel content 
(Park et al., 
1998c) 
Crosslinking PHA-g-MA 
(maleic 
anhydride) 
Tea plant fibre 
(TPF) 
Increase water resistance 
and biodegradability, 
lower melt viscosities 
(Wu, 2013) 
Crosslinking P(3HB-co-
3HU) 
Thiol-ene Increase in tensile 
strength and 
biocompatibility 
(Levine et al., 
2015) 
Introduction 
 
 
47 
IN
T
R
O
D
U
C
T
IO
N
 
Modification PHA type Functional group Properties improved Reference 
Crosslinking P(3HU) Peroxide Decreased stiffness and 
flexibility of the polymer 
(Chung et al., 
2018) 
Carboxylation P(3HO-co-
3HU) 
Carboxyl group Improve hydrophilicity (Lee and Park, 
2000) 
Carboxylation P(3HO) Carboxyl group Improve hydrophilicity (Kurth et al., 
2002) 
Hydroxylation P(3HB-co-
4HB) 
Branched 
poly(ethyleneimine) 
Low cytotoxicity (Zhou et al., 
2012) 
Chlorination Unsaturated 
PHA 
Chlorine Increase the melting point 
and crystallinity 
(Arkin et al., 
2000) 
Chlorination P(3HO) Chlorine Increase in melting and 
glass transition 
temperatures 
(Arkin and 
Hazer, 2002) 
Chlorination P(3HB) 
 
Chlorine Increase in melting 
temperature 
(Arkin and 
Hazer, 2002) 
Fluorination P(3HB-co-
3HHx) 
Fluorine Thermo-chemical 
changes 
(Mahmood et 
al., 2013) 
Grafting P(3HB-co-
3HV) 
2-
hydroxyethylmetha
crylate (HEMA) 
Improve crystallinity and 
wettability 
(Lao et al., 
2007) 
Grafting PHA Tetrahydrofuran 
(THF) and 
poly(methyl 
methacrylate) 
(PMMA) 
Multi-graft copolymer with 
controlled molecular 
weight 
(Macit et al., 
2009) 
Grafting P(3HO) Vinyl-imidazol Increase antimicrobial 
activity and 
biocompatibility 
(Chung et al., 
2012) 
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Modification PHA type Functional group Properties improved Reference 
Grafting P(3HB-co-
3HV) 
N-vinylpyrrolidone Improve antibacterial 
activity 
(Saad et al., 
2012) 
Grafting P(3HB) Poly (vinyl acetate) 
(PVA) 
Decrease crystallinity and 
increase biodegradability 
(Torres et al., 
2015) 
Grafting P(3HO-co-
3HHX) 
Glycerol 1,3-
diglycerolate 
diacrylate (GDD) 
Increase hydrohilicity (Ansari and 
Annuar, 2018) 
Thiolation P(3HO-co-
3HU) 
Jaffamine Increase hydrophilicity 
and exhibit 
thermosensitive behaviour 
(Fer et al., 
2012) 
Blending P(3HB) P(3HB-co-3HHx) Increase biocompatibility 
and tensile strenght, 
reduce crystallization 
degree 
(Yang et al., 
2002; Kai et 
al., 2003; Ye 
et al., 2009) 
Blending P(3HB) P(3HO) Increase tensile strength, 
Young’s modulus and 
biocompatibility 
(Basnett et al., 
2013) 
Blending mcl-PHA Polylactide (PLA) Improved elongation at 
break, lower 
crystallization and higher 
biocompatibility 
(Takagi et al., 
2004) 
Blending P(3HB-co-
3HV) 
PLA Improve thermal stability 
and significant ductile 
plastic deformation 
(Gerard and 
Budtova, 
2012) 
Blending P(3HB) Lignin Reduced crystallization 
and slower degradation 
ratios 
(Mousavioun 
et al., 2013) 
Blending P(3HB-co-
3HHx) 
Polycaprolactone Improve degradation and 
mechanical properties 
(Lim et al., 
2013) 
See the Abbreviation section for full names. 
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Objectives  
The potential to confer novel functionalities to the PHA make these polymers highly 
attractive for biotechnological purposes. In this research we explore the use of previously 
described tools in the functionalization of PHA materials following in vivo and in vitro 
approaches that could expand their use in value-added applications. This general goal is 
approached through the following specific objectives: 
 
1. Characterize the interfacial properties of phasins at different hydrophobic-hydrophilic 
interfaces. 
2. Design an optimized tag to in vivo and in vitro display value-added proteins on 
the surface of PHA nanoparticles. 
3. Analyse the effect of PHA nanoparticles on pulmonary surfactant properties for their 
potential use as carriers to transport drugs to the lungs. 
4. Develop PHA nanoparticles functionalized with pulmonary surfactant proteins for lung 
therapy. 
5. Increase the variety and properties of PHAs through metabolic and genetic engineering 
tools. 
6. Explore postfunctionalization strategies to obtain novel polymers with value-
added properties. 
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1. Strains, media and growth conditions 
The bacterial strains used in this study are listed in Table 5. E. coli and P. putida strains 
were grown routinely in Lysogeny Broth (LB) medium (Sambrook and Russell, 2001) at 37°C 
and 30°C, respectively, in a horizontal shaker (200 rpm). Solid media were supplemented with 
1.5 % (w/v) agar. Appropriate antibiotics were added when needed: 50 µg/ml kanamycin, 100 
µg/ml ampicillin, 34 µg/ml chloramphenicol. For PHA production, the experiments were 
performed in LB or a nitrogen-limited minimal medium 0.1 N M63 (13.6 g of KH2PO4, 0.2 g 
(NH4)2SO4, 0.5 mg FeSO4·7 H2O to 1L, adjusted to pH 7.0 with KOH) supplemented with an 
excess of carbon source to get a C/N ratio of 40 mol/mol. The carbon source concentrations 
were equimolar: 20 mM glucose (C6H12O6) or 15 mM sodium octanoate (C8H15NaO2) or 11 mM 
(E)-undec-2-enoic acid (C11H20O2, from now on “undecenoic acid”) or 6.7 mM sodium (Z)-
octadec-9-enoate (C18H33NaO2, from now on “oleate”) or 6.7 mM sodium octadecanoate 
(C18H35NaO2, from now on “stearate”). To enhance the solubility of sodium stearate and sodium 
oleate, the stocks were prepared at 10 mM in a 70 mM cyclodextrin solution. Cyclodextrins 
were completely dissolved in water at high temperature. Minimal medium was supplemented 
with 1 mM MgSO4 and a solution of trace elements (1,000x solution contents: FeSO4·7H2O 
2.78 g, MnCl2·4H2O 1.98 g, CoSO4·7H2O 2.81 g, CaCl2·2H2O 1.47 g, CuCl2·2H2O 0.17 g, 
ZnSO4·7H2O 0.29 g, HCl 1 N to 1 L). When necessary, 3-methylbenzoate (3MB) and isopropyl 
β-D-1-thiogalactopyranoside (IPTG) were added at the specified concentrations. Due to the 
disturbance turbidimetry caused by PHA content, in specified cases growth was also monitored 
by colony-forming units (CFU) across time. To calculate cell viability, serial dilutions from 10-1 
to 10-7 were made in saline solution (0.9 % NaCl). Three different spots of each dilution from 
10-3 to 10-7 were plated on LB solid medium and colony-forming units (cfu) were counted. For 
each strain, three different experiments were carried out. 
Two different culture strategies were employed. In the one-stage culture strategy, a pre-
culture of the strains was cultivated overnight in LB medium, washed with saline solution and 
inoculated at OD600 0.3 in LB or M63 0.1N medium plus the specified carbon source. Two-
stage culture strategy includes two steps: (1) cells grown 16 h in shaking flask in LB medium 
and subsequently, (2) the cells collected from step 1 were washed with saline solution and 
diluted 1:2-fold in 0.1 N M63 medium supplemented with the selected carbon source for the 
PHA production (Escapa et al., 2011). 
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Table 5. Strains, plasmids and primers used in this study. Underlined nucleotides indicate 
restriction sites. 
Strains Description Reference 
Pseudomonas 
putida 
  
KT2440 Wild-type strain derived of P. putida mt-2 cured of 
the pWW0 plasmid 
(Bagdasarian et al., 
1981) 
KT2440 Δpha KT2440 strain with the cluster pha deleted  This work 
KT2440 Δpha+C1 Strain with phaC1 genes integrated into the 
genome of KT2440 Δpha under the control of P14a 
promoter 
This work 
KT2440 Δpha 
PHB 
KT2440 strain lacking pha cluster with phbCAB 
genes from C. necator integrated into the genome 
using the plasmid pMAB26 
This work 
KT2440 FadBA KT2440 strain lacking PP_2136 and PP_2137 
genes (fadB, fadA) 
This work 
KT2440 PHB KT2440 strain with phbCAB operon from C. 
necator integrated into the genome using the 
plasmid pMAB26 
This work 
KT2440 PsrA KT2440 derivative strain lacking psrA gene  (Fonseca et al., 
2014) 
Escherichia coli   
BL21 (DE3) Basic IPTG-inducible strain containing T7 RNAP 
(DE3) 
Novagen, Merck, 
Germany 
CC118 λpir Host strain for plasmid pTnS-1 (Herrero et al., 
1990) 
DH10B Host strain for plasmid construction Invitrogen, Thermo 
Fisher Scientific, 
USA 
DH5αλpir Host strain for plasmid construction De Lorenzo’s lab 
HB101  Host for plasmid pRK600  (Boyer and 
Roulland-Dussoix, 
1969) 
M15 [pREP4] Transformation strain for His6-protein expression 
containing the pREP4 plamid 
Qiagen N.V., 
Germany 
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Plasmids   
pAV1 pACYC184 derivative plasmid enconding phb 
operon from C. necator, CmR, ori p15A, TcR 
(Pais et al., 2014) 
pBG KmR GmR, ori R6K, Tn7L and Tn7R extremes, 
BCD2–msfgfp fusion 
(Zobel et al., 2015) 
pEMG Gene deletion vector; KmR, ori R6K, lacZ-α with 
two flanking I-SceI sites 
(Martínez-García 
and de Lorenzo, 
2011) 
pMAB20-GFP-
LYTAG 
pMAB20 derivative plasmid harboring the fusion 
BioF-GFP-LYTAG 
Biomedal S.L., 
Spain 
pMAB26 pCNB5 derivative plasmid containing phbC, phbA 
and phbB genes from C. necator inserted in the 
mini-Tn5 element; KmR, Ptrc 
(Pais et al., 2014) 
pProEX-
I+proSPBΔC 
pProEX-I derivative vector encoding the SP-B 
precursor proSPBΔC 
(Serrano et al., 
2006) 
pQE32 AmpR, ori ColE1, T5/lac Qiagen N.V., 
Germany 
pQE32-BioF pQE-32 derivative for the expression of His6-BioF This work 
pQE32-phaF pQE-32 derivative for the expression of His6-PhaF (Tarazona et al., 
2019) 
pRK600  CmR, ori ColE1, tra+mob+ of RK2 (Kessler et al., 
1992) 
pSB1 pSEVA238 derivative plasmid encoding the 
synthetic SP-B mature protein 
This work 
pSB2 pSEVA238 derivative plasmid encoding the SP-B 
mature protein preceded by the bicistronic design 
BCD2 
This work 
pSB3 pSEVA238 derivative plasmid encoding the 
chimeric protein BioF-SP-Bh, preceded by the 
bicistronic design BCD2 
This work 
pSEVA238 KmR, ori pBBR1, XylS/Pm (Silva-Rocha et al., 
2013) 
pSMinPN pSP1 derivative plasmid containing the minP 
sequence followed by a glycine rich region and a 
MCS 
This work 
pSMinP-1 pSPMinPN derivative plasmid containing the GFP 
sequence cloned into XhoI and HindIII sites 
This work 
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Plasmids   
pSP1 pSEVA238 derivative plasmid containing an RBS 
cloned into XbaI and HindIII sites 
This work 
pSP1Bi1-G pSP1 derivative plasmid harboring Bi1 fusion to 
GFP 
This work 
pSP1Bi2-G pSP1 derivative plasmid harboring Bi2 fusion to 
GFP  
This work 
pSP1Bi3-G pSP1 derivative plasmid harboring Bi3 fusion to 
GFP 
This work 
pSP1BioF-G pSP1 derivative plasmid harboring BioF fusion to 
GFP 
This work 
pSP1Bi4-G pSP1 derivative plasmid harboring Bi4 fusion to 
GFP 
This work 
pSW-I Helper plasmid used for deletions; AmpR, oriV 
(RK2), xylS/Pm  
(Wong and 
Mekalanos, 2000) 
pTnS-1 Tn7 transposase expression plasmid; AmpR, ori 
R6K, TnSABC+D operon 
(Choi et al., 2005) 
pTn7-M Plasmid for genomic integration of the xylS 
regulator into the Tn7 insertion site; KmR GmR, ori 
R6K, Tn7L and Tn7R extremes, standard multiple 
cloning site 
(Zobel et al., 2015) 
pTn7-ModC1 pTn7-M derivative plasmid harboring phaC1 gene This work 
 
Oligonucleotide primers 
BamHI-GFP-F GGAAGTCTGGATCCATGCGTAAAGGAGAAGAACT 
BCD2-F TAAGCAGAATTCGCCCAAGTTCACTTAAAAAGGAGAT 
BCD2-R GGCAGTGGGATCGGGAACATTAGAAAACCTCCTTAGCAT 
Bio1-F GGAAGTCCATATGGCTGGCAAGAAGAACAC 
Bio1-R ATGCACTCGAGCTTCACCAGCGAGTCGAACA 
Bio3-F GGAAGTCCATATGCTTAACAGCGCCATCTCG 
Bio3-R ATGCACTCGAGGCGCGACGAAATCGGCGTAA 
Bio4-R ATGCACTCGAGAGTGGTCGAAGACTTGGCAGT 
BioF R ATGCAAAGCTTAGCGCGACGAAATCGGCGTAA 
BioF-R GCGCGACGAAATCGGCGTAA 
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Oligonucleotide primers 
EcoRI-BCD2-F TAAGCAGAATTCGCCCAAGTTCACTT 
GFP-F GGAAGTCCATATGGAACCGCTCGAGATGATCATGGGAATTCATAA 
GFP-R CATGCAAAGCTTTATTTGTAGAGTTCATCCATGCCG 
F ΔPHA TCAGCCTCACCTACGCACCC 
R ΔPHA CTTCGACAGGTCCGGCATGA 
F1-For TTTGGATCCTTATCTAGGCATGGATGTAACGG 
F1-For-Sec CTTCCGGGTGTTGGTTTCTTAAC 
F1-Rev AAACAAAACCGGGGCACTAGGCACGATATGGAAGCTGAACTGTA 
F2-For CCTAGTGCCCCGGTTTTGTTT 
F2-Rev TTTAAGCTTGGTAATTTCGTTGAACACCACGC 
F2-Rev-SecB CGAAACCATGTAACCGACCAC 
MinPNt-F GGAAGTCTGAATTCAATAATTTTGTTTAACTTTAAGAAGGAGATAT
ACATATGGCTGGCAAGAAGAAC 
MinPNt-R ATATCAAGCTTCTGCAGGTCGACTCT 
PhaF_pQE32_fwd GATGGATCCGAGCTGGCAAGAAGAACACCG 
RpoD F ATGTCCGGAAAAGCGCAACA 
RpoD R TCGTTGACCTCCGCGTAAGTC 
SP-B F TCCCGATCCACTGCCGTAC 
SP-B R CAGGACCAGGCGGCAGACCA 
SPBgene-F  ATGTTCCCGATCCCACTGCC 
SPBgene-R  ACGCGGCCGCAAGCTTTTACATC 
SPBh-BioF-F TTA CGC CGA TTT CGT CGC GCT TCC CCA TTC CTC TCC CCT A 
SPBh-HindIII-R ATG CAA AGC TTT CAC ATG GAG CAC CGG AGG A 
TS1F ACCTGCCCGCCGAATTCCTGC 
TS1R GTTTTCCACCACTCATGAGCGTGACCAGTGATAAGGAACA 
TS2F GCTCATGAGTGGTGGAAAACCGC 
TS2R ATGCAGGATCCTGAATTTGAAACACATGGGGT 
XhoI-GFP-R ATATCCTCGAGTGGTACCGGCCACCCCCT 
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2. Molecular biology techniques 
DNA manipulations were performed as previously described (Sambrook and Russel, 
2001). All oligonucleotides used for strain and plasmid constructions are listed in Table 5.  
DNA agarose gel bands and PCR products were purified with illustraTM GFX PCR DNA 
and Gel Band Purification Kit (GE Healthcare, UK). Plasmid isolation was performed using the 
High Pure plasmid isolation kit (Roche Applied Science, Germany). Genomic DNA from P. 
putida KT2440 was isolated with the IllustraTM bacteria genomicPrep Mini Spin Kit (GE 
Healthcare, UK). DNA concentrations were measured with Nano Drop® 2000 
Spectrophotometer (Thermo Fisher Scientific, USA). All cloned inserts and DNA fragments 
were confirmed by DNA sequencing with fluorescently labeled dideoxynucleotide terminators 
and AmpliTaq FS DNA polymerase (Applied Biosystems Inc., Thermo Fisher Scientific, USA) 
in an ABI Prism 377 automated DNA sequencer (Applied Biosystems Inc., Thermo Fisher 
Scientific, USA). The enzymes Phusion® DNA polymerase, T4 DNA ligase and the restriction 
enzymes were acquired from New England Biolabs (USA).  
Transformation of E. coli strains was carried out by electroporation or by chemical 
transformation using the RbCl method (Sambrook and Russell, 2001). For electroporation, a 
20 ml overnight culture in LB medium was washed five times with 10 % glycerol and 
resuspended in a final volume of 500 µl. Aliquots of 100 µl were transferred to a 2 mm gap 
electroporation cuvette and 100 ng of plasmid were added. After a pulse of 25 µF, 2.5 kV and 
200 Ω, 1 ml of LB medium was added to the cells and incubated for 1 hour at 30 ºC at 200 
rpm. For chemical transformation, 100 ng of plasmid were applied to 100 µl aliquot of 
chemically competent cells. Cells were incubated for 15 minutes on ice and a heat shock was 
applied for 3 minutes at 37 ºC followed by 5 minutes on ice. After this, 1 ml of LB medium was 
added to the cells and incubated for 1 hour at 37 ºC at 200 rpm. 
Transformation of P. putida strains was performed following the protocol previously 
described (Choi et al., 2006). Briefly, a 20 ml overnight culture in LB medium was washed five 
times with 300 mM sucrose and resuspended in 500 µl of sucrose. Aliquots of 100 µl were 
transferred to a 2 mm gap electroporation cuvette and 100 ng of plasmid were added. After a 
pulse of 25 µF, 2.5 kV and 200 Ω, 1 ml of LB medium was added to the cells and incubated 
for 1 hour at 30 ºC at 200 rpm. 
 
3. Protein production and purification 
Overproduction of the PhaF protein from P. putida KT2440, containing a 6xHis fused to 
its N-terminus end, was achieved in recombinant Escherichia coli M15 [pREP4] harbouring 
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pQE32-phaF as described before (Tarazona et al., 2019).  For the overproduction of His-BioF, 
the nucleotide coding sequence was cloned into a pQE32 expression vector using the primers 
PhaF_pQE32_fwd and BioF R (Table 5) at BamHI and HindIII restriction sites, yielding the 
plasmid pQE32-BioF. This plasmid was transferred to E. coli M15 [pREP4] cells by 
electroporation (Sambrook and Russell, 2001). To overproduce His-BioF, cells were induced 
with 1 mM of IPTG at OD600 of 0.6 at 20 ºC. Proteins His-PhaF and His-BioF were purified by 
metal ion affinity chromatography (IMAC) using an ÄKTA chromatography system (GE 
Healthcare, USA). The eluted protein was dialyzed against 50 mM Tris-HCl 300 mM NaCl pH 
7.5 (His-PhaF) or 50 mM Tris-HCl pH 7 (His-BioF) and concentrated to approximately 5-10 
mg/ml using Amicon® Ultra 15 ml Centrifugal Filters (Merck, Germany) with a cutoff of 10,000 
NMWL (Nominal Molecular Weight Limit). Protein concentration was measured in a UV-Vis 
spectrophotometer at A280 (NanoDrop™, Bionova Scientific, Inc. USA) using Molar Extinction 
Coefficient (ε= 19480 M-1 cm-1 for both BioF and PhaF since there are no tyrosine and 
tryptophan residues in the C-terminal domain of PhaF) and the purity was analysed in 12% 
SDS-PAGE (sodium dodecylsulfate-polyacrylamide gel electrophoresis). Purified proteins 
were kept at -20ºC and stored for further assays (Figure 12). 
 
 
Figure 12. Production and purification of BioF. SDS-PAGE in 12% acrylamide gel stained with 
Coomassie blue. Lane 1, molecular weight standards; lane 2, supernatant fraction of the crude extract; 
lane 3, protein fraction not bound to the metal ion affinity chromatography (IMAC); lanes 3-9, fractions 
from column elution applying increasing concentrations of imidazole. 
 
4. Electrophoresis and Western blot analyses 
Sodium dodecylsulfate-polyacrylamide gel electrophoresis (SDS-PAGE) was performed 
using 12.5 % (except otherwise specified) and 4 % acrylamide in the separating and stacking 
gels, respectively. Unless otherwise indicated, electrophoresis was performed under reducing 
17 KDa
10 KDa
1 2 3 4 5 6 7 8 9 10
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conditions in the presence of 5% β-mercaptoethanol. Gels were stained with Coomassie 
brilliant blue R-250. For western blot analysis, proteins were transferred to polyvinylidene 
difluoride (PVDF) membranes in an electrophoresis chamber (Bio-Rad Laboratories Inc., USA) 
set at 300 A for 60 min. PVDF membranes were blocked overnight at 4 °C in PBS containing 
0.1 % Tween-20 and 1.5 % non-fat dried milk. Incubation with primary antibody was done using 
PBS containing 0.1 % Tween-20 and 1.5 % non-fat dried milk, for 2 h, at room temperature. 
Following washing with PBS containing 0.1 % Tween-20, the membranes were incubated for 
another 2 h with the secondary antibody (peroxidase-conjugated) and washed again. Western 
blot analysis was performed with the ECL Western Blotting Detection Kit (Amersham 
Biosciences, UK) according to the protocol described by the manufacturer. The primary 
antibodies used were anti-SP-B or anti-proSP-B polyclonal antibodies, generously provided by 
Dr. T. E. Weaver (Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA). In the 
first case, the secondary antibody was ani-rabbit IgG peroxidase-conjugated (Sigma-Aldrich, 
Merck, Germany) while in the latter case was anti-mouse IgG peroxidase-conjugated (Sigma-
Aldrich, Merck, Germany). 
 
5. Interfacial characterization of phasins 
5.1. Interfacial adsorption of phasins 
Adsorption of PhaF and BioF proteins into an air-liquid interface was assessed using a 
Wilhelmy Teflon trough (NIMA technologies, UK) as previously described (Lopez-Rodriguez et 
al., 2016). Briefly, the microbalance was filled with 1.8 ml of buffer (5 mM Tris-HCl, 150 mM 
NaCl, pH 7 prepared with double distilled water), and the ability of the proteins to adsorb into 
the air-water interface was determined after injection of the protein into the subphase at a final 
concentration ranging from 0.18 to 2.5 µM (His-PhaF) or 0.16 to 5 µM (His-BioF) by monitoring 
the variation of surface pressure (ΔΠ) over time. The subphase was continuously stirred at a 
constant temperature of 25 ºC. 
5.2. Interaction of PhaF and the BioF domain with preformed phospholipid 
films 
Lipid mixtures were obtained by dissolving the appropriate amounts of lipids in 
chloroform:methanol (2:1, v/v). The phospholipids employed were 1,2-dipalmitoyl-sn-glycero-
3-phosphocoline (DPPC), 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC), 1,2-
dipalmitoyl-sn-glycero-3-phosphoglycerol (DPPG), 1-palmitoyl-2-oleoyl-sn-glycero-3-
phosphoglycerol (POPG). E. coli Polar Lipid Extract (Avanti Polar Lipids, USA), containing 67% 
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phosphatidylethanolamine (PE), 23.2 % phosphatidylglycerol (PG) and 9.8% cardiolipin (CA), 
was also tested. Methanol and chloroform were obtained from Scharlab (Spain). 
The interaction of His-PhaF and His-BioF with monolayers made of different 
phospholipids (DPPC, DPPG, POPC, POPG, DPPC/POPG (7:3 w/w)) or of E. coli Polar Lipid 
Extract, pre-formed at different initial surface pressures (Πi), was also monitored by folloeing 
the changes in surface pressure (ΔΠ) over time after the injection of the protein into the 
subphase (5 mM Tris HCl, 150 mM NaCl, pH 7 prepared with double distilled water). The 
experiments were performed using a Langmuir-Wilhelmy Teflon trough (NIMA technologies, 
UK). Adsorption and insertion of the proteins into the phospholipid monolayer can be typically 
detected by an increase in the surface pressure.  
The different phospholipid monolayers were formed by spreading small volumes of the 
corresponding lipid solutions (1 mg/ml in chloroform/methanol 2:1, v/v) on top of the aqueous 
surface, until reaching different initial surface pressures (Πi). After 10 minutes to allow for 
solvent evaporation, the protein was injected into the subphase at a final concentration of 0.375 
µM. The subphase was continuously stirred at a constant temperature of 25 ºC. The highest 
increment in pressure (ΔΠ) and the critical insertion surface pressure (Πc) were determined 
from ΔΠ versus Πi plots for each specific phospholipid. 
5.3. Π-A compression isotherms and compression-expansion cycles 
The interfacial behavior of the protein PhaF during successive compression-expansion 
cycles was analysed using DPPC and DPPC/DPPG (7:3 w/w) phospholipid monolayers 
formed in a Langmuir-Blodgett ribbon trough (NIMA Technologies, UK) at constant stirring and 
temperature of 25 ºC. Phospholipid monolayers were formed on the top of the subphase (Tris 
HCl 5 mM, NaCl 150 mM, pH 7 prepared with milliQ H2O) as described above. After 10 minutes 
of solvent evaporation, different concentrations of the protein were injected into the subphase. 
The monolayers, either in the presence or in the absence of the protein, were compressed and 
expanded at 65 cm2/min for five cycles while surface pressure-area data (Π-A) were collected.   
 
6. Strains construction 
6.1. Construction of a pha deletional strain 
Following the protocol described by Martínez-García and de Lorenzo (2011) a deletional 
P. putida KT2440 Δpha has been constructed (Figure 13). Briefly, two pairs of primers (TS1F-
TS1R, TS2F-TS2R) were designed to amplify the flanking fragments of the pha cluster. An 
overlap PCR was carried out giving a product of 1 kb that was cloned into pEMG plasmid 
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(Table 5) using EcoRI and BamHI restriction sites. After cointegration, the pSW1 plasmid 
(Table 5) carrying a SceI restriction enzyme was induced activating the reparation innate 
system of the cell allowing the deletion of the pha cluster. Positive clones were selected by 
kanamycin resistance. Curation of the plasmid pSW1 was achieved after several passes. 
Genome sequencing reads for the P. putida KT2440 Δpha strain were deposited in the National 
Center for Biotechnology Information Sequence Reads Archive under the accession number 
SRX3133083 (2017) (http://www.ncbi.nlm.nih.gov/sra). 
 
Figure 13. Construction of a pha nule strain. A) PHA gene cluster with primers used for overlap 
extension PCR. B) Construction of P. putida KT2440 Δpha strain by applying the I-SceI system. 
 
6.2. Construction of a synthetic PHA producer strain 
For the construction of the strain carrying the PhaC1 polymerase, a modulable cluster 
was in silico designed (Figure 14). The synthesis was carried out by GenScript USA Inc. (USA). 
The cluster allows the introduction of different modules through Gibson Assembly technique 
(Iverson et al., 2016) by using the overlap neutral regions (named as “1, 2”). Besides, 
promoters and cargo genes can be easily exchanged using XbaI/XhoI/BamHI restriction sites. 
The cluster is flanked by two NotI sites to be cloned into pTn7-M transposon for integration in 
P. putida KT2440 Δpha genome. The phaC1 gene was introduced under the control of a 
constitutive synthetic promoter (P14a promoter) (Zobel et al., 2015) between the neutral regions 
called “P” and “1”, yielding the M1-PhaC1-T0 module. This module was synthetized modifying 
the nucleotide sequence of the phaC1 gene (Annex 1) to avoid the restriction sites specified 
phaC1 phaZ phaC2 phaD phaF phaI
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2
4
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3
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B
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in Figure 14 and introduced in the pTn7-M plasmid for integration in P. putida KT2440 Δpha 
genome. The corresponding strain was called P. putida KT2440 Δpha+C1. 
 
 
Figure 14. pha minimal cluster containing the M1-PhaC1-T0 module for the construction of P. 
putida KT2440 Δpha+C1. 14a: Promoter (Zobel et al., 2015); T0: Lambda T0 terminator. phaC1: PhaC1 
synthase coding gene from P. putida KT2440. P, S, 1 and 2: overlap regions for Gibson Assembly 
technique (Iverson et al., 2016). 
 
6.3. Construction of a FadBA mutant 
In this work, a P. putida KT2440 FadBA mutant strain was constructed. The PP_2136 
(fadB) and PP_2137 (fadA) genes, codifying a 3-hydroxyacyl-CoA dehydrogenase and 3-
ketoacyl-coenzyme A (CoA) thiolase respectively, have been deleted, creating a strain with 
weakened β-oxidation (Figure 15). This strain was constructed following the protocol described 
by Martínez-García and de Lorenzo (2011). Two pairs of primers (F1-For, F1-Rev and F2-For, 
F2-Rev) were designed to amplify the flanking fragments of the operon FadBA. An overlap 
PCR was carried out and the resulting product was cloned into the pEMG plasmid (Table 5) 
using EcoRI and BamHI restriction sites. After transconjugation, the pSW-I plasmid (Table 5) 
encoding an inducible I-SceI restriction enzyme was transformed, resulting in the 
recombinatorial deletion of the cluster. Positive deletion clones were selected by kanamycin 
resistance and curing of the plasmid pSW-I was done using several growth passages in LB 
medium. The genomic deletion was confirmed by colony PCR and sequencing using F1-For-
Sec and F2-Rev-SecB primers (Table 5).  
 
Figure 15. FadBA mutant construction. Schematic representation of the PP_2136 (fadB) and 
PP_2137 (fadA) genomic locus in P. putida KT2440 showing in red the genes deleted to create the P. 
putida KT2440 FadBA mutant strain (red), hypothetical genes (grey) and primers employed (blue 
crooked arrows).  
SacI
phaC1 (PP_5003)14a T0
XbaI
1P 2 S
KpnI KpnI SphI PstIBamHIXhoI
PP_2134 PP_2136
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6.4. Construction of P(3HB) producer strains 
For the construction of P. putida strains with the ability to produce P(3HB), pMAB26 
plasmid (Table 5), containing the genes for P(3HB) production (phbA, phbB and phbC) from 
C. necator under the control of the Ptrc promoter in a Tn-5 transposon, was transferred to the 
target strains by the filter-mating technique (Herrero et al., 1990) yielding P. putida KT2440 
PHB and P. putida KT2440 Δpha PHB. 
 
7. BioF library construction 
7.1. Protein structure prediction 
All predicted α-helical sequences (18-aa windows) of the N-terminal domain of phasin 
PhaF (BioF module) were analyzed for their hydrophobicity and amphipathicity with the 
HeliQuest utilities (http://heliquest.ipmc.cnrs.fr/) (Gautier et al., 2008) using the Fauchere and 
Pliska scale (Fauchère and Pliska, 1986) to calculate the mean hydrophobicity (H), while the 
mean hydrophobic moment (µH) was calculated according to Eisenberg et al. (Eisenberg et 
al., 1982). The hydrophobic moment is a measure of the amphipathicity of a helix where each 
amino acid is assigned a value (positive or negative) according to its hydrophobicity. Mean 
hydrophobicity is the sum of the hydrophobicity values divided by the number of residues 
(GenScript, s.f.). These analyses have been performed in collaboration with Prof. Jesús Sanz 
(CIB-CSIC). 
7.2. BioF-based tags design 
Based on structure prediction and hydropathic profile of BioF, several potential PHA 
affinity tags were constructed (for details see Figure 20 in Chapter 2). Different PCR products 
were obtained using the oligonucleotides Bio1-F and Bio1-R (Bi1); Bio1-F and Bio4-R (BioF); 
Bio2-F and Bio1-R (Bi2); Bio3-F and Bio3-R (Bi4); Bio2-F and Bio3-R (Bi3) with P. putida 
KT2440 genomic DNA as template (Table 5). The corresponding DNA fragments were cloned 
into pSP1 plasmid (Table 5) using NdeI and HindIII restriction enzymes, giving the plasmids: 
pSP1Bi1, pSP1Bi2, pSP1Bi3, pSP1Bi4 and pSP1BioF (Table 5). To allow the in vivo 
localization of each BioF-derived polypeptide, the gene coding for the GFP was amplified from 
pMAB20-GFP-LYTAG plasmid (Dinjaski and Prieto, 2013) by using the GFP-F and GFP-R 
oligonucleotides (Table 5) and cloned onto the 3’ end of the Bi segments between the XhoI 
and HindIII restriction sites. The plasmids were finally transformed by electroporation into P. 
putida KT2440. The most promising designs were also introduced into P. putida KT2440 
Δpha+C1. 
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8. Fluorescence microscopy  
Strains P. putida KT2440 and P. putida KT2440 Δpha+C1 carrying the corresponding 
plasmid: pSP1Bi1-G, pSP1Bi2-G, pSP1Bi3-G, pSP1Bi4-G or pSP1BioF-G (Table 5) were 
grown in PHA producing media for 24 h at 30 ºC and 200 rpm. The induction of the 
corresponding genes was carried out at OD600 0.8 by the addition of 1 mM 3MB. After 20 h of 
induction, the cells were directly observed through a Widefield Multidimensional Microscopy 
System Leica AF6000 LX for live cell imaging. 
 
9. PHA granule isolation 
Granules were isolated following the protocol previously described (Dinjaski and Prieto, 
2013). Bacterial cells from a 14 ml of an OD600 2-3 culture (except otherwise specified) were 
harvested by centrifugation at 12,000 xg for 20 min, suspended in 7 ml of 15 mM Tris HCl pH 
8.0, and disrupted twice by French Press (1,000 psi). The resulting suspension was centrifuged 
30 min at 12,000 xg, and the pellet fraction was dissolved in 5 ml of 15 mM Tris HCl pH 8.0 
and layered over 5 ml of 55 % glycerol. The solution was centrifuged at 17,000 xg for 30 min, 
and the isolated granules were washed twice with 15 mM Tris HCl pH 8.0 to remove the 
residual glycerol, and suspended into 0.5-1 ml of 15 mM Tris HCl pH 8.0.  
 
10. Stability of MinP-GFP attached to the PHA granule 
An aliquot of 100 µl of isolated granules from KT2440 Δpha+C1 (see PHA granules 
isolation) containing the plasmid coding for the corresponding BioF-derived polypeptide were 
collected by centrifugation, suspended in Triton X-100 at different concentrations (0.015%, 
0.15%, 1.5% in 15 mM Tris HCl pH 8.0, v/v) and incubated for 2 h at room temperature. The 
binding stability of Bi1-G proteins to the PHA granules was also tested under different 
temperature, pH and ionic strength conditions conditions as previously described (Moldes et 
al., 2004). An aliquot of 100 µl of purified granules from P. putida KT2440 Δpha+C1 (pSP1Bi1-
G) (see PHA granules isolation) was incubated for 2 h at 4 °C (i) in 100 µl of 15 mM Tris HCl 
pH 8.0 at different temperatures: -20, 4, 37 or 60 °C; (ii) in 100 µl of 0, 10, 100, 1000 mM NaCl; 
(iii) in 100 µl of 15 mM sodium citrate pH 3.0 or 5.0,  in 100 µl of 15 mM Tris-HCl pH 7.0 or 9.0. 
In all cases, after 2 h of incubation time, the granules were centrifuged at 12,000 xg for 15 min 
at 4 °C and the retained and soluble protein fractions were analyzed separately and estimated 
by SDS-PAGE as specified bellow. The percentage of discharged protein was obtained by 
subtracting the amount of protein liberated from the granules from the total amount of protein 
(sum of the soluble and insoluble fractions). Every assay was performed in duplicate.  
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11. Protein quantification 
The content of the different BioF-based-tag proteins on the granule surface was 
determined by imaging the bands separated on 12.5% SDS-PAGE and estimating the amount 
of protein present using the software package ImageJ. Pellet and granule protein fractions of 
the crude extract and the granule fraction isolated from each culture were separated by SDS-
PAGE and stained with Coomassie brilliant blue G-250 following the described protocol 
(Sambrook and Russell, 2001). The amount of protein anchored to the surface of the granules 
was estimated by imaging the Coomassie stained gels and taking into account the amount of 
isolated granules loaded in each well and calibrating against Precision Plus Protein Standards 
(Bio-Rad Laboratories Inc., USA). 
 
12. Design of pSMinPN plasmid 
For the construction of the pSMinPN plasmid, the sequence containing the minP gene 
followed by a linker and flanked by XhoI restriction sites and a multiple cloning site (MCS) was 
rationally designed and synthetized. The construction was amplified using primers MinPNt-F 
and MinPNt-R (Table 5) and cloned into pSEVA238 by using the EcoRI and HindIII restriction 
enzymes. The gene coding for green fluoresce protein (GFP) was cloned into the pSMinPN 
plasmid between the XhoI and HindIII sites to generate pSMinP-1 and transformed by 
electroporation into P. putida KT2440 Δpha+C1 (Table 5). 
 
13. Production and characterization of PHA nanoparticles 
The preparation of nanoparticles (NP) was carried out by the nanoprecipitation method 
(Budhian et al., 2007). Briefly 37.5 mg of P(3HHx-co-3HO) from Bioplastech Ltd (Ireland) were 
dissolved in 3.75 ml of acetone (Merck, Germany). After complete dissolution of the polymer 
in the solvent, the mixture was added dropwise using a glass Pasteur pipette over 1.25 ml of 
distilled water under constant stirring at 400 rpm. The solvent was evaporated on a rotary 
evaporator at 30 ºC under vacuum, obtaining nanoparticles at a final concentration of 30 
mg/ml.  
The particle size distribution of the NP suspension was determined by dynamic light 
scattering (DLS) using a Malvern Nanosizer NanoZS Instrument (UK) equipped with a 4 mW 
He-Ne laser (λ = 633 nm) at a scattering angle of 173°. Measurements of NP dispersions were 
performed in square polystyrene cuvettes (Sarstedt, Germany) and the temperature was kept 
constant at 25 °C. The autocorrelation function was converted in an intensity particle size 
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(1) 
distribution with ZetaSizer Software 7.10 version, to get the mean hydrodynamic diameter (Dh) 
and the particle dispersion index (PDI) between 0 (monodisperse particles) and 1 
(polydisperse particles) based on the Stokes−Einstein equation (equation 1), assuming the 
particles to be spherical: 
𝐷 =
𝑘𝐵𝑇
6πμ𝑅0
 
Where D is the diffusion coefficient (m2/s), µ is the solvent viscosity (kg/m·s), R0 the 
hydrodynamic radius (m), kB the Boltzmann’s constant (J/K= kg·m2/s2·K) and T the temperature 
(K). For each sample, the statistical average and standard deviation of data were calculated 
from 3 measurements of 11 runs each one.  
The zeta potential (ξ) of NP dispersions was determined by laser Doppler electrophoresis 
(LDE) using a Malvern Nanosizer NanoZS Instrument. The ξ statistical average and standard 
deviations were calculated from 3 measurements of 20 runs each one.  
The average diameter of the nanoparticles was estimated to be 239 ± 16 nm with a 
polydispersity index of 0.05 ± 0.03 and a zeta potential of -23 ± 1. 
 
14. Pulmonary surfactant purification 
Pulmonary surfactant purification was performed as previously described (Taeusch et 
al., 2005). Native surfactant (NS) was obtained from total bronchoalveolar lavages with ice-
cold 0.9 % NaCl buffer of fresh lungs from slaughtered adult pigs. Buffer was introduced in 
aliquots into the trachea and withdrawn. The recovered fluid was centrifuged at 1,000 xg for 5 
min to remove debris. The fluid was then ultra-centrifuged at 105,000 xg for 1 h. The 
supernatant was discarded, and the pellets were combined and homogenized in 24 ml 16 % 
NaBr and 0.9 % NaCl. To form discontinuous density gradients, 4 ml of the homogenate was 
put into each of six tubes, and then 6 ml of 13 % NaBr in 0.9 % NaCl was layered into each 
tube, and a final layer of 2.5 ml of 0.9 % NaCl was added. These tubes were centrifuged in a 
swinging bucket rotor at 120,000 xg for 2 h at 4 ºC. The lipid bands were removed, re-
homogenized in 0.9 % NaCl, and centrifuged (105,000 xg for 1 h). Pellets were placed in 0.9 
% NaCl buffer and centrifuged a second time. The concentration of pulmonary surfactant was 
measured as described by Rouser and collaborators (1966). This method quantifies the 
colorimetric signal of the phospholipid phosphorous present in the sample upon its conversion 
to inorganic phosphate using perchloric acid at 260 ºC. The reaction was performed at 100 ºC 
for 7 minutes after addition of water, ammonium heptamolybdate 2.5 % (w/v) and ascorbic acid 
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10 % (w/v). The resultant absorbance at 820 nm in a UV/Visible spectrometer was interpolated 
in a standard curve made with inorganic phosphate. The DPPC molecular weight (732.04 
g/mol) was used to calculate the concentration considering the high abundance of this 
phospholipid in the surfactant. 
 
15. Incubation of PHA nanoparticles with pulmonary surfactant and 
labelling 
Native surfactant (at a final concentration of 0.15 mg/ml) was mixed with PHA 
nanoparticles (NP) at different proportions (1:10, 1:1, 10:1 NP:NS, w/w) in 5 mM Tris-HCl buffer 
(pH 7.4, 150 mM NaCl). A control of the highest concentration of nanoparticles in the absence 
of native surfactant was also employed. The mixtures and the nanoparticles control were 
incubated for thirty minutes at 37°C with alternative cycles of stirring for 10 minutes and 
stopping for 10 minutes, to allow for the combination of both materials (NS and NP). After this 
first incubation step, a second one was performed for sample staining in the presence of 
BODIPY-PC (Molecular Probes, Life Technologies, USA), prepared into dimethyl sulfoxide at 
a concentration of 1 mg/ml) at 37°C for other thirty minutes to obtain a final molar ratio of 2% 
(dye/surfactant or dye/surfactant+nanoparticles) (Autilio et al., 2017).  
 
16. Surfactant adsorption test (SAT) 
Surfactant adsorption test (SAT) measures the accumulation of fluorescently labelled 
surfactant at the interface in a bulk solution of light-absorbing agent (Brilliant Black) during a 
specified period of time. The assay was performed as previously described (Ravasio et al., 
2008), measuring the accumulation of surfactant at the interface. This was done in 96-well 
microtiter plates, with a volume of bulk solution of 50 µl in each well carrying a light-absorbing 
agent (Brilliant Black, Sigma-Aldrich, Merck, USA) at a final concentration of 6.25 mg/ml. 
Analyses were performed with a FLUOstar OPTIMA Microplate Reader (BMG Labtech, 
Germany). The plate was inserted into the microplate reader, and after reaching 37°C, the 
obtained signals were taken as background values. 20 µl of the samples (containing 3 µg of 
NS and the corresponding amount of NP) were then injected into the bulk solution. 
Fluorescence intensity reaching the surface was followed at 37°C for 118 minutes (for 60 
readings). Fluorescence kinetic cycles were characterized by a measurement start time of 0.2 
second, a cycle time of 120 seconds, a shaking time of 3 seconds, double orbital shaking, and 
a fluorescence gain of 2000. Experiments were performed in triplicate, and results are reported 
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as relative fluorescence units (RFU). All data were corrected by subtraction of the measured 
background and labelled buffer of each run. 
 
17. Compression isotherms and epifluorescence 
DPPC:DPPG (7:3, w/w) phospholipid monolayers (PSL) were formed on the top of the 
subphase of a Langmuir−Blodgett ribbon trough (NIMA Technologies, UK) by spreading small 
volumes of the lipid mixture solutions (1 mg/ml in chloroform/methanol 2:1, v/v) on top of the 
aqueous surface at 25 ºC (5 mM TrisHCl, 150 mM NaCl, pH 7.4), until reaching a surface 
pressure of 1 mN/m (22-23 µg of lipid mixture). After 10 minutes to allow for solvent 
evaporation, different amounts of PHA nanoparticles (corresponding to 1:10, 1:1, 10:1 NP: PS, 
w/w) were homogeneously applied dropwise on the top of the monolayer. After 5 minutes, the 
monolayers were compressed at 65 cm2/min while surface pressure-area data (Π-A) were 
collected. The isotherm of NP was performed by applying 300 µg of nanoparticles on top of a 
clean aqueous phase. After 5 minutes, the layer was compressed at 65 cm2/min. 
For epifluorescence experiments, NBD-PC (Avanti Polar Lipids, USA) (1:100, probe:lipid 
molar ratio) was included into the lipid mixtures and the protocol was performed in the same 
way. In this case, the films were later transferred onto a glass slide that was previously 
immersed in the subphase, to form Langmuir−Blodgett films. The monolayers were 
compressed at the transfer rate of 25 cm2/min, thus allowing the correct transference without 
altering its structure (Wang et al., 2007). Fluorescence observation of supported films was 
performed under a Leica DM4000B microscope (Leica Microsystems, Germany) by using a 
Hamamatsu camera (C10600−10B ORCA-R2, Germany). Images were obtained at different 
positions from the transferred films, and subsequently assigned to the corresponding surface 
pressures achieved during film transfer at those positions.  
 
18. Pulmonary surfactant spreading 
These experiments were performed in a double surface trough connected by an 
interfacial bridge (a wet no. 1 Whatman filter paper) as previously described (Hidalgo et al., 
2017a) with some modifications. Briefly, NS samples previously incubated with or without PHA 
nanoparticles (1:0.6 NS:NP, w/w), were deposited by spreading a volume of 30 µl at an initial 
concentration of NS of 25 mg/ml onto the interface of the donor trough (300 mm2). The 
adsorption to the interface of the donor trough, and the diffusion through the interfacial bridge 
until the recipient trough, was monitored by changes in surface pressure in both compartments. 
Subphase volumes of 1.8 ml in the donor trough and 90 ml in the recipient trough consisted in 
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buffer 5 mM TrisHCl, 150 mM NaCl, pH 7.4. The material was collected from both troughs to 
analyse the presence of PHA through gas chromatography-mass spectrometry (GC-MS). 
 
19. SP-B constructions 
DNA manipulations were performed as previously described (Sambrook and Russell, 
2001). All oligonucleotides used for strain and plasmid constructions are listed in Table 5. The 
nucleotide sequence codifying for the mature module of SP-B protein was optimized through 
Codon Optimizer program, synthetized by ATG:biosynthetics GmbH (Germany) and cloned 
into pSEVA238 yielding pSB1 via XbaI and HindIII restriction sites. The bicistronic design 
BCD2 was amplified by using BCD2-F y BCD2-R primers and pBG plasmid as template (Table 
5). BCD2 includes a downstream region of the promoter that encodes a small peptide thereby 
reducing the effects of the 5 'non-coding region of the gene of interest. This design limits the 
formation of secondary structures of the mRNA in the 5’ non-coding region and fixes the 
translation efficiency. It contains two Shine-Dagarno sequences, the first (SD1) is followed by 
a small coding region and the second (SD2) is followed by the sequence of the gene of interest. 
The SP-B synthetic gene was amplified using SPBgene-F y SPBgene-R primers and pSB1 as 
template. An overlap extension PCR allowed to fusion both fragments that were introduced 
into the pSEVA238 plasmid using EcoRI y HindIII restriction sites yielding pSB2 plasmid. 
The N-terminal module of phasin PhaF from P. putida KT2440, BioF (Moldes et al., 
2004), was fused to the nucleotide sequence of the human pulmonary surfactant protein SP-
B. The BCD2 bicistronic element was included upstream the gene. Oligonucleotides EcoRI-
BCD2-F and BioF-R were used for amplification and SPBh-BioF-F and SPBh-HindIII-R were 
employed for SP-B amplification using the plasmid pProEx-1+proSP-BΔC as template. An 
overlapped PCR was carried out using EcoRI-BCD2-F and SPBh-HindIII-R oligonucleotides 
and cloned with EcoRI and HindIII restriction sites into pSEVA238 plasmid yielding pSB3 
plasmid.  
 
20. Real-time RT-qPCR assays 
For the extraction of total RNA, 20 ml of the cultures of the strains P. putida KT2440 
(pSEVA238) and P. putida KT2440 (pSB1) grown under PHA production conditions (with and 
without 3-MB) were employed. Samples were taken in exponential phase at OD600 0.6 and 
stationary phase at OD600 4-5. RNA purification was carried out following the indications of the 
RNeasy kit (Qiagen N.V., Germany). Contaminant DNA was removed by treatment with the 
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DNase and Removal treatment kit (Ambion, Thermo Fisher Scientific, USA) following the 
manufacturer's specifications. The RNA obtained was analyzed on 1.5% agarose gel (w/v).  
Synthesis of total cDNA was carried out in 20 μl of reaction containing 1 μg of RNA, 0.5 
mM dNTPs, 200 U of SuperScript II Reverse Transcriptase (Invitrogen, Thermo Fisher 
Scientific, USA) and 5 mM of random hexamers as primers, in the buffer recommended by the 
manufacturer. Samples were incubated for 5 min at 25 ° C, for 60 min at 50 ° C and 10 min at 
85 ° C. 
Real time PCR was performed in a LightCycler® 480 (Roche Life Science, Switzerland) 
using LightCycler® 480 SYBR Green I Master and 0.2 µM of each target primer and cDNA as 
template. The analysis was performed in three technical replicates from three biological 
samples as follows: 95ºC for 10 min; 45 cycles of 95ºC 30 s, 60ºC 30 s and 72ºC 30s with 
fluorescence measurement and a melting curve. The primers used for the housekeeping 
(rpoD) amplification were RpoD-F and RpoD-R and those employed for spB amplification were 
SPB-F and SPB-R. Analysis of the results was performed using the iQ5 Optical System 
Software (version 2.0) (Bio-Rad Laboratories Inc., USA). Results were analysed using the 2-
ΔΔCt method that analyze the relative changes in gene expression (Livak and Schmittgen, 2001): 
ΔΔCt = (Ct(𝑟𝑝𝑜𝐷) − Ct(𝑡𝑎𝑟𝑔𝑒𝑡))1 − (Ct(𝑟𝑝𝑜𝐷) − Ct(𝑡𝑎𝑟𝑔𝑒𝑡))0 
 
21. PHA quantification 
Monomer composition and cellular content of PHA were determined by gas 
chromatography-mass spectrometry (GC-MS) following the previously described protocol (de 
Eugenio et al., 2010a). PHA monomers were obtained by acid methanolysis with 2 ml of 
methanol acidified with 15 % H2SO4 (v/v) and 2 ml of 0.5 mg/ml of 3-methyl benzoate in 
chloroform as an internal standard. This mixture was incubated for 5 h in an oil bath at 100 °C. 
After cooling, 1 ml of distilled water was added to the mixture and centrifuged for 10 min at 
3,000 xg to separate the phases. A second step of extraction was performed to remove the 
residual H2SO4. Finally, a small amount of Na2SO4 powder was added to remove residual 
water. The organic layer was analysed using an Agilent 7890A GC (Agilent Technologies, 
USA) equipped with a DB-5HT capillary column (30 m length, 0.25 mm internal diameter, 0.1 
µm film thickness), and mass data were acquired and processed with an Agilent 5975C mass 
spectrometer (Agilent Technologies, USA). The oven temperature program was set at an initial 
temperature of 80 °C for 2 min, then from 80 °C up to 115 °C at a rate of 5 °C/min for efficient 
separation of peaks. Spectra were obtained as electron impacts with an ionizing energy for 
MS operation of 70 eV. 
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Biomass calculation was carried out as previously described (de Eugenio et al., 2010a). 
Fifty millilitres of culture medium were centrifuged for 30 min at 3,000 xg at 4 °C and pellets 
were lyophilized for 24 h and weighted. 
 
22. Polymer extraction 
The polymer extraction was performed following the protocol described by Liu and 
collaborators (2011). The lyophilized biomass of 100 ml of culture was extracted with 10 ml of 
chloroform and stirred on a stir plate at 90 ºC for 4 hours. A filtration step was included to 
remove the debris. The organic phase was evaporated in the fume hood until 5 ml of chloroform 
remains and then the polymer was purified by precipitation with 10 volumes (50 ml) cold 
methanol (-20 ºC) and manually agitated. The mixture was centrifuged at 8,500 xg for 15 
minutes and the supernatant (organic solvents) was removed. The residual organic solvents 
in the sample were evaporated in the fume hood for overnight. 
 
23. Thermal properties characterization 
Differential scanning calorimetry (DSC) measurements were conducted on a Diamond 
DSC (PerkinElmer Inc., USA). The polymers (extracted following the Polymer Extraction 
protocol) were exposed to successive thermal cycles (heat–cool–heat): first heating cycle from 
20 to 200ºC at 20ºC/min; isotherm at 200ºC, 5 minutes; cooling cycle at 20ºC/min until 20ºC; 
second heating cycle from 20 to 200ºC at 20ºC/min between −90°C and 180°C at 10°C min−1. 
DSC was used to determine melting temperature (Tm). This analysis has been carried out in 
AIMPLAS facilities (Spain). 
 
24. 1H NMR and FTIR spectroscopy 
All solvents were dried according to standard procedures. Reagents were used as 
purchased. All air-sensitive reactions were carried out under argon atmosphere. Nuclear 
magnetic resonance (NMR) spectra were recorded on a Bruker Avance 300 (1H: 300 MHz; 
13C: 75 MHz) spectrometer (Bruker Corporation, USA) at 25 ºC using partially deuterated 
solvents as internal standards. Fourier-transform infrared (FT-IR) spectra were recorded on a 
Bruker Tensor 27 (ATR device) spectrometer (Bruker Corporation, USA). UV-Vis spectra were 
registered on a Jasco-V630 spectrophotometer (Jasco, USA) equipped with a Peltier 
thermoelectric temperature controller. The spectra were recorded in the continuous mode 
between 200 and 800 nm, with a wavelength increment of 1 nm, a response time of 4 s, and 
a bandwidth of 1 nm. A 1 cm path length quartz cuvette (Hellma, USA) was used. These 
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analyses have been carried out in the group of Dr. Luis Sánchez (Facultad Ciencias Químicas, 
UCM, Spain). 
 
25. Synthesis of functionalized biopolymers PHOU-1 and PHOU- 2 
The postfunctionalization has been carried out in collaboration with the group of Dr. Luis 
Sánchez (Facultad Ciencias Químicas, UCM, Spain). The copolymer poly(3-
hydroxyoctanoate-co-3-hydroxyundecenoate) (from now on PHOU) with 75 % of 3-
hydroxyoctanoate (3HO) and 25 % of 3-hydroxyundecenoate (3HU) was employed for the 
postfunctionalization. Oligophenylene and dansyl derivatives were selected as fluorescent 
probes. These probes were properly funtionalized before coupling them to the PHOU 
derivatives. The synthesis of the oligophenylene derivative 1 has been carried out in a 
multistep synthetic sequence using p-hydroxybenzaldehyde (3) as starting material (Scheme 
1). Thus, alkylation of 3 with iodohexane using potassium carbonate as base enabled the 
obtaining of aldehyde 4, whose further Wittig-Horner coupling with dimethyl 4-
bromobenzylphosphonate afforded oligophenylene derivative 5. The presence of the bromine 
atom in 5 permits its further functionalization by the subsequent introduction of an aldehyde 
group in a one-pot Bouveault reaction. The sodium borohydride reduction of compound 6 
yields the hydroxymethyl oligophenyle derivative 1.  
 
 
Scheme 1. Synthesis of target chomophores 1 and 2. 
 
The synthesis of the dansyl derivative 2 is more straightforward and involves an 
amidation reaction between dansyl chloride with N-methyl aminoethanol using 1-ethyl-3-(3-
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dimethylaminopropyl carbodiimide hydrochloride (EDC) as activating agent and 4-
dimethylaminopyridine (DMAP) as catalytic base (Yi et al., 2008). All the products obtained 
have been characterized by the usual spectroscopic techniques and they exhibit the same 
features as previously described. 
 
 
Scheme 2. Synthesis of functionalized PHOUs PHOU-1 and PHOU-2. 
 
The terminal unsaturations in PHOU-3 enables its functionalization. Among the different 
approaches available for the post-polymerization functionalization of this kind of compounds, 
only the radical addition of thiols to terminal double bonds has been described to proceed 
satisfactorily (Hany et al., 2004). Thus, thiol-ene reaction between PHOU-3 and 11-
mercaptoundecanoic acid in the presence of azobisisobutyronitrile (AIBN) as radical initiator 
generates the carboxylic acid functionalized PHOU-4. The success of this strategy has been 
proved by 1H NMR and FTIR spectroscopy.  Importantly, 1H NMR further corroborates that this 
protocol does not affect the integrity of the PHOU polymer main chain. The versatility of the 
carboxylic acid present in PHOU-4 enables its further functionalization. Thus, by following a 
classical esterification procedure with the previously synthesized alcohols 1 and 2, PHOU-1 
and PHOU-2, endowed with electroactive moieties as pendant groups are obtained.  
PHOU-1 and PHOU-2 have enough solubility in common solvents to allow its 
characterization by usual spectroscopic techniques like 1H NMR and FTIR spectroscopy 
(Figure 16).  
 
PHOU-3 PHOU-4 PHOU-1
PHOU-2
PHOU-1 PHOU-2
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Figure 16. FTIR spectrum of the functionalized polymers PHOU-1 and PHOU-2 obtained by 
chemical postfunctionalization.
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INTRODUCTION 
Biosurfactants comprise a wide range of amphiphilic compounds produced by 
microorganisms with the ability to reduce the surface tension of liquids and form micelles and 
microemulsions between two different phases (Banat et al., 2010; Sunde et al., 2017). These 
molecules are widely distributed in nature playing essential roles in many biological processes, 
such as water/nutrient/gaseous transport and the maintenance of cellular structures. 
Biosurfactants include glycolipids, lipopeptides and proteins (Nakano et al., 1992; Ren et al., 
2013; Parra and Pérez-Gil, 2015; Schor et al., 2016). Surfactant proteins (also known as 
surface-active or interfacially active proteins) have been divided into three rough categories: i) 
those whose function is associated to lipids (e.g. pulmonary surfactant proteins); ii) small 
amphiphilic peptides (e.g. surfactin of Bacillus subtilis; and iii) non-lipid-associated globular 
proteins including hydrophobins, the most comprehensively studied surface-active proteins. 
Surface-active proteins are relatively rare, but they play many essential physiological roles. 
For instance, pulmonary surfactant proteins, specially the hydrophobic SP-B and SP-C, avoid 
the collapse of alveoli in mammalian lungs (Serrano and Pérez-Gil, 2006; Parra and Pérez-
Gil, 2015), and fungal hydrophobins reduce the surface tension at air-water interfaces enabling 
the growth of aerial structures (Valo et al., 2010; Khalesi et al., 2012). In this context, phasins 
have been postulated as a new family of surfactant proteins (Wei et al., 2011; Sunde et al., 
2017). They are located at the interphase between the hydrophilic cytoplasm and the 
hydrophobic core of the PHA granules playing an essential structural role by avoiding 
deleterious effects to the cell. Based on these properties, an interesting application has been 
recently developed by Wei and collaborators consisting in the potential use of phasins PhaP 
and PhaR from Aeromonas hydrophila 4AK4 as biosurfactants (Wei et al., 2011; Ma et al., 
2013). 
According to structural models and experimental evidences, the amphipathic character 
of PhaF anticipates high interfacial activity of this protein (Maestro et al., 2013). The present 
chapter is aimed at evaluating the surfactant properties of PhaF and its BioF domain, at 
different hydrophobic-hydrophilic interfacial environments, which may be relevant for a deeper 
understanding of PhaF activity. 
RESULTS  
1. PhaF adsorbs to the air-liquid interface 
Preliminary results demonstrated the ability of His-PhaF to spontaneously interact not 
only with PHA but also with phospholipid layers, which anticipates high surface-active 
properties in different hydrophobic-hydrophilic interfacial environments (Mato et al., 2019). 
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Figure 17 shows how the injection of His-PhaF protein into the subphase of a Wilhelmy trough 
immediately promotes adsorption of the protein into the air-water interface, reaching maximum 
surface pressure values of around 22 mN/m, similarly to other amphipathic proteins with affinity 
for interfaces (Dennison et al., 2005; Lopez-Rodriguez et al., 2016; Elderdfi and Sikorski, 
2018). These adsorption properties are influenced by the His-PhaF final concentration in the 
subphase. A specific concentration of 0.375 µM of His-PhaF was selected for further 
experiments to avoid saturation of the interface. 
 
Figure 17. Interfacial adsorption kinetics of PhaF from P. putida KT2440 to air-liquid interfaces. 
Π-t isotherms of different amounts of PhaF injected into the subphase (composed of 5 mM Tris HCl, 150 
mM NaCl, pH 7) of a Langmuir trough. 
 
Even when adsorption of the protein can be affected by other processes such as 
conformational changes, change on its orientation in the interface, or cooperative processes, 
some biophysical parameters like the surface excess concentration (Γ) and the surface 
molecular area (A) have been calculated from Gibbs adsorption equation 2 and equation 3 
(Elderdfi and Sikorski, 2018) (Table 6):  
Γ =  −
1
𝑅T
𝑥
𝛥𝜋
Δ ln 𝐶
 
𝐴 =  
1
Γ𝑁
 
where Γ is equivalent to the interfacial concentration in units of mol/m2, R is the gas 
constant = 8.314 J/K·mol, T is the temperature of the assay in K (298 K), Δπ is the maximum 
increment in surface pressure reached for each specific concentration and N is the Avogadro’s 
constant number = 6.022 × 1023 mol−1.  
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Table 6. Surface excess (Γ) and area/molecule of phasin PhaF. 
C 
(µM) 
Γ 
(mol/m2) 
A 
(nm2/molecule) 
0.18 3.35 x 10-7 4.96 
0.37 4.35 x 10-7 3.82 
0.74 5.1 x 10-7 3.25 
1.48 5.78 x 10-7 2.87 
2.96 6.45 x 10-7 2.57 
3.7 6.66 x 10-7 2.49 
 
This interfacial behaviour of phasin PhaF confirms its affinity to associate with 
hydrophobic surfaces and materials, establishing a interfacial layer that could be important to 
facilitate the existence in close proximity of hydrophobic/hydrophilic environments, a typical 
action of biosurfactants in general or of other interfacial proteins like oleosins (Lopez-
Rodriguez et al., 2016). In fact, previous results had already shown that PhaF has affinity to 
associate with other hydrophobic compounds such as oleic acid, or with chromatographic 
resins such as phenyl-sepharose (Maestro et al., 2013). 
 
2. PhaF inserts into preformed phospholipid monolayers 
Langmuir devices have been applied to increase our knowledge about phasin His-PhaF 
affinity for phospholipids of different chemical structure. Many other surface-active proteins 
have been widely studied using phospholipid monolayer models (Elderdfi and Sikorski, 2018). 
Various phospholipid species (DPPC, DPPG, POPC and POPG) were tested to compare the 
behaviour of the protein under several polarity and fluidity conditions. Besides, we have 
assayed a mixture of DPPC/POPG (7:3 w/w) that mimics the pulmonary surfactant 
environment (Lukovic et al., 2006) where some highly surface active proteins such as SP-B 
and SP-C are present (Lopez-Rodriguez and Pérez-Gil, 2014). Furthermore, the E. coli lipid 
mixture was employed to study His-PhaF interfacial activity in an environment that mimics the 
proposed surface of the PHA granule. 
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Figure 18. Insertion/adsorption kinetics of PhaF into preformed phospholipid monolayers. 
Monolayers of A) POPC; B) POPG; C) DPPC; D) DPPG; E) E. coli polar phospholipid extract or F) 
DPPC/POPG (7:3 w/w), were pre-formed at different initial surface pressures indicated in the plots. 
Insertion kinetics was monitored by following the increase in surface pressure upon injection of 0.375 
µM of PhaF into the subphase. 
 
The ability of His-PhaF protein to adsorb to interfaces previously occupied with different 
phospholipid monolayers was assayed at different initial pressures (Πi). In all cases, the 
injection of the protein produced a practically instantaneous increment in pressure (ΔΠ) as a 
consequence of the insertion of the protein into the interfacial film (Figure 18). At initial surface 
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pressures above 25 mN/m, injection of the same amount of protein into the subphase produced 
negligible effects in DPPC or POPC phospholipid monolayers (Figure 19A). However, the 
protein was still able to insert into DPPG or POPG monolayers even at higher initial surface 
pressures, suggesting a contribution of the electrostatic charge to establish and sustain these 
phospholipid-protein interactions (Figure 19B). The injection of the protein had a similar effect 
in both cases, indicating an equivalent contribution of the PG polar head to the interfacial 
activity of the protein, independently of the acyl chains and the concomitant chain packing of 
the films at 25ºC (Figure 19C). 
We have estimated the critical pressure of insertion (Πc), the theoretical maximum initial 
pressure that still allow the insertion of the protein within preformed monolayers (Lopez-
Rodriguez et al., 2016), by plotting the change in pressure caused by the injection of His-PhaF 
as a function of the initial pressure of the corresponding monolayer. This value gives a 
comparative idea about the nature and extent of protein-lipid interactions against different films 
formed at the interface. It has been proposed that lateral packing in lipid bilayers can be 
mimicked by monolayers reaching surface pressures of around 30 mN/m. As a consequence, 
proteins exhibiting Πc above this reference value are commonly considered as potential 
candidates to spontaneously interact or insert into lipid membranes (Plasencia et al., 2005). 
Πc calculated for His-PhaF differed depending on the phospholipid tested. The highest Πc 
values were obtained when PG polar head is present, yielding around 31 mN/m for DPPG, 31 
mN/m for DPPC/DPPG (7:3 w/w) and 30 for E. coli Polar Lipid Extract. The highest Πc value 
corresponded to the insertion of PhaF in POPG monolayers, with a critical pressure of insertion 
(Πc) of 37 mN/m, which could be indicative of specific interaction between the protein and this 
phospholipid specie. As mentioned before, this is probably due to a combination of 
hydrophobic and ionic forces because of the net charges of the protein (positive) and PG 
phospholipid (negative). The surface pressure reached by the protein adsorbed/inserted into 
DPPG films, 31 mN/m, indicates that higher packing due to the acyl chains likely prevents 
deeper insertion of the protein despite the polar head.  
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Figure 19. Critical insertion pressure of PhaF into phospholipid monolayers. Plots represent the 
increase in surface pressure (ΔΠ) versus the initial pressure (Πi) of preformed phospholipid monolayers 
made of: A) DPPC and POPC; B) DPPG and POPG; C) DPPC/POPG (7:3 w/w) and E. coli lipid extract, 
upon injection of PhaF into the subphase at a final concentration of 0.375 µM. The critical insertion 
pressure Πc of PhaF was calculated by the intersection of each of the plots with the abscise. R2 values 
were higher than 0.96 in all cases. 
 
3. Compression isotherms and compression-expansion cycles of 
phospholipid-PhaF films 
To study the behaviour and stability of the phospholipid/protein films, we have analysed 
the effect of different concentrations of His-PhaF protein during the compression of DPPC or 
DPPC/DPPG (7:3 w/w) phospholipid monolayers. We have also performed compression-
expansion cycles to analyse the possible hysteretic behaviour of the phospholipid/protein 
interaction upon cycling, which could be connected with the stability of the lipid/protein 
complexes at the interfacial environment. Films of both phospholipid compositions to assess 
the differences related to the presence of DPPG, the phospholipid towards which His-PhaF 
exhibited the highest affinity, have been chosen. The injection of increasing amounts of the 
protein into the subphase produced a clear effect on the compression isotherms of both 
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phospholipids (Figure 20), expanding the isotherm presumably as a consequence of the area 
occupied by the protein at the interface. The presence of the protein raises the surface 
pressure of the liquid-expanded-to-liquid-condensed transition plateau that occurs at 10 mN/m 
at 25 ºC in DPPC and DPPG monolayers. The isotherms of the phospholipids in the presence 
of the protein show an extended plateau at 25 mN/m likely associated to the squeeze-out of 
the protein at this surface pressure. This is in accordance with the results obtained for Πc 
values (Figure 19). The exclusion of the protein seems to be accompanied with the squeeze-
out of some lipid molecules as we can conclude from the lower area per molecule reached 
after His-PhaF total exclusion, suggesting lower amounts of phospholipids at the interface. 
This is particularly evident in the case of DPPC/DPPG (7:3 w/w) phospholipid monolayers. 
 
 
Figure 20. Compression Π-A isotherms of lipid and lipid-protein films. Films of (A) DPPC or (B) 
DPPC/DPPG (7:3 w/w) in the absence (blue) or presence of the different indicated concentrations of 
PhaF injected into a subphase of 5 mM Tris-HCl (150 mM NaCl pH7) at constant stirring and 25 ºC. The 
compression rate was 65 cm2/min.  
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The compression isotherms were comparable after successive compression-expansion 
cycles (Figure 21 and Figure 22). This indicates that most of the protein is reinserted into the 
interface when the area is increased and the surface pressure relaxes to be again squeezed-
out at the same surface pressure (25 mN/m) during compression, when a high packing is again 
reached.  
 
 
Figure 21. Effect of PhaF on the compression-expansion isotherms of DPPC interfacial films. 
Compression-expansion Π-A isotherms were obtained from A) PhaF at 0.036 µM; B) DPPC; C) DPPC 
plus 0.0036 µM PhaF; D) DPPC plus 0.018 µM PhaF; E) DPPC plus 0.036 µM PhaF injected into the 
subphase. 
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Figure 22. Effect of PhaF on the compression-expansion isotherms of DPPC/DPPG interfacial 
films. Compression-expansion Π-A isotherms were obtained from: A) DPPC/DPPG (7:3 w/w); B) 
DPPC/DPPG (7:3 w/w) plus 0.0036 µM PhaF; C) DPPC/DPPG (7:3 w/w) plus 0.018 µM PhaF; D) 
DPPC/DPPG (7:3 w/w) plus 0.036 µM PhaF injected into the subphase.  
 
4. BioF retains interfacial properties of the whole protein 
The N-terminal domain of PhaF phasin, BioF, is the responsible for the interaction with 
the PHA granule (Moldes et al., 2004). We have therefore studied the surface-active properties 
of the His-BioF domain at clean and phospholipid-occupied air-water interfaces using the 
Wilhelmy trough, in order to compare its behaviour with that of the whole protein. 
The surface pressure achieved by His-BioF at air-liquid interfaces is similar to that 
reached by the whole protein, around 22 mN/m (Figure 23). However, a faster adsorption of 
His-BioF is observed at equivalent molar concentrations. Based on the equations 2 and 3, we 
have calculated the protein surface excess concentration (Γ) and the area per molecule (A) 
(Table 7). 
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Figure 23. Interfacial adsorption kinetics of the N-terminal domain, BioF, from Pseudomonas 
putida KT2440. Π-t isotherms of different amounts of BioF injected into the subphase (composed of 5 
mM Tris HCl, 150 mM NaCl pH 7, prepared with double distilled water) of a Langmuir trough. 
 
Table 7. Surface excess and area/molecule of BioF. 
C 
(µM) 
Γ 
(mol/m2) 
A 
(nm2/molecule) 
0.16 4.87 x 10-7 3.41 
0.27 5.11 x 10-7 3.25 
0.625 5.73 x 10-7 2.89 
0.81 6.23 x 10-7 2.67 
1.25 6.49 x 10-7 2.56 
5 7.45 x 10-7 2.23 
Figure 24 and Figure 25 show how His-BioF is able to interact with different phospholipid 
monolayers preformed at the interface in a similar way as observed in the case of the whole 
protein, His-PhaF. We calculated even higher critical pressures of insertion in the case of His-
BioF in the presence of the tested phospholipid, including potential specific interaction with 
POPG with a critical pressure of insertion of 40 mN/m.  
The BioF N-terminal module consists of an α-helix which is responsible of the binding of 
PhaF to the PHA granules, partially unfolded in the absence of a hydrophobic support (Maestro 
et al., 2013). The present results suggest that the surfactant capacity of PhaF lies on the BioF 
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module. In fact, the areas occupied per molecule of PhaF and BioF are similar in all the films 
tested, suggesting that the same regions in both proteins could be inserting with a similar 
orientation at the air-water interface. Whether the PhaF conformational rearrangement in the 
presence of its support might be involved in the surfactant abilities of the protein, including the 
favourable exposure of the BioF module, similarly to the mechanism of other surface-active 
proteins such as beta-lactoglobulin (Husband et al., 2001), latherin (Vance et al., 2013) or 
immunoglobulin G (Sahin and Burgess, 2003), needs to be further confirmed.  
 
Figure 24. Critical insertion pressure of BioF into preformed phospholipid monolayers. The 
increase in surface pressure (ΔΠ) has been plotted versus the initial pressure (Π i) of phospholipid 
monolayer made of: A) DPPC and POPC; B) DPPG and POPG and C) DPPC/POPG (7:3 w/w), upon 
injection of the protein into the subphase at a final concentration of 0.375 µM. The intersection with the 
abscise estimates the critical insertion pressure Πc. R2 values were higher than 0.98 in all cases. 
 
PhaF and BioF also share their preference to bind phospholipids such as PG, with 
negatively-charged polar heads. Despite BioF has lower net charge at pH 7 (+5.2) than the 
whole PhaF protein (+25.2), the critical pressure of insertion is even higher in the case of BioF 
(above 30 mN/m against PG monolayers), which is commonly considered as indicative of 
potential to interact and insert into lipid bilayers (Lopez-Rodriguez et al., 2016). Although the 
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net charge of the His-tag is very low (+1.4) when compared to that of PhaF or BioF proteins, 
indicating a likely marginal contribution to the binding, we can not discard a possible minor 
influence in this result. The ability of PhaF, though its BioF module, to insert into phospholipid 
monolayers would certainly allow a simultaneous interaction of the phasin with a phospholipid 
layer, if these molecules were present, at the surface of the PHA granule and with the polyester 
located at the core of the inclusion.  
 
Figure 25. Insertion/adsorption kinetics of BioF into preformed phospholipid monolayers. 
Insertion kinetics of BioF into preformed phospholipid monolayers made of A) DPPC; B) DPPG; C) 
POPC; D) POPG; E) DPPC/ DPPG (7:3 w/w), prepared at different initial surface pressures, upon 
injection of 0.375 µM of BioF into the subphase.  
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INTRODUCTION 
Display of functional proteins on solid supports constitutes an important tool for many 
industrial and biomedical purposes (Hay et al., 2015). In this vein, nanoparticles functionalized 
with peptides and proteins may be widely employed for therapeutic applications, acting as drug 
carriers, anti-tumor and bactericidal drugs or cellular targeting moieties (Li and Loh, 2017). 
Strategies for protein immobilization vary depending on the matrixes employed and the final 
application, and they may include non-specific adsorption, chemical cross-linking or the use of 
affinity tags (Barbosa et al., 2015).  
As previously exposed, the complex architecture of PHA granules offers a toolbox to 
display molecules of interest on their surface (Parlane et al., 2017). GAPs have been used as 
anchoring tags to immobilize value-added proteins on the surface of PHA materials. Among 
GAPs, phasins have been widely used to functionalize PHA supports for a variety of 
applications, which have been extensively reviewed in the Introduction (Table 2). 
PhaF from P. putida is a prototypic and well characterized phasin (Moldes et al., 2004). 
It is a partially intrinsically disordered protein consisting of two domains connected by a leucine 
zipper motif that is responsible for its oligomerization (Maestro et al., 2013; Tarazona et al., 
2019). The 142-aa BioF module, that contain the N-terminal and leucine zipper domains, has 
been extensively demonstrated to bind to PHA granules (Moldes et al., 2004; Moldes et al., 
2006; Dinjaski and Prieto, 2013). Even more, the BioF domain binds not only to PHA materials 
in vitro but also to other hydrophobic-hydrophilic interfaces such as those containing 
phospholipids, making it a versatile tag to combine with a variety of hydrophobic supports 
(Maestro et al., 2013; Bello-Gil et al., 2018b). One of the drawbacks of applying the BioF tag 
for biomedical applications is its size, as a smaller peptide would be more desirable to reduce 
potential interferences with correct folding and activity of the tagged protein of interest (Terpe, 
2003). 
Based on the predicted structural model of PhaF that supports a conformational-
dependent binding of the BioF fragment to the PHA granule (Maestro et al., 2013), we have 
explored the ability of reduced segments of BioF to maintain the capacity to bind PHA, with the 
aim of finding a shorter, yet fully functional, BioF segment to be used as an efficient affinity tag 
for recombinant protein immobilization. 
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RESULTS  
1. BioF-based-tag design based on structure prediction 
The N-terminal domain of the PhaF (N-PhaF) is predicted to form a long, largely 
amphipathic α-helix that interacts with PHA through hydrophobic interactions while exposing 
the hydrophilic side to solvent or cytoplasmic fraction of the cell (Maestro et al., 2013). A 
HeliQuest analysis of the N-PhaF sequence shows the mean hydrophobicity (H) and the 
amphipaticity (i.e., hydrophobic moment, µH) of all possible 18-aa α-helical stretches within 
this (Figure 26A) and reveals fluctuations of both properties throughout the domain.  
 
Figure 26.  Evaluation of the structural aspects of the N-terminal domain of phasin PhaF (BioF) 
and design of a set of BioF-based fragments. A) Analysis of mean hydrophobicity (H) and mean 
hydrophobic moment (µH) of predicted α-helical stretches within the PHA binding and leucine zipper 
motifs of PhaF. Calculations were performed with the HeliQuest utilities using a sequence window size 
of 18 aa (Gautier et al., 2008). B) Schematic representation of the battery of BioF-based peptides 
designed. BioF amino acid residue positions are indicated above, pink corresponds to the N-terminal 
domain of PhaF, light pink corresponds to the conserved highly hydrophobic motif (WLAGLGI), blue 
corresponds to the central leucine zipper motif. 
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Interestingly, the region consisting of residues 33-49 simultaneously exhibits relatively 
high values of both H and µH, while residues 58-91 displayed the lowest values of H and 
µH. This latter region has been suggested to be natively unfolded in solution when not 
complexed with PHA (Maestro et al., 2013) (Figure 26A).  
To further determine the contributions of different segments of N-PhaF to the binding to 
PHA, we designed shortened versions of BioF (Figure 26B), differing in polarity, amphipaticity 
and length, namely Bi1, Bi2, Bi3 and Bi4.  The Bi1 segment contains the N-terminal region and 
the most hydrophobic stretches, including the 26-32 subsequence  (WLAGLGI) that is 
conserved in all PhaF-like phasin proteins and has been proposed to play a fundamental role 
in the interaction of phasins with PHA granules (Moldes et al., 2004). Bi2 contains the 33-49 
subsequence mentioned above, whereas Bi3 starts with the Bi2 segment and extends to 
contain the central leucine zipper region. Finally the Bi4 segment was designed on a different 
basis, as it only contains the predicted leucine zipper motif involved in PhaF oligomerization 
along with a short adjacent sequence (Maestro et al., 2013; Tarazona et al., 2019). 
 
2. In vivo localization of BioF-based fragments in P. putida KT2440 
To study the in vivo PHA binding properties of the different Bi segments we created C-
terminal green fluorescent protein (GFP) fusion constructs, which allowed for the determination 
of their intracellular localization. Each construct (named Bi1-G, Bi2-G, Bi3-G, Bi4-G and BioF-
G) was inserted in the pSEVA238 plasmid under the control of the XylS/Pm regulator/promoter 
system (Table 5) (Silva-Rocha et al., 2013) and introduced into P. putida KT2440.  
Cultures were grown in 0.1 N M63 plus 15 mM of octanoate to favour PHA accumulation, 
and the expression of the corresponding recombinant protein was induced at OD600 0.8 by the 
addition of 1 mM of 3-MB. After 24 h of growth, cells were observed through epifluorescence 
microscopy (Figure 27A). A common phenotype was detected in the strains containing BioF-
G, Bi1-G, Bi3-G and Bi4-G fusions, which showed an enriched ring of fluorescence surrounding 
the PHA granules (Figure 27A). This pattern suggests the localization of these fusion proteins 
on the surface of the granules. A different phenotype could be observed in cells containing the 
shortest segment Bi2-G, in which the protein was observed to be homogeneously distributed 
throughout the cytoplasm.   
This localization technique was complemented by glycerol gradient separation and 
isolation of PHA granules from cells expressing the Bi-G segments (see Materials and Methods 
section for details). Supernatant and pellet fractions of crude extracts and purified granules 
were separated by SDS-PAGE (Figure 27B). Bi1-G, Bi3-G and BioF-G proteins were detected 
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in the granule fraction while Bi2-G was only detected in the supernatant of the crude extract, 
validating the results obtained microscopically. Some Bi3-G and BioF-G proteins were also 
detected in the supernatant fraction of the crude extract. The inability to detect Bi4-G in any 
fraction by SDS-PAGE suggests either that this polypeptide is expressed at a low level, it is 
unstable, or forms aggregates that cannot enter the gel. Due to these possibilities the Bi4 
segment was discarded for further studies. 
 
 
Figure 27.  Localization of the different Bi segment-GFP fusion proteins in P. putida KT2440 after 
24 h of growth in 0.1 N M63 plus 15 mM of octanoate, induced at OD600 0.8 with 1 mM of 3-MB. 
BioF-G: P. putida KT2440 (pSP1BioF-G); Bi1-G: P. putida KT2440 (pSP1Bi1-G); Bi2-G: P. putida 
KT2440 (pSP1Bi2-G); Bi3-G:  P. putida KT2440 (pSP1Bi3-G); Bi4: P. putida KT2440 (pSP1Bi4-G). A) 
In vivo localization of BioF-based tag segments fused to GFP by epifluorescence and phase contrast 
microscopy. B) SDS-PAGE stained with Coomassie brilliant blue. The lanes contain the fractions 
isolated (SP: crude extract supernatant, P: crude extract pellet, GR: isolated PHA granules). EV: P. 
putida KT2440 (pSP1) empty vector. The volume loaded in each well was 15 µL. Red arrows indicate 
the predicted molecular weights of the recombinant proteins. 
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3. In vivo localization of BioF-based fragments in a P. putida KT2440 Δpha 
strain containing PhaC1 synthase 
Phasins covering the PHA granule have been demonstrated to interact with other granule 
associated proteins (GAPs) through the leucine zipper motif (Tarazona et al., 2019). In order 
to avoid potential interference by the presence of other GAPs on the surface of the PHA 
granule, a P. putida KT2440 mutant lacking the pha gene cluster was employed as a host to 
introduce solely the phaC1 synthase gene, sufficient to produce a low level of PHA (Tarazona 
et al., unpublished data). The phaC1 expression was under the control of a weak constitutive 
promoter and integrated in the chromosome via the pTn7-M transposon system. The resulting 
strain was named P. putida KT2440 Δpha+C1 and employed to confirm the ability of the Bi 
fragments to maintain their affinity for the PHA granule in the absence of other phasins and 
GAP proteins.  
The plasmids coding the different Bi segment-GFP fusion constructs were introduced 
into the Δpha+C1 strain and assessed for localization by epifluorescence microscopy. The Bi1-
G protein was observed to localize in rings surrounding the PHA granules as the control BioF-
G protein (Figure 28A), and both proteins were detected in the pellet and PHA granule 
fractions, with additional presence of BioF-G in the supernatant portion (Figure 28B). Bi3-G 
showed a similar localization pattern as BioF-G, with some fluorescence observed in the 
cytoplasm out from the granule surface (Figure 28A).  
These results are in agreement with the fractionation studies (Figure 28B), as some Bi3-
G and BioF-G were detected in the soluble fraction. Besides, some degradation of Bi3-G 
seemed to occur indicated as double red arrows in Figure 28B. In the case of Bi2-G, the 
fluorescence was found distributed inside the whole cell suggesting again that this segment is 
unable to bind to PHA granules (Figure 28A). This hypothesis is further confirmed by the lack 
of granule association in the fractionation experiment (Figure 28B).  
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Figure 28. Localization of the different Bi segment-GFP fusion proteins in P. putida KT2440 
Δpha+C1 after 24 h of growth in 0.1 N M63 plus 15 mM of octanoate, induced at OD600 0.8 with 1 
mM of 3-MB. Bi1-G: P. putida KT2440 Δpha+C1 (pSP1Bi1-G); Bi2-G: P. putida KT2440 Δpha+C1 
(pSP1Bi2-G); BioF-G: P. putida KT2440 Δpha+C1 (pSP1BioF-G); Bi3-G: P. putida KT2440 Δpha+C1 
(pSP1Bi3-G). A) In vivo localization of BioF-based tag segments fused to GFP by epifluorescence and 
phase contrast microscopy. B) SDS-PAGE stained with Coomassie brilliant blue. The lanes contain the 
fractions isolated (SP: crude extract supernatant, P: crude extract pellet, GR: isolated PHA granules). 
EV: P. putida KT2440 Δpha+C1 (pSP1) empty vector. The volume loaded in each well was 15 µL. Red 
arrows indicate the predicted molecular weights of the recombinant proteins. 
 
4. Stability of BioF-based structures on the PHA granule 
Previous work had demonstrated the stability of adsorption of BioF fusion proteins to 
isolated PHA granules through the application of a panel of detergents (Moldes et al., 2004; 
Bello-Gil et al., 2018a). One of the most effective detergents for disrupting the BioF-PHA 
granule interaction is Triton X-100. Thus, we used this detergent to assess the binding strength 
of the three efficient adsorption variants to PHA, Bi1-G, Bi3-G and BioF-G. PHA granules 
isolated from a 50 mL culture of P. putida KT2440 Δpha+C1 strains were resuspended in 
different concentrations of Triton X-100 and incubated 2 h at room temperature. After the 
treatment, the supernatant and pellet fractions of the suspension were separated, and the 
protein released from the granules was evaluated   by SDS-PAGE (Figure 29).  
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Figure 29. Coomassie stained SDS-PAGE of PHA granules extracted from P. putida KT2440 
Δpha+C1 expressing Bi1-G, Bi3-G or BioF-G. The stability of the Bi segments interacting with PHA 
granules was assessed by exposure to 0.15 % Triton X-100 for 2 hours. Lane M, molecular weight 
markers; Lanes 1, 1’, 3, 3’, 5 and 5’ respective Bi segments replicates in soluble fraction after 2 hours 
in 0.15 % Triton X-100; Lanes 2, 2’, 4, 4’, 6 and 6’ pellet fraction replicates of respective Bi segments 
retained on PHA granule after 2 hours in 0.15 % Triton X-100. Volumes loaded correspond to 15 µl of 
the supernatant and retained fractions obtained from the initial quantity of granules.  
 
The gel band intensities were used to calculate the percentage of Bi segment protein 
released from the PHA granules (Figure 30).  
 
Figure 30. Percentage of protein released from isolated PHA granules. Percentage of protein 
released from isolated PHA granules of P. putida KT2440 Δpha+C1 (pSP1Bi1-G), P. putida KT2440 
Δpha+C1 (pSP1BioF-G) and P. putida KT2440 Δpha+C1 (pSP1Bi3-G) after treatment for 2 h with 
various concentrations of Triton X-100 at room temperature and separating released (supernatant) and 
PHA-bound protein (pellet). Percentages refer to the ratio between soluble fraction to the total amount 
of protein (sum of soluble and insoluble fractions) using ImageJ to quantitate band intensities on 
Coomassie-stained SDS-PAGE.  
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The data indicate that Bi3-G presents the weakest interaction with the PHA granules, 
even in the absence of detergent. In contrast, the protein Bi1-G was not released in the 
absence of detergent and, in any case, it remained adsorbed in c.a. 90 % on the granule even 
at 1.5 % of Triton X-100, surpassing the native BioF-G. This indicates that Bi1 displays an 
affinity to PHA granules similar or even higher than BioF and therefore we focused our efforts 
to further evaluate this segment as a potential tag for biotechnological uses. 
Next, the stability of the binding between Bi1-G and PHA granules under different 
physicochemical conditions (temperature, ionic strength and pH) was evaluated. An aliquot of 
PHA granules containing Bi1-G was resuspended in buffer containing the specified condition 
and incubated for 2 h at the indicated temperature, or otherwise 4 °C, and followed by 
separation of the supernatant and pellet fractions. As can be observed in Figure 31, the protein 
mostly remained attached to the granule at the different temperatures (-20 °C, 4 °C, 37 °C and 
60 °C), ionic strengths (10 mM, 100 mM and 1 M NaCl) and pH's (pH 3.0, pH 5.0, pH 7.0 and 
pH 9.0) tested, although some degradation occurred upon incubation at pH 3.0.  
 
 
Figure 31. Coomassie stained SDS-PAGE of PHA granules extracted from P. putida KT2440 
Δpha+C1 expressing Bi1-G. The stability of Bi1-G interacting with PHA granules was assessed by 
exposure a range of temperatures (A), pH (B) and ionic strength (C) for 2 h. A) Lanes 1- 4 released 
soluble fraction after at -20 °C, 4 °C, 37 °C and 60 °C, respectively. Lanes 5-8, PHA granule retained 
protein fraction after treatment at -20 °C, 4 °C, 37 °C and 60 °C, respectively; Lane 9, untreated isolated 
granules. B) Lanes 1-4 released soluble fraction after treatment with pH 3.0, 5.0, 7.0 and 9.0, 
respectively. Lanes 5- 8, PHA granule retained protein fraction after treatment at pH 3.0, 5.0, 7.0 and 
9.0, respectively. Lane 9, untreated isolated granules. C) Lanes 1-4 released soluble fraction after 
treatment with 0, 10, 100 and 1000 mM NaCl, respectively. Lanes 5- 8, PHA granule retained protein 
fraction after treatment with 0, 10, 100 and 1000 mM NaCl, respectively. Lane 9, untreated isolated 
granules. Volumes loaded correspond to 15 µL of the soluble and insoluble fractions obtained after the 
treatment of the granules. 
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5. Influence of fusion proteins on PHA production and functionalization 
efficiency 
The Bi1 segment was considered a promising choice as an optimized PHA affinity tag 
due to the short size of the fragment, co-localization with PHA granules in vivo and its 
persistent interaction with PHA ex vivo under different physicochemical conditions, comparable 
to the BioF-PHA interaction. With the aim of studying the potential of Bi1 to be used as an 
affinity tag, the effect of the expression of this protein on PHA production and PHA granule 
functionalization was evaluated. Strains expressing BioF-G and Bi1-G, or harbouring an empty 
vector as a control, were analysed for PHA production (Table 8). 
 
Table 8. Quantification of PHA production by GC-MS and determination of PHA granule 
associated protein. 
 
The presence on any plasmid whether empty vector or BioF-G or Bi1-G encoding genes 
resulted in a roughly 20 % decrease in PHA production in wild type strains. Interestingly, in the 
Δpha+C1 background the presence of the whole BioF increased the percentage of PHA when 
compared to Bi1-G expressing or empty vector cells, 38 % versus ~27 %, respectively. 
Conversely, this effect was not maintained in the wild type strain, where the PHA accumulation 
was similar among all the strains containing plasmid. The concentration of granule-associated 
proteins was also measured by quantifying bands from SDS-PAGE isolated PHA granules. In 
the Δpha+C1 background, a higher amount of granule-associated BioF-G (8 mg per gram of 
PHA) was observed compared to Bi1-G (5.8 mg per gram of PHA). However, in molar terms, 
Strain 
CDW 
(g/L) 
PHA 
(% of CDW) 
Protein on granule 
surface 
(mg/g PHA) 
Protein on 
granule surface 
(µM/g PHA) 
KT2440 1.47 ± 0.04 71 ± 4 - - 
KT2440 pSP1 0.79 ± 0.00 51 ± 2 - - 
KT2440 pSP1BioF-G 0.91 ± 0.03 54.7 ± 0.6 6 ± 1 0.14 ± 0.03 
KT2440 pSP1Bi1-G 0.98 ± 0.05 54.7 ± 2.4 7.4 ± 1.3 0.2 ± 0.04 
KT2440 pSP1Bi2-G 0.82 ± 0.01 55 ± 2 - - 
Δpha+C1 0.73 ± 0.04 23 ± 2 - - 
Δpha+C1 pSP1 0.63 ± 0.00 28 ± 4 - - 
Δpha+C1 pSP1BioF-G 0.74 ± 0.05 38 ± 3 8.0 ± 0.7 0.17 ± 0.01 
Δpha+C1 pSP1Bi1-G 0.65 ± 0.01 27 ± 4 5.8 ± 0.9 0.16 ± 0.02 
Δpha+C1 pSP1Bi2-G 0.59 ± 0.01 27 ± 3 - - 
CHAPTER 2: Dissecting the polyhydroxyalkanoate-binding domains of phasins: rational design of a minimized affinity tag 
104 
little difference was detected between the two segments, with the presence of protein at 0.17 
µM and 0.16 µM per gram of PHA for BioF-G and Bi1-G, respectively.  
 
6. Construction of a plasmid based on MinP for PHA functionalization 
The Bi1 fragment demonstrated an interaction with PHA granules with superior 
functionalization efficiency and a strong stability making this construct suitable to be used as 
a tag to display functional proteins on the surface of PHA materials. Based on this optimized 
tag, hereafter named MinP, a fusion plasmid based on pSEVA238 was designed to simplify 
the production of protein-functionalized PHA nanobeads. The MinP fusion plasmid allows for 
induced expression under the control of xylS/Pm system and was modified to incorporate a 
RBS followed by the MinP tag to enable N-terminal fusions of the target protein (Figure 32A).  
 
 
Figure 32. MinP tag-based design for PHA functionalization. A) pSMinPN plasmid derived from 
pSEVA238 to generate MinP N-terminal fusion proteins for the production of customized protein 
functionalized PHA nanobeads. B) In vivo localization of the MinP-GFP expressed by the pSMinP-1 
plasmid with GFP inserted between the XhoI and HindIII restriction sites and introduced into P. putida 
KT2440 Δpha+C1 after 24 h of growth in PHA producing conditions. C) Nucleotide sequence of the 
minP-Linker-MCS construction. minP gene is represented in pink, Linker region in light green and 
restriction sites are underlined with different colours (NdeI, XhoI, KpnI, BamHI, PstI, XhoI, HindIII). 
T1
T0
Pm
RBS
XhoINdeI
XhoI
Acc651
KpnI
XmaI
SmaI
AvaI
BamHI
XbaI
SalI
HincII
AccI
BspMI
PstI
HindIII
NotI
minP Linker MCS
XhoI
pSMinPN
A
B
>minP-Linker-MCS
CATATGGCTGGCAAGAAGAACACCGAAAAAGAAGGCAGCTCCTGGGTCGGCGGGATCGAGAAAT
ACTCCCGCAAGATCTGGCTGGCGGGGCTGGGTATCTATTCGAAGATCGACCAGGACGGCCCGAA
GCTGTTCGACTCGCTGGTGAAGCTCGAGGCAGAAGCGGCAGCCAAAGAGGCGGCGGCAAAGG
AGGCAGCCGCAAAAGAAGCAGCAGCGAAGGAAGCGGCTGCGAAAGCCGCAGGCTCGGGTGGG
TCGGGTGGCTCCGGCGGACTCGAGGGTACCCGGGGATCCTCTAGAGTCGACCTGCAGAAGCTT
C
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The novel plasmid, called pSMinPN, contains a multicloning site (MCS) separated from 
the minP sequence by a glycine-rich linker region (Linker) which can be removed if desired by 
using two engineered flanking XhoI sites. This linker can also be replaced by other spacer 
regions or to include an intein site, expanding its potential applications. As a proof of concept, 
a minP-GFP fusion gene was constructed in pSMinPN, transformed into Δpha+C1, and co-
localization of MinP-GFP with PHA granules was observed by florescence microscopy 
following induction (Figure 32B).
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INTRODUCTION 
The inhaled route has become a promising way of entry of drugs not only for local but 
also for systemic treatments. The large respiratory surface (around 100 m2), the thin layer of 
epithelium and the high permeability and vascularization of lungs facilitate the absorption and 
targeting of drugs (Hidalgo et al., 2017b). Nevertheless, the complexity of the respiratory 
system introduces some aspects that need to be considered when drug delivery strategies 
through this route are designed. Lungs are complex structures in which gaseous exchange 
(breathing) occurs, capturing oxygen and eliminating carbon dioxide. The process of 
respiration takes place specifically in the alveoli, structures in a range of 75 to 300 µm of 
diameter (Orgeig et al., 2007). A thin layer of water covers the alveolar epithelium. On top of 
this aqueous layer, a lipid-protein surface-active material, called the pulmonary surfactant 
(PS), performs its essential physiological function (Figure 33). 
 
Figure 33. Schematic representation of pulmonary surfactant proteins interacting with surfactant 
phospholipid layers on the surface of the thin layer of water that covers the lung epithelium 
(Lopez-Rodriguez and Pérez-Gil, 2014). 
 
The important role of pulmonary surfactant lies in its capacity to reduce the surface 
tension of water facilitating the work of breathing. When water molecules are exposed to the 
air, interactions among them turn unbalanced and the contact area with the airspace tends to 
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minimize. The expansion of the surface area in contact with the air requires energy, known as 
surface tension. The pulmonary surfactant reduces that energy, decreasing the work the lung 
must invest in expanding the alveoli during inspiration and preventing their collapse. Besides, 
pulmonary surfactant constitutes the first barrier found by pathogens and harmful compounds 
(Lopez-Rodriguez and Pérez-Gil, 2014).  
The pulmonary surfactant is a mixture of approximately 90 % of lipids and 10 % of 
proteins (Veldhuizen and Haagsman, 2000). Surfactant proteins include the small hydrophobic 
SP-B and SP-C and the large hydrophilic SP-A and SP-D (Figure 33). The most abundant 
phospholipid is dipalmitoylphosphatidylcholine (DPPC), which is the main responsible of the 
PS surface-active properties; the two-saturated acyl chains enable DPPC to be packed very 
tightly in interfacial films, minimizing the exposure of water molecules to the air and reducing 
dramatically surface tension. However, the interfacial adsorption of lipids is not energetically 
favourable. DPPC adsorbs very slowly by itself at the interface. Furthermore, in the state of 
maximum compression, DPPC films are highly unstable and any disturbance can cause the 
collapse of the interfacial film. This has led to propose the existence of surfactant material 
below and associated to the interfacial monolayer. The phospholipids could efficiently be re-
incorporated in the form of a multilayer structure that favours the mechanical stability of the 
interfacial films, where the highly hydrophobic SP-B and SP-C proteins would play a key role. 
SP-C would allow the formation of these reservoirs and SP-B would promote the connections 
between the bilayers that constitute the reservoirs. Rapid re-extension of surfactant material, 
required to maintain low surface tension during the successive compression-expansion cycles 
of breathing, would thus be associated with the presence of these proteins (Bernardino de la 
Serna et al., 2013). Conversely, the hydrophilic SP-A and SP-D proteins are collectins and 
have mainly defensive functions. 
Lack or deficiencies of pulmonary surfactant are associated to several pathologies. One 
of the most well-known surfactant-related desease is the Neonatal Respiratory Distress 
Syndrome (NRDS), suffered by premature infants due to the immaturity of alveolar epithelial 
type II cells (ATII), where surfactant synthesis, assembly and secretion takes place  (Hallman 
et al., 2002). Other widely studied pathology is the Acute Respiratory Distress Syndrome 
(ARDS), a respiratory disease characterised by the inactivation of pulmonary surfactant as a 
consequence of inflammation and leakage of serum and plasmatic proteins into alveolar 
spaces (Pérez-Gil, 2008; Dushianthan et al., 2011). The surfactant replacement therapy using 
clinical surfactant preparations has improved enormously the survival of premature babies. For 
other diseases like ARDS, the effectiveness of exogenous surfactants is low due to its 
susceptibility to inactivation. The development of novel surfactant preparations is essential to 
obtain well-controlled composition in large amounts, at a reasonable price, as well as higher 
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resistance to inactivation. In this sense, much research has focused in the replacement of 
animal-derived surfactant therapies with synthetic surfactants based on SP-B and SP-C 
versions, produced synthetically or by overexpression of recombinant proteins in biofactories 
and reconstituted with selected synthetic lipids (Walther et al., 2007). 
The exceptional biocompatibility and biodegradability properties of PHAs make this 
material an excellent candidate for the development of nanocarriers and vehicles to transport 
drugs to the lung. The potential to immobilize molecules on their surface taking advantage of 
granule-associated proteins (GAPs) increases their use as drug targeting agents. However, 
exposure to particles of different materials and sizes can alter the functionality of pulmonary 
surfactant (Farnoud and Fiegel, 2012). The evaluation of the effect of PHA nanoparticles on 
pulmonary surfactant biophysical properties is thus a prerequisite to develop their potential 
application as drug delivery devices for lung therapy. Here, we address this issue by applying 
different biophysical techniques. In addition, to explore further the potential of PHA 
nanoparticles as delivery devices, we have approached the obtention of nanoparticles 
functionalized with the pulmonary surfactant protein B (SP-B) as a novel strategy for 
therapeutic applications.  
RESULTS 
1. Effect of PHA nanoparticles on pulmonary surfactant biophysical properties 
1.1. Effect of PHA on native surfactant adsorption capacity 
Pulmonary surfactant should show a fast interfacial adsorption, reaching and spreading 
into the interface from the sub-phase to rapidly form a surface-active interfacial film (Lopez-
Rodriguez and Pérez-Gil, 2014).  
A simple and cost-effective method like the surfactant adsorption test (SAT) allows for 
the evaluation of the adsorption properties of pulmonary surfactant in many samples 
simultaneously. In this Thesis, we have assayed the effect of different concentrations of PHA 
nanoparticles (NP) on the adsorption capacity of a sample of porcine pulmonary surfactant 
(native surfactant or NS). The native surfactant adsorbed very quickly during the first 30 
minutes as reflected by the rapid increase of fluorescence at the interface (Figure 34). After 
this point, the adsorption slowed down. The nanoparticles showed adsorption capacity by 
themselves since an increase of the fluorescence was observed at the interface only a few 
minutes after the injection of the sample at the bottom of the well. This occurred at high levels 
of nanoparticles. The adsorption kinetics of the native surfactant in the presence of low 
concentrations of PHA nanoparticles was not substantially affected while higher proportions of 
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PHA nanoparticles (NS:NP, 1:10, w/w) leaded to a faster accumulation of fluorescence at the 
interface. Despite these, there were not significant differences in the surface accumulation of 
fluorescently labelled surfactant during the experiment suggesting that the amount of material 
that reached the interface was similar independently of the proportion of PHA nanoparticles 
added. The results obtained in this experiment demonstrated that PHA nanoparticles did not 
affect negatively the adsorption of native surfactant.  
 
Figure 34. Surface accumulation of fluorescently labelled surfactant in the absence or presence 
of PHA nanoparticles at 37 ºC. The light blue line represents the native surfactant purified from pigs 
without any treatment (NS). Orange, pink and yellow lines represent the mixture of NS and PHA 
nanoparticles (NP) in 10:1, 1:1 and 1:10 proportions in w/w, respectively. The amount of NS in each well 
was constant (3 µg) in all the experiments. Dark blue and green lines represent the behaviour of 30 µg 
and 3 µg of plain NP, respectively. The short vertical grey lines represent SDs from the triplicate 
experiments.  
1.2. Effect of PHA nanoparticles on the compression isotherms and structure of 
phospholipid interfacial films 
To study the effects of foreign material on the structure and behaviour of surfactant 
interfacial films many authors typically use surface balances (Arick et al., 2015). The effects of 
different types of particles can be assessed on models consisting of interfacial monolayers 
made of lipid-protein mixtures or pure lipids present in the lung surfactant (Harishchandra et 
al., 2010; Farnoud and Fiegel, 2012; Guzmán et al., 2012). From the analysis of the surface 
pressure- area (Π/A) isotherms (compression isotherms), information about the structural 
organization of the monolayer can be obtained (Guzmán et al., 2012) and how it is perturbed 
by the presence of the nanoparticles. Here, we have analysed the effect of different 
concentrations of PHA nanoparticles on the compression isotherms and morphology of 
DPPC:DPPG (7:3, w/w) monolayers using a Langmuir−Blodgett surface balance equipped 
with a ribbon barrier. 
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Different concentrations of PHA nanoparticles were added over previously formed 
DPPC:DPPG (7:3, w/w) monolayers (PSL) to study the effect on the isotherms during 
compression. Plain DPPC:DPPG monolayers exhibited a plateau at around 10 mN/m 
corresponding to a liquid-extended (LE) to liquid-condensed (LC) phase coexistence (Figure 
35). The collapse pressure (maximal surface pressure achieved) was near 72 mN/m, which 
indicates that DPPC retains the ability to reduce the surface tension to values near 0 mN/m. 
The isotherm obtained for pure nanoparticles showed their capacity to form a layer film at the 
air-water interface by themselves, reaching a surface pressure of around 18 mN/m, confirming 
the ability of the nanoparticles to adsorb at the interface as observed in the SAT experiments. 
At this surface pressure, the particles started to be squeezed-out from the interface (Figure 
35B). The addition of PHA nanoparticles over the DPPC:DPPG monolayer did not affect the 
maximum surface pressure achieved by the mixture. Nanoparticles introduced a kink at 49 
mN/m that could indicate the exclusion at that pressure of the nanoparticles from the 
phospholipid monolayer. In addition, higher concentrations of PHA nanoparticles at the 
monolayer reduced the liquid-expanded-to-liquid-condensed coexistence plateau (LE-LC) and 
increased the area per molecule. In the presence of the highest concentration of PHA 
nanoparticles, another plateau region was detected at a pressure of 18 mN/m that was 
attributed to the exclusion of most of the NPs.  
 
Figure 35. Effect of PHA nanoparticles on surface pressure-area (Π-A) compression isotherms 
of DPPC:DPPG (7:3, w/w) monolayers. A) Surface pressure-area (Π-A) compression isotherms of 
DPPC:DPPG (7:3) monolayers (PSL) obtained after deposition of different concentrations of PHA 
nanoparticles (NP) (PSL:NP at proportions 10:1, 1:1 and 1:10, w/w). The phases identified in the 
different segments of the isotherms are labelled as LE (liquid-expanded), LC-LE (liquid-condensed/ 
liquid-expanded coexistence region) and LC (liquid-condensed). Collapse of the phospholipid 
monolayer occurs at 72 mN/m. B) Surface pressure-area (Π-A) compression isotherm of 300 µg of pure 
PHA nanoparticles. The experiments were performed by depositing the PHA nanoparticles on a 
previously formed phospholipid monolayer in a Langmuir-Blodgett ribbon trough. 
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The compression isotherms were analysed in terms of compressibility (Cs
-1 or 
compressibility modulus), calculated according to the equation 4: 
𝐶𝑠
−1 = −𝐴 (
𝑑п
𝑑𝐴
) 
Where A is the molecular area and Π is the surface pressure. The compressibility 
modulus of the DPPC:DPPG monolayer showed a minimum at a surface pressure of around 
9.5 mN/m corresponding to the LC-LE phase coexistence (Figure 36). The compressibility 
modules of the LE phase were in the order of 12-50 mN/m while those of the LC phase were 
in the range of 100-200 mN/m. Nanoparticles increased the maximum value of the 
compressibility module (from 147 to 200 mN/m), indicating that the stiffness of the monolayer 
increased. At low concentrations, the nanoparticles remained at the monolayer until 49 mN/m. 
At high concentrations, two exclusion points of the nanoparticles were observed. Most of them 
get excluded from the monolayer at 20 mN/m, since the compressibility value drastically 
decreased at the highest concentration of NPs. However, a low proportion of the NPs could 
maintain its association with the phospholipids up to surface pressure values of 49 mN/m. 
 
Figure 36. Compressibility modulus (Cs-1)-surface pressure dependencies for DPPC:DPPG (7:3, 
w/w) monolayers in the absence or presence of different concentrations of PHA nanoparticles 
(PSL:NP at weight ratios of 10:1, 1:1 and 1:10). The start of the LE-LC coexistence plateau and the 
exclusion of the PHA nanoparticles are indicated with black arrows.  
 
Epifluorescence images of DPPC:DPPG monolayers labelled with NBD-PC in the 
presence of different PHA nanoparticle concentrations were obtained at various pressures. 
The phase transition region started at a surface pressure of around 10 mN/m, in which DPPC 
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condensed domains can be detected as multi-lobed structures that exclude the fluorescent 
lipid (Figure 37). As observed in Figure 37, the domain formation was altered in the presence 
of increasing concentrations of PHA nanoparticles. At low surface pressures, the presence of 
high concentrations of nanoparticles lead to the formation of small dark domains that can be 
related with the earlier appearance of the condensed phase. Different patterns were observed 
depending on the concentration of nanoparticles applied. On the one hand, low concentrations 
of nanoparticles tend to increase the size of the domains suggesting that they promote 
condensation of the monolayer. In constrast, higher concentrations of nanoparticles seemed 
to increase the number of domains probably by favouring the nucleation whereas the size of 
the domains was smaller when compared with the film in the absence of NPs.  
 
 
Figure 37. Epifluorescence images of phospholipid films in the absence or presence of PHA NPs. 
Images correspond to films transferred onto glass supports at the indicated surface pressure. 
DPPC:DPPG (7:3, w/w) monolayers (PSL) contained NBD-PC (green) to allow for observation of 
phospholipid phase distribution. Different concentrations of PHA nanoparticles were added after 
phospholipid monolayer formation (PSL:NP at weight ratios of 10:1, 1:1 and 1:10). 
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1.3. Effect of PHA nanoparticles on the spreading capacity of pulmonary 
surfactant 
Once at the air-water interface, surfactant has to spread efficiently along it. The effect of 
PHA nanoparticles on PS spreading properties was evaluated after previous incubation of both 
materials during 30 minutes. To analyse the spreading properties, a device previously 
designed by Hidalgo and collaborators (2017a) was employed. The system consists of two 
different troughs connected by an interfacial bridge that monitors the movement of the 
surfactant material through the air-liquid interface following changes of surface pressure in 
both the donor and the recipient troughs.  
The deposition of the native surfactant material at the donor trough leaded to an 
immediate increase of the surface pressure to around 40 mN/m as a consequence of a very 
efficient transfer of phospholipid into the interface (Figure 38A). After approximately 5 minutes, 
the surface pressure began to increase in the recipient trough due to the diffusion along the 
connecting bridge to reach surface pressures of around 25 mN/m. The surface pressure at the 
donor trough maintained despite the transfer of material to the recipient trough indicating that 
a continuous adsorption and replacement of material takes place. As observed in Figure 38B, 
the interfacial transfer kinetics was not significantly affected when NS was previously incubated 
with NP. This confirms that the nanoparticles did not alter the adsorption and spreading 
capabilities of the NS. PHA nanoparticles themselves (Figure 38C) showed an adsorption 
kinetics similar to the one obtained using the Langmuir-Blodgett ribbon trough explained in the 
previous section, reaching a surface pressure of 16 mN/m but no changes of surface pressure 
were detected in the recipient trough. This indicates that in the absence of surfactant, the NPs 
cannot travel along the interface. 
The spreading capacity of pulmonary surfactant has been proposed as a potential 
delivery tool for hydrophobic drugs and devices (Hidalgo et al., 2015). In this sense, various 
attempts were made to study the transference of the nanoparticles in combination with 
pulmonary surfactant along the interfacial bridge. Material from both the recipient and the 
donor troughs was collected in order to evaluate the presence of PHA nanoparticles by GC-
MS. However, no signal was detected in the recipient trough. In the case of the donor trough, 
the signal was so low that made the quantification not feasible nor trustful (data not shown). 
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Figure 38. Adsorption/spreading isotherms of native surfactant (NS). A) In the absence and B) in 
the presence of PHA nanoparticles (NP) in a proportion 1:0.6 (NS:NP, w/w) showing the increase in 
surface pressure detected in the donor (pink line) or in the recipient (blue line) troughs over time. C) 
Adsorption/spreading isotherm of plain PHA nanoparticles monitored as the increment in surface 
pressure in the donor (pink line) and recipient (blue line) troughs over time. Standard deviation is shown 
in grey. 
 
2. Functionalization of PHA nanocarriers with the pulmonary surfactant protein 
B (SP-B) for therapeutic applications 
Since the combination of PHA nanoparticles with pulmonary surfactant showed 
negligible effects on the pulmonary surfactant functionality, here we explore the possibility to 
use different PHA materials in combination with the SP-B protein for therapeutic applications.  
The high hydrophobicity of pulmonary surfactant proteins has supposed a so-far 
insuperable challenge with respect to their production by overexpression in heterologous 
systems. Furthermore, they promote aggregation, fusion and disorganization of membranes, 
making these proteins extremely toxic for cells. The SP-B protein has been only produced as 
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a recombinant version of its precursor form (Serrano et al., 2006). Other strategies attempting 
the production of chimeras in which the protein is fused to a soluble protein module have 
allowed production of the recombinant surfactant protein SP-C (Lukovic et al., 2006) in bacteria 
but have failed in the case of SP-B.  
As a potential alternative, the hydrophobicity of SP-B could facilitate its binding to a 
hydrophobic support like PHA granules or nanoparticles through non-polar interactions or by 
taking advantage of GAPs fusions permitting the expression and compartimentalization of the 
protein without perturbing cell structures. Therefore, in this Thesis we have explored the 
possibility of producing immobilized SP-B protein in vivo in a hydrophobic support such as 
PHA. Several constructions based on SP-B were designed in different PHA producer strains. 
In this Thesis, we have selected to illustrate the most representative ones. 
2.1. P(3HB) granules functionalized with SP-B precursor 
The SP-B protein is synthetized in lung pneumocytes as a propeptide that is 
proteolitically processed along the secretion route of the protein upon assembly of surfactant 
membranes (Lopez-Rodriguez and Pérez-Gil, 2014). A previous work developed by Serrano 
and collaborators (2006) demonstrated the feasibility of producing a recombinant C-terminal 
truncated precursor of the human SP-B, called ProSP-BΔC, in E. coli C43 (DE3), a strain 
frequently used to overexpress toxic proteins (Dumon-Seignovert et al., 2004).  
Here, the plasmid pProEx-1 codifying the proSP-BΔC (Table 5) was introduced in an E. 
coli BL21 (DE3) carrying the plasmid pAV1 (Table 5), which encodes the genes for P(3HB) 
production under a constitutive promoter. In the pProEx-1 plasmid, the expression of the gene 
proSP-BΔC is driven by the Ptrc promoter inducible by IPTG. This strain was cultured in LB 
medium supplemented with 20 mM of glucose as P(3HB) precursor. The induction was 
performed with 1 mM of IPTG for the production of the protein. Granules were isolated using 
a glycerol gradient and the different cell fractions (supernatant and pellet of the crude extract 
and isolated granules) were separated in a SDS-PAGE gel and analysed through Western 
Blot. As observed in Figure 39, a protein of the expected weight (32 kDa) was observed, 
corresponding to the proSP-BΔC. It was only detected in the pellet and granule fractions 
confirming the successful production and immobilization of this protein on P(3HB) granules. 
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Figure 39. Western-Blot detection of proSP-BΔC protein. Detection of proSP-BΔC (~31 kDa) in E. coli 
(pAV1) (pProEx-1) strains growing in LB plus 20 mM of glucose and induced with 1 mM of IPTG for 24 
hours using anti-proSPB antibody onto a polyvinylidene difluoride (PVDF) membrane. Lane 1: 
supernatant protein fraction in E. coli (pAV1) (pProEx-1). Lane 2: supernatant of the crude extract in E. 
coli (pAV1) (pProEx-1+ proSP-BΔC). Lane 3: pellet of the crude extract in E. coli (pAV1) (pProEx-1). 
Lane 4: pellet of the crude extract in E. coli (pAV1) (pProEx-1+ proSP-BΔC). Lane 5: granule fraction E. 
coli (pAV1) (pProEx-1) Lane 6: granule fraction in E. coli (pAV1) (pProEx-1+ proSP-BΔC). The red arrows 
indicate the position of the heterologous protein. The volume loaded in each well was 30 µL. 
 
2.2. PHA granules functionalized with mature SP-B protein 
As previously exposed, the mature module of protein SP-B has never been produced in 
a recombinant way. Nevertheless, the high hydrophobicity of the PHA granule might offer a 
non-polar environment for binding during its production, which could avoid deleterious effects 
inside the cell. We explored this approach as a possibility to obtain SP-B immobilized on the 
PHA granules surface.  
The pSB1 plasmid (Table 5) containing the synthetic mature module of the SP-B protein 
was introduced into P. putida KT2440 and incubated in 0.1N M63 plus octanoate 15 mM. The 
induction was carried out from the beginning with 2 mM of 3MB and the different fractions of 
the culture were separated in a SDS-PAGE gel and analysed through Western Blot. Figure 40 
shows various unspecific bands corresponding to other proteins but no bands corresponding 
to the SP-B expected size were obtained by applying this strategy.   
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Figure 40. Western-Blot detection of SP-B protein. Detection of SP-B (~10 kDa) in P. putida KT2440 
strain growing in 0.1N M63 plus octanoate 15 mM and induced with 2 mM of 3MB for 24 hours using 
anti-SP-B antibody onto a polyvinylidene difluoride (PVDF) membrane. Lane 1: positive control (porcine 
purified SP-B). Lane 2: crude extract fraction in P. putida KT2440 (pSB1). Lane 3: crude extract fraction 
in P. putida KT2440 (pSEVA238). Lane 4: granule fraction in P. putida KT2440 (pSB1). Lane 5: granule 
fraction in P. putida KT2440 (pSEVA238). The volume loaded in each well was 30 µL. 
 
Various causes can be proposed to explain these results including problems at i) 
transcriptional level (promoter strength, lack of effective induction), ii) translational level 
(mRNA secondary structure, degradation, effective ribosome binding) or iii) post-translational 
level (proteases, toxicity). Problems at transcriptional level have been discarded by analysing 
gene expression through RT-qPCR (Figure 41).  
 
 
Figure 41. Fold change in gene expression analysis by RT-qPCR. Data represents the fold change 
in expression of the SP-B transcripts of the induced cultures relative to the non-induced culture. 1) P. 
putida KT2440 (pSB1) without adding 3MB. 2) P. putida KT2440 (pSB1) induced with 2 mM of 3MB at 
time 0h. 3) P. putida KT2440 (pSB1) induced with 2 mM of 3MB at time 4h. rpoD was used as 
housekeeping gene in all cases. 
 
1 2 3 4
SP-B
5
17 kDa
-
0
50
100
150
200
250
300
350
400
450
1 2 3
F
o
ld
c
h
a
n
g
e
CHAPTER 3: Exploring PHA nanoparticles as drug delivery carriers for lung therapy 
 
121 
C
H
A
P
T
E
R
 3
 
To rule out the potential translational level problems, the BCD2 element, that fixes the 
translation efficiency, was introduced upper stream of the SP-B sequence (pSB2 plasmid). The 
construction was introduced in P. putida KT2440 strain and cultured in 0.1N M63 plus 
octanoate 15 mM. The induction was performed using 2 mM of 3MB from the beginning. 
However, the strain containing the BCD2-SPB protein was unable to grow demonstrating the 
high toxicity of the protein. The induction after PHA production was explored obtaining viable 
cultures but no protein was obtained following this approach (results not shown). 
2.3. Functionalization of PHA granules with BioF-SP-B 
Since the production of the mature module of SP-B was unsuccessful due to its high 
hydrophobicity and toxic character, a third strategy was employed. We evaluated the use of 
BioF as a tag to obtain a SP-B chimeric protein immobilized on the surface of PHA granules. 
BioF was fused to SP-B and introduced in P. putida KT2440. The BCD2 element was also 
included in the construction. The strain P. putida KT2440 (pSB3) (Table 5) was cultured under 
PHA producing conditions (0.1 N M63) using octanoate as carbon source and induced with 2 
mM of 3MB after 16 hours of growth. In this case, the production of the protein was successful 
as occurred in the case of ProSP-BΔC. The BioFSP-Bh chimeric protein was detected in the 
pellet and granule fractions (Figure 42). The results confirm the potential to obtain 
functionalized PHA granules.  
 
 
Figure 42. Western-Blot detection of BioFSP-Bh protein. Detection of BioF-SP-Bh (~25 kDa) in P. 
putida KT2440 (pSEVA238) and P. putida KT2440 (pSB3) strains growing in 0.1 N M63 plus 15 mM 
octanoate and induced with 2 mM of 3MB after 16 hours of growth using anti-SP-B antibody. Lane 1: 
pellet of the crude extract in P. putida KT2440 (pSEVA238). Lane 2: pellet of the crude extract in P. 
putida KT2440 (pSB3). Lane 3: granule fraction in P. putida KT2440 (pSEVA238). Lane 4: granule 
fraction in P. putida KT2440 (pSB3). The red arrows indicate the position of the heterologous protein.
28 kDa
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INTRODUCTION 
Structural diversity is critical to define PHA potential applications since the physical, 
thermal and mechanical properties of the resulting polymer depend on the monomer 
composition and the molecular structure of the polymer.  
Control of the final PHA monomer composition requires a broad and precise knowledge 
about the complex PHA metabolic machinery that includes PHA accumulation through different 
metabolic pathways (Chen et al., 2016). When structurally related substrates like fatty acids 
are employed, a close relationship has been observed between their structure and length and 
the composition of the final PHA produced. As mentioned in the Introduction section, these 
substrates can be incorporated into PHA directly as β-oxidation intermediates without complete 
oxidation to acetyl-CoA. Non-related substrates can also be used for PHA production through 
oxidation to acetyl-CoA and entering in the de novo synthesis pathway (Figure 10) (Huijberts 
et al., 1992; Lee et al., 2001).  
The potential to edit and redirect the cell system using metabolic and genetic engineering 
lead to create PHA rationally designed (Nogales et al., 2008; Prieto et al., 2016). This has been 
demonstrated by controlling the carbon flow through the β-oxidation pathway, obtaining higher 
percentage of shorter monomers in the PHA when a repressor of this pathway, psrA, is deleted 
(Fonseca et al., 2014) or longer monomers when the β-oxidation pathway is weakened 
(Ouyang et al., 2007; Escapa et al., 2011; Liu et al., 2011). Additionally, novel functionalities 
can be incorporated into the polymer by chemical modifications (Table 4).  
This chapter aims at the development of a wide range of diverse PHA with different final 
monomeric composition and properties through a combination of fermentation conditions, 
carbon sources and metabolic and genetic engineering strategies performed in P. putida 
KT2240 strains. Furthermore, the postbiosynthetic modification of functionalized polymers is 
explored. 
RESULTS 
1. β-oxidation mutants to control monomeric composition 
In this work, we evaluated the influence of the β-oxidation cycle rates in PHA production 
and composition by using different mutated strains. On the one hand, a P. putida KT2440 
mutant lacking the genes fadA (PP_2137) and fadB (PP_2136) was constructed to slow down 
the β-oxidation pathway. On the other hand, a strain with the psrA repressor of the β-oxidation 
pathway deleted was used to evaluate the influence of an accelerated β-oxidation in PHA 
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production (Fonseca et al., 2014). The wild type strain was used as a control in all the 
conditions tested (Table 5). 
The long-chain fatty acid sodium stearate (C18H35NaO2) was employed as carbon source 
to obtain a varied composition of monomers in the final PHA. Long-chain fatty acids are also 
interesting as part of plant oils, one of the most employed substrates for PHA production from 
renewable sources. The first strategy for PHA production consisted in the one-culture 
approach carried out in nitrogen limited mineral medium (0.1 N M63) plus 6.7 mM of stearate. 
Following this strategy, the 0.1 N M63 medium was inoculated at OD600 0.3 with a preculture 
of the corresponding strain. The concentration of stearate employed was equimolar to the 
concentration of octanoate used in the previous sections in order to achieve the same amount 
of carbon getting a C/N ratio of 40 mol/mol, as explained in the Materials and Methods section. 
The wild type and P. putida KT2440 PsrA mutant were able to grow and produce high yields 
of PHA, 63 % of CDW and 51.3 % of CDW, respectively. However, P. putida KT2440 FadBA 
strain was not able to grow (Figure 43A). Therefore, the P. putida KT2440 FadBA mutant was 
cultured in LB rich medium to sustain the growth (Figure 43B) and stearate to produce PHA. 
Nevertheless, very little amount of PHA (0.46 % of CDW) was obtained (Table 9). Conversely, 
the wild type strain showed a different pattern when grown in these conditions obtaining a PHA 
production of 24 % of CDW (Table 9). 
 
Figure 43. Number of viable cells growing in PHA producing conditions. A) P. putida KT2440, P. 
putida KT2440 PsrA and P. putida KT2440 FadBA growing in 0.1N M63 plus stearate 6.7 mM. B) P. 
putida KT2440 and P. putida KT2440 FadBA growing in LB plus sodium stearate 6.7 mM. 
 
Since previous works with a  β-oxidation mutant of Pseudomonas confirmed the efficient 
production of PHA by applying the two-stage culture approach (Escapa et al., 2011) we tried 
this strategy, that has been described in detail in the Materials and Methods section. The 
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strains were first grown in LB medium for an overnight to obtain high yields of biomass. After 
this step, biomass was transferred to PHA producing conditions (0.1 N M63 plus 6.7 mM 
stearate). Following this approach, the percentage of PHA in P. putida KT2440 FadBA was 24 
% of CDW and the wild type produced around 37 % of CDW (Table 9).  
In order to increase PHA production yields we explored the influence on P. putida 
KT2440 FadBA and wild type strains of the addition of octanoate since this metabolite has 
been proposed to have an induction effect on the β-oxidation pathway or the PHA 
accumulation cycle (Escapa et al., 2013). With this purpose, the two-culture stage strategy 
was followed adding 1 mM of octanoate to the first and second steps. As observe in Table 9, 
the addition of octanoate had not an effect in the PHA yields. 
 
Table 9. Biomass and PHA production of different strains growing in various fermentation 
conditions and carbon sources.  
Results shown were obtained from three independent experiments. WT (P. putida KT2440), FadBA (P. 
putida KT2440 FadBA), MM (0.1N M63), C18 (6.7 mM stearate), C18+C8 (stearate 6.7 mM plus 
octanoate 1 mM), C18:1 (6.7 mM oleate), C18:1+C8 (oleate 6.7 mM plus octanoate 1 mM), C11: 1 
(undecenoic acid 11 mM). 
Media Carbon 
source 
Strain Culture 
approach 
Total CDW 
(g/L) 
PHA % CDW PHA g/L 
0.1N M63 C18 WT One-stage 1.15 ± 0.16 63.3 ± 1.4 0.81 ± 0.00 
0.1N M63 C18 PsrA One-stage 0.95 ± 0.22 51.7 ± 2.2 0.5 ± 0.1 
LB C18 WT One-stage 2.9 ± 0.02 24.4 ± 2.7 0.7 ± 0.08 
LB C18 FadBA One-stage 2.94 ± 0.06 0.46 ± 0.05 0.01 ± 0.0 
0.1N M63 C18 WT Two-stage 2.85 ± 0.12 36.9 ± 3.5 1.05 ± 0.06 
0.1N M63 C18 FadBA Two-stage 1.4 ± 0.02 24 ± 1 0.34 ± 0.02 
0.1N M63 C18+C8 WT Two-stage 2.57 ± 0.18 31.8 ± 3.5 0.82 ± 0.15 
0.1N M63 C18+C8 FadBA Two-stage 1.42 ± 0.05 23.3 ± 3.2 0.33 ± 0.06 
0.1N M63 C18:1 WT One-stage 1.04 ± 0.16 45.8 ± 2.5 0.47 ± 0.05 
0.1N M63 C18:1 PsrA One-stage 0.84 ± 0.12 32.9 ± 4.7 0.27 0.02 
0.1N M63 C18:1 WT Two-stage 2.8 ± 0.1 26.9 ± 1 0.74 ± 0.04 
0.1N M63 C18:1 FadBA Two-stage 1.18 ± 0.11 17.1 ± 0.8 0.2 ± 0.02 
0.1N M63 C18:1+C8 WT Two-stage 2.7 ± 0.1 23.8 ± 2.4 0.64 ± 0.08 
0.1N M63 C18:1+C8 FadBA Two-stage 1.32 ± 0.04 16.3 ± 1.4 0.22 ± 0.02 
0.1N M63 C11:1 WT One-stage 1.27 ± 0.15 22.5 ± 0.8 0.29 ± 0.04 
0.1N M63 C11:1 PsrA One-stage 0.6 ± 0.07 14 ± 1 0.1 ± 0.02 
LB C11:1 WT One-stage 3.02 ± 0.06 8.7 ± 2.9 0.26 ± 0.08 
LB C11:1 FadBA One-stage 3.55 ± 0.25 18.1 ± 0.9 0.64 ± 0.13 
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In addition, monomer composition was analyzed (Table 10). As previously reported for 
other precursors (Ouyang et al., 2007; Liu et al., 2011), the percentage of long-chain-length 
monomers in the P. putida KT2440 FadBA strain significantly increased when stearate was 
used as substrate. On the contrary, a higher proportion of short-length PHA monomers was 
obtained in the P. putida KT2440 PsrA strain. Similar monomer proportions were observed in 
the wild type strain following the one-stage and two-stage culture strategies. Both the wild type 
and the P. putida KT2440 PsrA strains contained a majority of C8 and C10, while P. putida 
KT2440 FadBA contained mostly longer monomers: 47.4 % and 21.5 % of C12 and C14, 
respectively.  
 
Table 10. Monomer composition of β-oxidation mutant strains growing in different fermentation 
conditions and long-chain fatty acids as carbon sources.  
Results were obtained from three independent experiments with a SD < 15%. C6 (3-hydroxyhexanoate), 
C8 (3-hydroxyoctanoate), C10 (3-hydroxydecanoate), C12 (3-hydroxydodecanoate), C14:1 (3-
hydroxytetradecenoate), C14 (3-hydroxytetradecanoate). WT (P. putida KT2440), FadBA (P. putida 
KT2440 FadBA), MM (0.1N M63), C18 (6.7 mM stearate), C18:1 (6.7 mM oleate), C18+C8: (stearate 
6.7 mM plus octanoate 1 mM), C18:1+C8 (oleate 6.7 mM plus octanoate 1 mM), One-st (one stage), 
Two-st (two stage). Bold type numbers correspond to the most relevant results. 
Media Carbon 
source 
Strain Culture 
approach 
Monomer composition (% of molar PHA) 
C6 C8 C10 C12 C14:1 C14 
MM C18 WT One-st 2.71 29.27 41.57 20.08 - 5.93 
MM C18 PsrA One-st 3.94 43.74 37.07 12.38 - 2.87 
LB C18 WT One-st 3.79 40.4 42 12.76 - 1.06 
LB C18 FadBA One-st 0.28 3.6 49.1 36.63 - 10.44 
MM C18 WT Two-st 2.52 26.3 43.33 20.29 - 6.27 
MM C18 FadBA Two-st 0.08 1.1 27.83 47.44 - 21.51 
MM C18+C8 WT Two-st 3.06 34.6 41.45 17.27 - 3.56 
MM C18+C8 FadBA Two-st 0.99 36.86 13.69 27.59 - 20.2 
MM C18:1 WT One-st 3.93 36.8 40.61 12.79 5.87 - 
MM C18:1 PsrA One-st 5.62 51.85 33.42 6.83 2.27 - 
MM C18:1 WT Two-st 2.51 29.62 38.86 15.44 13.1 0.47 
MM C18:1 FadBA Two-st 0.06 1.16 28.84 34 28.22 7.73 
MM C18:1+C8 WT Two-st 3.42 40.62 37.06 12.26 6.52 0.11 
MM C18:1+C8 FadBA Two-st 1.37 51.93 12.69 16.09 12.78 5.14 
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The addition of 1 mM of octanoate to the culture influenced the final PHA composition 
obtaining considerable higher proportions of C8 and C6 in the P. putida KT2440 FadBA strain 
(Table 10). All these experiments demonstrated that it is possible to tailor the monomer 
composition. 
 
2. β-oxidation mutants growing in functionalized precursors 
Unsaturated precursors have been traditionally used to incorporate chemical 
modifications in the lateral chain of PHA monomers in a post-biosynthetic way (Raza et al., 
2018). Double bonds are susceptible of crosslinking, grafting, carboxylation and other chemical 
reactions that may contribute to enhance the physicochemical properties (Arkin and Hazer, 
2002) as well as the biocompatibility and biodegradability of the final material (Levine et al., 
2015). As described in the Introduction and demonstrated in the previous section, the 
manipulation of the β-oxidation pathway leaded to a controllable monomer composition. Taking 
this into account, the use of unsaturated precursors by the modified strains could be interesting 
to obtain controllable unsaturated monomer ratios. This has been achieved before by co-
metabolic strategies using saturated and unsaturated precursors in different proportions (Park 
et al., 1998a). 
Firstly, we tried the long-chain unsaturated precursor sodium oleate (C18H33NaO2). 
Similar behavior to that obtained for stearate was observed using its unsaturated counterpart. 
Feeding the wild type and P. putida KT2440 PsrA mutant with oleate through the one-stage 
culture approach leaded to a PHA production of 45.8 % of CDW and 32.9 % of CDW, 
respectively (Table 9). However, two-stage culture approach implied a reduction of PHA 
production in the wild type strain to 26.9 % of CDW while the P. putida KT2440 FadBA mutant 
produced 17 % of CDW in the same conditions (Table 9).  
The use of sodium oleate as precursor leaded to the presence of C14:1 unsaturated 
monomers in all the strains while neither longer nor shorter unsaturated monomers could be 
detected (Table 10). One of the most interesting aspects was the increment of C14:1 in the P. 
putida KT2440 FadBA strain (28.2 %) compared to 13.1 % obtained in the case of the wild 
type strain following the two-stage culture strategy. P. putida KT2440 PsrA growing with this 
substrate through the one-stage culture approach contained a low percentage of this monomer 
(2.3 %). Low proportions or absence of C12 and C14 were obtained in the wild type and P. putida 
KT2440 PsrA strains, while P. putida KT2440 FadBA contained 34 % and 7.73 % of C12 and 
C14, respectively.  
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Co-metabolic strategies were also applied for the wild type and P. putida KT2440 FadBA 
strains using oleate as carbon source through the two-stage culture approach by adding 1 mM 
of octanoate to both stages. As occurred in the case of stearate, the PHA production was no 
affected by the addition of octanoate while the percentage of C6 and C8 increased dramatically 
in the case of the P. putida KT2440 FadBA strain. 
Additionally, as one of the most employed substrates to incorporate unsaturated 
monomers in the polymer is the 10-undecenoic acid (Hazer, 2010) we decided to test the 
differences in the PHA for the mutants constructed. When P. putida KT2440 FadBA was grown 
in rich medium plus 10-undecenoic acid, the strain was capable to grow (Figure 44) and 
produced PHA in an efficient way (Table 9). After 24 hours of growth, the production of PHA 
was significantly higher in the P. putida KT2440 FadBA mutant, obtaining 0.64 g/L of PHA, 
versus the 0.26 g/L of PHA of the wild type. The higher production of PHA in the P. putida 
KT2440 FadBA using the one-stage culture strategy and rich medium was previously reported 
for other medium-chain-length fatty acids (Ouyang et al., 2007).  
 
 
Figure 44. Number of viable cells of P. putida KT2440 and P. putida KT2440 FadBA growing in 
LB plus 11 mM 10-undecenoic acid. 
 
Related to the monomer composition (Figure 45A), a near homopolymer was obtained 
when fed with 10-undecenoic acid, yielding 96.3 % of C11:1 and a small proportion of C9:1 (3.7 
%). The wild type strain contained a similar percentage of C9:1 monomers (50.3 %) and C11:1 
(47.7 %) with little amounts of C7:1 (1.96 %). This culture strategy was the only tested due to 
the inability of the P. putida KT2440 FadBA mutant strain to grow in minimal medium.  
Besides, we compared the production and monomer composition of the P. putida 
KT2440 PsrA mutant and the wild type strain in 0.1N M63. The PHA production when 10-
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undecenoic acid is used as sole carbon source was lower in the P. putida KT2440 PsrA strain 
(0.1 g/L) while the wild type produces 0.28 g/L of PHA. No significant differences were 
observed in the monomer composition, only a slightly higher percentage of C9:1 in the mutant 
strain P. putida KT2440 PsrA than the wild type (Figure 45B). 
 
Figure 45. Monomer composition of β-oxidation mutant strains growing in different fermentation 
conditions using 11 mM of undecenoic acid as carbon source. A) Relative monomer content of P. 
putida KT2440 FadBA and P. putida KT2440 growing in LB medium plus 11 mM of undecenoic acid for 
24 hours. B) Relative monomer content of P. putida KT2440 PsrA and P. putida KT2440 growing in 0.1 
N M63 plus 11 mM of undecenoic acid for 24 hours. Results shown were obtained from three 
independent experiments with a SD < 15%. OH-C7:1 (3-hydroxyheptenoate), OH-C9:1 (3-
hydroxynonenoate), OH-C11:1 (3-hydroxyundecenoate). 
 
3. β-oxidation mutants growing in glucose   
Non-related carbon sources are incorporated into the PHA through the de novo synthesis 
of fatty acids instead of β-oxidation (Figure 10). As the P. putida KT2440 FadBA mutant is 
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affected in the β-oxidation pathway, we expected a similar PHA production and monomer 
composition than the wild type growing in carbohydrates. We have verified that these 
parameters were not affected by the deletion of β-oxidation genes (Figure 46). The production 
of PHA in the wild type and the P. putida KT2440 FadBA strains in 0.1N M63 plus 20 mM of 
glucose did not show significant differences, yielding 24.42 % of CDW and 20.64 % of CDW 
respectively. The monomer content was similar in both strains, with a slightly higher 
percentage of C12:1 in the case of the wild type strain. On the contrary, P. putida KT2440 PsrA 
strain contained lower amount of PHA and higher proportions of C8 and C10, what could be 
explained by the PHA increased degradation ratios due to the accelerated β-oxidation.  
 
Figure 46. Percentage of PHA per total biomass and monomer composition of β-oxidation mutant 
strains growing in 0.1 N M63 plus 20 mM of glucose. P. putida KT2440 FadBA, P. putida KT2440 
PsrA and P. putida KT2440 strains percentage of PHA per total biomass and monomer molar 
percentage of total PHA after 24 hours of growth. Results shown were obtained from three independent 
experiments with a SD < 15%. OH-C6 (3-hydroxyhexanoate), OH-C8 (3-hydroxyoctanoate), OH-C10 (3-
hydroxydecanoate), OH-C12:1 (3-hydroxydodecenoate), OH-C12 (3-hydroxydodecanoate). 
 
4. Efficient in vivo P(3HB)-P(3HO) blends production using recombinant 
strains 
As exposed in the Introduction, the PHA synthase of P. putida KT2440 incorporates 
longer monomeric units than C6. To incorporate shorter units, we explored the expression of 
the genes for P(3HB) production from C. necator. The pMAB26 plasmid (Table 5), a derivative 
plasmid of miniTn5, containing the genes for P(3HB) production (β-ketothiolase (phbA), 
NADPH-dependent acetoacetyl-CoA reductase (phbB) and PHB synthase (phbC) under the 
control of the Ptrc promoter, was introduced in P. putida KT2440 Δpha. The operon was 
integrated into the genome of P. putida KT2440 expecting the production of a blend of scl-PHA 
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and mcl-PHA. These blends are usually generated by producing both polymers separately in 
C. necator and P. putida, isolating them, and dissolving the appropriate amounts of the 
polymers in a solvent. Here, an easier and cost-effective way to produce these blends in an 
only step in vivo is proposed. Since these genes are controlled by the Ptrc promoter, different 
proportions P(3HB) can be obtained by varying the concentration of the inductor. Following 
this approach, we developed a strain capable of produce 63.3 % P(3HB)/P(3HO-co-3HHx) 
blend of CDW (0.78 g/L) growing in 0.1 N M63 plus 15 mM of sodium octanoate inducing with 
1 mM of IPTG, obtaining a composition of 57 % P(3HO-co-3HHx) of CDW and 43 % P(3HB) 
of CDW (Table 11). The P. putida KT2440 Δpha strain with phb genes showed an efficient 
P(3HB) production of 68.67 % of CDW or 1.47 g/L, similar to the yields of P(3HO-co-3HHx) 
obtained in P. putida KT2440 growing in these conditions. 
 
Table 11. Biomass, PHA production and monomer composition of P. putida KT2440 and P. 
putida KT2440 Δpha strains carrying the phb operon from C. necator growing in 0.1N M63 plus 
15 mM of octanoate after 24 hours.  
Carbon 
source 
Strain Total 
CDW 
(g/L) 
PHA  
% CDW 
PHA 
g/L 
Monomer composition (% of molar 
PHA) 
C4 C6 C8 
C8 
 
WT PHB 
 
1.41 69.7 
 
0.99 
 
- 4.93 
 
95.07 
 
C8+ 
 
WT PHB 1.23 63.3 0.78 43.04 4.025 52.94 
 
C8 
 
Δpha PHB 
 
0.64 
 
ND ND 
 
ND ND ND 
C8 + 
 
Δpha PHB 
 
2.14 
 
68.7 1.47 100 ND ND 
Results shown were obtained from three independent experiments with a SD < 10%. WT PHB (P. putida 
KT2440 PHB), Δpha PHB (P. putida KT2440 Δpha PHB), C8 (15 mM octanoate), C8+ (15 mM 
octanoate plus 1 mM IPTG for the induction of Ptrc promoter), ND (not detected). 
 
5. A panel of PHA with different melting points  
The melting point of various selected polymers developed in the previous sections were 
determined by DSC. The polymer produced by the wild type strain growing in LB plus 
undecenoic acid was completely amorphous with no melting point detected. This is in 
accordance with previous results (Follonier et al., 2015). Interestingly, the polymer enriched in 
C11:1 produced by the FadBA mutant showed a Tm value of 52.76 ºC (Table 12), suggesting 
structural changes in the crystallinity of the polymer. In addition, a mixture of Tm values was 
obtained for the polymers containing a higher proportion of longer monomers produced by the 
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FadBA mutant. This pattern could be associated to the presence of a mixture of polymers. 
Nevertheless, the most abundant peack of the Tm values obtained may correspond to the most 
abundant polymer in the mixture. In this sense, the resulting values of these PHA (over 70 ºC) 
could be appropriate for blending with other industrial polymers. 
 
Table 12. Melting point (Tm) values of selected polymers. 
Medium 
Carbon 
source 
Strain 
Culture 
approach 
Thermal properties 
Tm a (ºC) 
LB C11:1 WT One-stage - 
LB C11:1 FadBA One-stage 52.76 
MM C18 WT Two-stage 51.04 
MM C18 FadBA Two-stage 45.71/68.50*/90.28 
MM C18:1 WT Two-stage 40.02 
MM C18:1 FadBA Two-stage 92.19/134.39* 
MM (0.1N M63), WT (P. putida KT2440), FadBA (P. putida KT2440 FadBA), C11:1 (10 mM undecenoic 
acid), C18 (6.7 mM stearate), C18:1 (6.7 mM oleate). 
a Melting temperature. 
* Highest proportion of this Tm. 
 
6. Postfuncionalizacion of unsaturated PHA 
As exposed in the Introduction, chemical modification of functional groups has been 
exploited to obtain value added PHAs with interesting properties (Raza et al., 2018). Here the 
postfuncionalization of unsaturated PHAs was explored by adding fluorescent groups. This 
could be extrapolated as a click chemistry approach for tailoring functionalized PHA with other 
groups of interest. 
In this research, double bonds in PHOU copolymer were employed for chemical 
modification. As a proof of concept, fluorescent probes were used for the functionalization. The 
polymer was produced in P. putida KT440 by feeding with a mixture of 10.5 mM of octanoate 
and 3 mM undecenoic acid. The final copolymer contained around 75 % of C8 and 25 % of 
C11:1. To obtain the functionalized PHOU, oligophenylene and dansyl derivatives were selected 
as fluorescent probes. Synthesis of both probes is detailed in the Materials and Methods 
section. 
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Functionalized PHOU nanoparticles with oligophenylene fluorescent probe (PHOU-1) 
were made through the nanoprecipitation method described in the Materials and methods 
section. Nanoparticles were observed through a Widefield Multidimensional Microscopy 
System Leica AF6000 LX (Figure 47). As shown in the figure, PHOU-1 nanoparticles could be 
detected as red fluorescent nanoparticles in a size ranging 300-500 nm that tended to form 
aggregates. 
 
 
Figure 47. Phase-contrast (left) and fluorescence (right) microscopy images of PHOU-1 
nanoparticles (in red). White scale bar at the bottom of the picture represents 1 µm. 
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Discussion 
The new challenges of this century require the search for viable alternatives to face 
modern society’s needs. The reduction of greenhouse gas emissions constitutes one of the 
main challenges that demands immediate solutions. The Intergovernmental Panel on Climate 
Change (IPCC) encourages policymakers to carry out unprecedented changes in order to limit 
global warming to 1.5 ºC. Our ways of production and consumption should be reconfigured 
towards a circular economy, sustainable and environmentally friendly. We must therefore 
invest our efforts on research aimed at replacing greenhouse gas emission, recalcitrant or toxic 
products by biodegradable and biocompatible formulations obtained from renewable sources. 
Plastics from petrochemical origin constitute an example of products to be substituted by other 
kind of materials due to their resistance to degradation and accumulation in oceans and 
landfills leaching toxic compounds. In this context, bioplastics play an essential role. Reducing 
our dependence on petroleum-based products means the exploration of different types of 
bioplastics to optimize the most promising aspects.  
In this scenario, the great versatility and reduced environmental impact that 
polyhydroxyalkanoates show convert their explotation in an interesting topic. Throughout this 
research we have deepened into those qualities focusing our efforts on the expansion and 
optimization of their properties. The results achieved will improve the applicability of these 
polymers in various fields.  
The research conducted here can be described as an attempt to facilitate the design of 
novel devices for high value-added applications, especially in the biomedical and food industry 
fields. The high biocompatility and non-toxicity properties of these polymers makes its use safe 
for those purposes. Moreover, our results provide information about structural and metabolic 
aspects related to PHA, opening new research possibilities. Thus, we have focused our 
research at exploring the available functionalization strategies of PHAs for expanding the 
possibilities of these polymers (Figure 48). 
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Figure 48. Schematic representation of the strategies employed for PHA functionalization for 
value added aplications. In vivo and in vitro PHA modification based on peptide functionalization of 
PHA granules or beads. Chemical functionalization through the incorporation of functional groups in the 
side chains of the polymer by metabolic and genetic engineering strategies or by postbiosynthetic 
functionalization. 
 
The complexity of the protein network covering the PHA granule can be exploited to 
display high value-added peptides both in vitro and in vivo. As exposed in the previous 
sections, many applications have been developed following this approach. Phasins constitute 
the most abundant group of proteins on the surface of the granule. Added to this, the structural 
and modular nature of these proteins make them highly versatile to be exploited as affinity 
tags. Here we have deepened into the binding of phasin PhaF to artificial hydrophobic supports 
in vitro (phospholipids) and natural supports in vivo (PHA granules) to explore novel 
functionalities of this protein and optimize the strategies of functionalization of PHA-based 
materials. The results obtained illustrate the vast potential of phasins derived from its 
amphipathic character and modular structure. 
Added to the versatility of phasins and their possible uses, an enormous variety of PHAs 
with different chain length, functional groups, thermal and mechanical properties can be 
obtained by metabolic engineering. The control of the metabolic pathways involving the PHA 
production has been demonstrated as an efficient tool to channel the metabolism and obtain 
on demand polymers. The combination of the metabolic engineering and systems biology 
strategies could significantly improve the predictions about the amount and composition of the 
polymers produced. 
Peptide PHA 
functionalization
Chemical 
functionalization of
PHA polymerPHA 
functionalization
Smart applications
In vitro functionalization
of PHA devices
Post-biosynthetic
functionalization
In vivo PHA beads
functionalization
Tailored properties
Metabolic and genetic
engineering
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The combination of the functionalization strategies exposed expands the plethora of PHA 
materials and the explotation of the protein network covering the granules for further 
applications that would be interesting to explore in the future.  
This work shows the benefits of a multidisciplinary approach to improve PHAs 
functionalization strategies. The integration of cutting-edge biotechnological techniques in 
combination with the Biophysics and Polymer Chemistry constitutes a promising research area 
to design novel materials and develop value-added devices. 
 
1. Phasins PhaF and BioF show interfacial activity at different 
hydrophobic-hydrophilic interfaces 
The results obtained in Chapter 1 demonstrate that PhaF, through its BioF domain, 
possesses the intrinsic ability to interact efficiently with hydrophobic/hydrophilic interfaces such 
as the air-water interface. This activity makes phasins in general, and PhaF in particular, 
perfectly suited to spontaneously adsorb at the surface of PHA granules, in the absence or 
presence of phospholipids, and be the basis of the coating that protects the granules of these 
hydrophobic polymers from the interaction with the cytosol and other cellular structures.  
Phasin PhaF, as well as its BioF domain, retains a high surface activity against interfaces 
occupied by different phospholipids, with a special preference to insert into interfaces 
containing negatively-charged phospholipids such as PG, one of the main phospholipid 
classes in bacteria such as E. coli or Pseudomonas. This supports the combined action of 
phasins and phospholipids to shape the external coating of PHA granules at the bacterial 
cytoplasm. At what extent the presence of phospholipids associated to phasins and PHA is 
established naturally during the assembly and metabolism of PHA granules or is a 
consequence of the affinity of phasins to interact and form complexes with anionic 
phospholipids exhibited during their production and purification, is something that still requires 
further clarification. 
Various proteins sharing similar features to phasins, such as the already mentioned 
hydrophobins and pulmonary surfactant proteins, play essential roles in the environment by 
reducing the surface tension at hydrophobic-hydrophilic interfaces, stabilizing emulsions or 
allowing surface motility or adhesion to interfaces. At the molecular level, surface-active 
proteins show a wide structural diversity but their amphipathic nature and ability to self-
assemble make them excellent candidates to develop advanced biomaterials or to be applied 
as biosurfactants in the food and cosmetic industries. The interfacial activity of PhaF and BioF 
confirm the potential of these proteins to interact and stabilize the surface of very different 
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hydrophobic materials. This expands the potential application of PhaF in combination with not 
only PHA polyesters but also with other different hydrophobic matrices, opening novel 
possibilities for exploiting them as biosurfactants for several biotechnological applications. 
Phasin-derived proteins could be particularly well suited as biosurfactants in applications 
related with the biomedical sector, such as immobilization at interfaces affecting properties of 
the surface or as antimicrobial agents (Gudiña et al., 2013). This application has been explored 
for other GAPs obtaining promising results derived from the high emulsifying capacity they 
show (Wei et al., 2011; Ma et al., 2013). It would be interesting to evaluate the emulsifying 
properties of phasin PhaF based on the preliminary results obtained here.  
As exposed in the Introduction, phasins have been employed to expose functional 
moieties onto the surface of PHA materials. The results described here open the range of 
materials phasin PhaF could bind thus expanding the potential functionalization of different 
hydrophobic supports. In addition, the binding of proteins to advanced materials have been 
demonstrated to modify the hydrophobic/hydrophilic properties increasing aspects like 
biocompatibility. In this sense, the module BioF could constitute a minimal unit compared with 
other larger surface-active proteins to decorate hydrophobic surfaces with different 
biocompatible functionalizing motifs. Surfactant proteins are specialized and relatively rare 
(Sunde et al., 2017) and they are usually very difficult to produce and purify (Askolin et al., 
2001). The potential to overproduce PhaF and BioF in large amounts in a cost-effective way 
make them suitable for such value-added applications.  
 
2. MinP novel minimal tag shows efficient PHA peptide functionalization 
and stability 
The second chapter of this Thesis has addressed two main goals: to gain a better 
understanding on the binding capacity of BioF to the PHA granule and to use this knowledge 
to obtain improved versions of the tag that expands its biotechnological potential.  
Many GAPs have been exploited as tags for the functionalization of PHA, especially PHA 
synthases and phasins. The mechanisms of the binding of these tags to the PHA material and 
the strength of the interaction are different, as well as the properties of each tag, making them 
suitable depending on the target application. Phasins constitute an attractive tool for tuning 
PHA materials due to their strong affinity to PHA. Despite that only a few studies have 
addressed the structural aspects of phasins, it is known that some common characteristics 
include the high proportion of disordered regions (Maestro et al., 2013; Mezzina et al., 2014), 
the presence of residues in α-helical conformation that increases in the presence of PHA 
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(Maestro et al., 2013; Mezzina and Pettinari, 2016), and their tendency to form oligomers in 
solution (Zhao et al., 2016; Maestro and Sanz, 2017; Tarazona et al., 2019).  
The PhaF phasin from P. putida, constitutes an attractive biotechnology tool, as its N-
terminal domain (the BioF affinity tag) binds to PHA granules by non-specific hydrophobic 
interactions. In this work, various polypeptides based on BioF have been designed, differing in 
polarity, amphipaticity and length: Bi1, Bi2, Bi3 and Bi4. All of them, except Bi2, were able to 
bind in vivo to PHA granules, suggesting that substrate recognition does not reside in a specific 
region. Bi2 was unable to bind to the granule, likely due to its short size preventing the 
establishment of sufficient hydrophobic interactions with the polymer. The binding of the BioF-
based peptides to PHA granules was demonstrated to be independent of the presence of other 
GAPs on the surface of the granule, indicating that the presence of other GAPs is dispensable 
for BioF segment binding and that a scaled down strain lacking most other GAPs can be used 
as a chassis for the expression of functionalized PHA nanobeads.  
The affinity of the truncated forms of the BioF tag to PHA was tested using various 
approaches. The Bi3 displays a similar PHA localization pattern than BioF although with a 
lower binding strength. On the other hand, and although localized predominantly on the PHA 
granule surface by microscopy, the Bi4 segment did not show effective binding to isolated PHA 
granules. Previous studies have demonstrated that the inclusion of a functional leucine zipper 
motif is important for the oligomerization of PhaF (Maestro et al., 2013; Maestro and Sanz, 
2017; Tarazona et al., 2019). However, as both Bi3 and Bi4 share the same leucine zipper 
region, these effects put into question the crucial relevance of this motif for PHA avidity. 
Regarding the Bi1 fragment, containing the BioF N-terminal region, it exhibited a PHA binding 
affinity similar to that of whole BioF, whereas Bi3, containing the C-terminal region of BioF, 
displayed a reduced binding strength, despite both peptides sharing a common region that 
corresponds to the Bi2 segment. This divergence could be attributed to the different 
hydrophobic and amphipathic characteristics of both polypeptides, rather than solely being a 
function of their lengths. In fact, mean hydrophobicity seems to be a dominant factor for PHA 
binding more so than amphipathicity, as the Bi1 fragment displays a clear higher value of H 
than Bi3, while it presents only a moderate value for the hydrophobic moment µH. Moreover, 
Bi3 also contains a region that is presumably natively unfolded in solution that may result in an 
increased propensity for proteolytic attack (Maestro et al., 2013). The two Bi3 bands observed 
may be due to this feature. 
The 48 amino acid segment Bi1 was chosen as an optimized tag for PHA 
functionalization and was renamed MinP. It showed a remarkable affinity for PHA granules in 
vivo both in the presence and absence of other GAPs, and its PHA binding under different 
physicochemical conditions were comparable or even stronger than full-length BioF (Moldes 
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et al., 2004). The stability of the binding between the tag and PHA is important to apply these 
devices across a variety of physicochemical conditions. Many industrial processes take place 
at extreme temperatures or pH, conditions in which we demonstrate that MinP is retained at 
the surface of the PHA granule (Littlechild, 2015; Sarmiento et al., 2015), conditions in which 
we demonstrate that MinP is retained at the surface of the PHA granule. Moreover, the stability 
of the tag across a range of pH and temperatures allows the incorporation of protein release 
systems such as intein-mediated methods to purify a protein of interest (Banki et al., 2005). 
The high stability of MinP on the surface of the PHA granule constitutes a good choice for a 
strong immobilization of proteins and complements the diversity of PHA affinity tags tailored to 
any need. 
The amount of fusion protein attached to PHA granules was observed to be similar for 
BioF and MinP, both in wild-type and Δpha+C1 strains. This suggests that the PHA-binding 
capability of BioF mainly resides in its N-terminal moiety, and that the presence of other GAPs 
on the surface of the granule does not impact in the functionalization efficiency when the levels 
of the recombinant protein inside the cell are much higher than other GAPs, as was previously 
observed (Moldes et al., 2004).  
Phasins have a positive effect on PHA production and PHA granule biogenesis (Galán 
et al., 2011; Dinjaski and Prieto, 2013). This has been proposed to be related the interfacial 
role of phasins that segregate the hydrophobic PHA granules away from hydrophilic cytoplasm, 
avoiding potential deleterious effects of PHA production (Wieczorek et al., 1995; Mezzina et 
al., 2015). We observed the positive effects of the expression of phasin segments in Table 1, 
where presence of BioF increased the amount of PHA produced in the Δpha+C1 strain, while 
MinP expression did not. BioF tag expression likely favours granule formation and thus 
improves the PHA production, whereas MinP appears to not have complete phasin activity. 
This could be due to the lack of the leucine zipper motif in MinP, which is important for 
oligomerization and to stablish the layer of GAPs that cover the PHA granule (Tarazona et al., 
2019). It could also be attributed to unknown roles of phasin PhaF in specific regions that are 
not present in MinP. Further research in that direction should be conducted to find out relevant 
features about the modular and possible multifaceted nature of phasin PhaF. In fact, other 
proteins of the family show several roles like regulatory actions or chaperone activity that have 
already been described (Maestro and Sanz, 2017; Mezzina and Pettinari, 2016). Therefore, it 
would not be a surprise that phasin PhaF fulfils other important roles where the leucine zipper 
domain plays an essential function. 
Finally, we propose a construction based on plasmid pSEVA238 to implement the 
expression of fusion proteins at the C-terminal domain of MinP tag, and containing a removable 
linker as well as a MCS for cloning. The SEVA plasmids constitute a versatile platform for 
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swapping modules as required (http://seva.cnb.csic.es/). A wide range of antibiotic resistance 
choices, multiple origin of replications and cargo modules are available. The host-range can 
be easily modulated by exchanging the origin of replication, increasing the applicability of the 
MinP tag in a broad range of hosts. The MinP module can be thus incorporated into the 
standardized synthetic biology library as a novel brick for polyester functionalization. 
The use of a third shorter in length peptide, which maintains the properties of the entire 
protein showing even a higher stability, constitutes an interesting advance for PHA 
functionalization both in vitro and in vivo. The ability of this fragment to maintain the adsorption 
and interfacial properties of the whole BioF in the presence of other hydrophobic supports 
would be a relevant aspect to be explored for its use in combination with other materials or as 
a biosurfactant in an equivalent manner.  
 
3. PHA nanoparticles could be used as drug delivery carriers for lung 
therapy 
Nanotechnology has emerged as an innovative field where multiple disciplines converge 
in order to develop advantageous devices for a wide range of applications. Specifically, the 
design of nanocarriers and nanovehicles in the biomedical field has enabled the development 
of advanced strategies in the diagnosis and treatment of diseases in a safer, accurate and 
personalized way (Hidalgo et al., 2017b). Nanotechnology has focused on the use of tuneable 
materials that allow the manipulation of the final properties depending on the target application. 
As an example, the use of polymers that can be functionalized increases the versatility and 
applicability of these materials. In this context, polymers of natural origin such as PHA play an 
essential role in the development of a next generation of biomaterials for nanomedical 
purposes (Dinjaski and Prieto, 2015; Michalak et al., 2017). The enormous versatility of PHA 
leads to the design of devices with desired properties through post-functionalization strategies 
taking advantage of the structural complexity of the in vivo surrounding protein layer that covers 
the PHA granule or by chemical modifications of functional groups present in the polymer. For 
instance, the incorporation of targeting ligands like folic acid (FA) or polyethylenimine (PEI) to 
PHA nanoparticles results in lower cytotoxicity and enhanced therapeutic efficiency due to the 
specific delivery to the target cell (Zhang et al., 2010; Kılıçay et al., 2011; Wu et al., 2014). 
Additionally, other advantages associated to the use of PHA nanoparticles as drug 
carriers have been described in the literature. The transport of poorly-water soluble drugs 
inside PHA beads has been related with an increase in the therapeutic effect attributed to the 
drug longer bioavailability. The chemotherapeutic molecule Docetaxel (DTXL) (Mascolo et al., 
2016), the anticancer drug Ellipticine (Masood et al., 2013) or a hydrophobic photosensitizer 
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(Pramual et al., 2016) are examples of improved bioavailability of drugs once encapsulated 
inside P(3HB) and P(3HB-co-3HV) nanoparticles. PHA beads have also aroused interest as 
drug delivery systems since several works report improved controlled release properties of 
various drugs encapsulated inside PHA microspheres and nanoparticles (Li and Loh, 2017). 
For example, rubomycin encapsulated inside P(3HB) microspheres showed high potential 
antitumoral effect against Ehrlich ascetic carcinoma improving survival of mice (Shishatskaya 
et al., 2008). A sustained released system of the antitumoral PI3K inhibitor (TGX221) based 
on PHA nanoparticles was developed obtaining gradual release and reducing the growth of 
cancer cell lines efficiently (Lu et al., 2011). Antibiotic-loaded PHA microspheres and rods 
showed a sustained release that has been proven to be highly effective against infections 
(Sendil et al., 1999; Li and Chang, 2005; Gursel et al., 2008; Xiong et al., 2010). 
Here we explored a potential application of PHA nanoparticles as nanocarriers to 
transport drugs to the lungs by studying potential effects on the first barrier they would find, the 
pulmonary surfactant. We carried out various experiments to evaluate the effects of naked 
PHA particles formed in vitro on the biophysical properties of pulmonary surfactant. Drug 
delivery through the inhaled route using nanocarriers has been widely addressed in both local 
and systemic diseases (Sung et al., 2007). Polymeric nanoparticles in a range of 200 to 400 
nm have been previously used to encapsulate different drugs such as insulin or antibiotics and 
delivered to the lung by nebulization (Kawashima et al., 1999; Sharma et al., 2004). As already 
mentioned, nanoparticles offer a well-controlled drug release and lipophilic environment for 
hydrophobic drugs. Depending on the size, they reach the alveoli through different ways. In 
the case of nanoparticles smaller than 0.5 µm, this occurs by diffusion (Hidalgo et al., 2017b). 
However, they may interact at the nanoscale with the pulmonary surfactant affecting its 
functionality, converting in essential the evaluation not only of possible toxicological effects 
derived from the use of nanoparticles as carrier agents but also of potential synergistic 
properties to improve drug delivery systems. Pulmonary surfactant must show a fast 
adsorption capacity to reduce the surface tension at the respiratory air-liquid interface in a few 
seconds, be efficiently re-spread as occurs during inspiration and form stable films during 
compression as occurs during expiration (López-Rodríguez et al., 2012). Several studies have 
analysed the effect of different types of nanoparticles not only on native surfactants but also 
on models consisting on lipid-protein mixtures or pure lipids present in the lung surfactant. 
Potential negative effects of these nanoassemblies are associated to the so-called corona 
formation that is influenced by the hydrophobicity, size and surface charge of the nanocarrier, 
as well as the dose administrated. For instance, anionic nanoparticles reduce surface pressure 
and cause hysteresis on lipid model monolayers while cationic ones have negligible effects 
(Arick et al., 2015). The size of the nanoparticle has been demonstrated to affect the surfactant 
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phase behaviour, diminishing the LE-LC coexistence region when larger nanoparticles are 
used (Dwivedi et al., 2014). In the case of polymeric nanoparticles, various studies observed 
more retention in the surfactant monolayer, aggregation, hindering of phase transition and 
higher degree of surfactant inhibition among other negative effects upon increase of 
nanoparticles concentration and hydrophobicity (Valle et al., 2014). However, other works 
observed altered phospholipid–model microstructure but no effects on the biophysical 
properties (Beck-Broichsitter et al., 2011; Farnoud and Fiegel, 2012; Beck-Broichsitter, 2018). 
The effect on lung surfactant has therefore to be carefully evaluated in a case by case basis. 
The results obtained for PHA nanoparticles shown here revealed small effects on the 
biophysical properties of native surfactant. The adsorption of native surfactant seems to be 
faster when a higher dose of nanoparticles is applied suggesting a kind of synergistic effect. 
This result may be explained by the accelerated rate of adsorption of the nanoparticles 
themselves. Native surfactant could be interacting with PHA nanoparticles due to hydrophobic 
forces favouring its faster adsorption. Interestingly, previous works reported positive effects of 
the addition of different polymers to pulmonary surfactant resulting in protection against 
exogenous inactivation (Taeusch et al., 1999; Taeusch et al., 2005; López-Rodríguez et al., 
2012). It would be thus interesting to study whether these are positive effects derived from 
PHA addition regarding an improvement of the resistence of native surfactant to inactivation.  
The study of the effect of PHA on the behaviour and structure of DPPC:DPPG (7:3, w/w) 
monolayers demonstrated that PHA nanoparticles did not affect the final surface pressure 
achieved, suggesting that phospholipid material remains at the interface until its collapse 
pressure at a surface pressure of ca. 70 mN/m. These results demonstrate negligible effect on 
the DPPC capacity to reduce the surface tension of water to values near 0 mN/m. However, 
different effects on the isotherm behaviour and domain formation can be observed which vary 
depending on the concentration of nanoparticles. The behaviour of the compression isotherms 
suggests the retention of a fraction of the nanoparticles at the interfacial film even at high 
surface pressures, without altering the collapse pressure. This could be explained by the 
potential hydrophobic interactions taking place between NPs and phospholipids. The ability of 
the nanoparticles to remain adsorbed at the interface in combination with the pulmonary 
surfactant opens the possibility of combining both materials for therapeutic purposes. The 
compressibility modulus showed that the presence of the nanoparticles at the interfacial film 
increases its stiffness. A plateau region was observed around 49 mN/m at all the PHA 
nanoparticles concentrations assayed, which could be attributed to the exclusion of a fraction 
of the nanoparticles. The second plateau at 18 mN/m in the presence of the highest proportion 
of NPs could be related with the early exclusion of an excess of nanoparticles that were not 
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interacting with the phospholipid monolayer, as indicated by the representation of the isotherm 
of plain NPs.  
In addition, we have evaluated the effect of PHA nanoparticles on the spreading 
capabilities of the pulmonary surfactant. This property was not affected by the presence of 
PHA nanoparticles. The spreading property of pulmonary surfactant offers unique 
opportunities to deliver drugs to the alveolar region, especially highly hydrophobic drugs and 
nanocarriers (Hidalgo et al., 2017a; Xu et al., 2017). In this sense, surfactant could facilitate 
the spreading of PHA nanoparticles, opening novel possibilities for their vehiculization in 
combination with pulmonary surfactant. We tried to detect PHA in the recipient trough to study 
the spreading of the nanoparticles in combination with the pulmonary surfactant. However, the 
detection of the polymer constitutes a limitation. Several techniques were tried, including GC-
MS, but they were not sensitive enough for the detection of nanoparticles. Therefore, higher 
sensitive methods should be explored in the future to achieve an efficient detection. We are 
currently exploring the possibility of functionalizing the particles with enzymes or fluorescent 
groups that could reveal the presence of NPs in targeted interfaces, directly or indirectly. 
These experiments offer preliminary results about the possible reactions associated with 
the presence of PHA nanoparticles. The limited effects of these particles on pulmonary 
surfactant functionality anticipate a vast potential for their use as drug delivery carriers to the 
lungs. Value added proteins can be incorporated on the PHA nanoparticle surface taking 
advantage of GAPs engineering. Following this strategy, SP-B functionalized PHA 
nanoparticles have been constructed. Several lung diseases are associated to a deficient 
pulmonary surfactant activity. The inactivation can be caused by exogenous substances, such 
as surface-active molecules that compete with surfactant for the interface or molecules that 
are inserted in the complexes disturbing the structure of surfactant (Fernsler and Zasadzinski, 
2009; Lu et al., 2011) or endogenously as a result of genetic disorders or failure of surfactant 
metabolism (Günther et al., 1999; Schmidt et al., 2001). For instance, SP-B deficiency causes 
lethal respiratory distress in humans, like NRDS, caused by its absence in premature infants. 
Replacement surfactants are currently obtained from animal lungs, an expensive and variable 
source that may cause transmission of animal-derived diseases or induce immunological 
reactions. For these reasons, the development of humanized synthetic standardized 
surfactants has become a matter of research. In this sense, the production of SP-B protein in 
a recombinant way on the surface of PHA granules could improve the development of novel 
efficient and cost-effective surface-active materials. The protein can be released through 
granules purification followed by organic solvent extraction, facilitating its potential application. 
Additionally, the combination of nanoparticles with pulmonary surfactant components such as 
SP-B protein has been proposed for biocompatibility improvement, facilitating the interaction 
 Discussion  
149 
D
IS
C
U
S
S
IO
N
 
   
R
E
F
E
R
E
N
C
E
S
 
of the nanoparticles with the endogenous surfactant and possibly reaching a more efficient 
distribution associated to the spreading properties of pulmonary surfactant (Lopez-Rodriguez 
and Pérez-Gil, 2014; Hidalgo et al., 2015). This could be exploited for drug delivery purposes. 
In the same time, other functional peptides or molecules with valuable properties could be 
incorporated on the surface of PHA beads, achieved through in vitro or in vivo fusion to BioF 
or to the novel tag designed, MinP. 
 
4. Exploiting PHA diversity to obtain a library of polyesters with different 
structures and properties 
The great structural versatility of PHA that can be obtained through various genetic and 
metabolic engineering strategies is a fundamental tool for the development of on-demand 
properties materials. This is especially interesting for high added value applications in fields 
such as biomedicine, where a variety of tailor-made chemical architectures, physical properties 
and surface characteristics are required (Chen and Wang, 2013); or packaging applications, 
where polymers with appropiate melting temperatures to allow for blending with other 
materials, higher elasticity and enhanced gas barrier properties (oxygen transmission rate 
(OTR) and water vapour transmission rate (WVTR)) are a prerequisite (Bugnicourt et al., 
2014).  
Mutants in the β-oxidation pathway lead to a better understanding of how the 
incorporation of different monomers into PHA takes place when fatty acids are employed as 
carbon sources (Tortajada et al., 2013). This knowledge make easier to control the final 
monomer contents and thus the properties of the polymer (Tripathi et al., 2013). The deletion 
of fadB and fadA genes was demonstrated to slowdown the β-oxidation process favouring the 
accumulation of longer monomers channelled to the PHA production. In this sense, the 
deletion of these genes was previously performed in P. putida KT2442 obtaining two or three 
times higher percentages of C8, C10 and C12 in the final polymer when octanoate, decanoate 
and dodecanoate respectively were used as carbon source (Ouyang et al., 2007). When 
shorter fatty acids like heptanoate were used in this strain, the resultant polymer consisted in 
a C7 homopolymer (Wang et al., 2009). The deletion of the other set of genes, fadAx and 
fadB2x (PP_2214 and PP_2215), that encode the FadBA complex had not a significant effect 
in the monomer content when a substrate like dodecanoate is used as reported by Ouyang 
and collaborators (2007). However, other genes like the PP_2047 encoding 3-hydroxyacyl-
CoAdehydrogenase and PP_2048 encoding acyl-CoAdehydrogenase seemed to have a 
relevant role when decanoate was used as carbon source leading to a homopolymer of C10 
(Liu et al., 2011). The biological meaning of the redundancy of enzyme activities related with 
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the β-oxidation cycle could be associated to different substrate specificity. As can be observed, 
the monomer content in the final polymer is very fluctuating and highly dependent on the 
deleted genes and the substrate used as a carbon source. Nevertheless, in all cases the 
increase of long-chain monomers leads to improved thermal and mechanical properties in the 
final PHA that constitute an interesting aspect for some specific applications like packaging 
(Liu and Chen, 2007; Ouyang et al., 2007; Khosravi-Darani and Bucci, 2015). Here we have 
addressed a combination of β-oxidation manipulated strains and growth on selected carbon 
sources to increase the diversity of PHA in P. putida KT2440. Long-chain and unsaturated fatty 
acids have not been tested before as substrates in β-oxidation mutants despite they constitute 
interesting carbon sources. Long-chain fatty acids are the major components of plant oils, one 
of the most widely employed substrates for PHA production (Ciesielski et al., 2015) while 
unsaturated carbon sources allow the post-functionalization of the PHA produced expanding 
their possible applications (Raza et al., 2018). Considering this, we carried out a detailed study 
about the production, composition and properties of PHA produced using stearate, oleate and 
undecenoic acid as carbon sources in P. putida KT2440 β-oxidation mutant strains. Following 
different culture approaches, various polymers differing in their monomer contents were 
obtained using the strains mutated in this central pathway.  
Several studies address the production of PHA using long-chain fatty acids (Table 12) 
or renewable sources like waste and plant oils in Pseudomonads (Impallomeni et al., 2011; 
Mozejko et al., 2012; Simon-Colin et al., 2012; Możejko and Ciesielski, 2013, 2014; Walsh, 
2015; Wecker et al., 2015). Similar findings to those described in the literature were detected 
in the wild type strain using stearate as carbon source, being C8 and C10 the most abundant 
monomers. No longer monomers than C14 were obtained in accordance with the affinity of the 
PhaC1 synthase that has been demonstrated to incorporate medium-chain length monomers 
into the polymer. The results for P. putida KT2440 PsrA strain showed a slightly higher 
percentage of shorter monomers attributed to the accelerated rates of the β-oxidation pathway 
(Fonseca et al., 2014). However, the results did not differ substantially from those obtained for 
the wild type strain. Differences in the final PHA yields of the wild type strain following the one-
stage and two-stage culture approaches with an excess of stearate or oleate can be attributed 
to the growth phase, since through the two-culture strategy bacteria start the PHA production 
in stationary phase in which lower metabolic activity exists. In the weakened β-oxidation mutant 
(P. putida KT2440 FadBA), a slightly lower percentage of PHA than the wild type was produced 
with significant abundance of C12 and C14. The presence of shorter monomers in this polymer 
can be explained because of the cycle is not completely blocked since several isoenzymes 
could perform these steps. This pattern was previously reported growing in dodecanoate in P. 
 Discussion  
151 
D
IS
C
U
S
S
IO
N
 
   
R
E
F
E
R
E
N
C
E
S
 
putida KT2442 strains that did not contain all the genes involved in these steps of the β-
oxidation pathway deleted (Ouyang et al., 2007; Liu et al., 2011).  
 
Table 12. Summary of PHA production and monomer composition of PHA from Pseudomonads 
using long-chain fatty acids. 
C16 (Palmitic acid), C18:1 (Oleic acid), C18 (Stearic acid), C22:1 (erucic acid), C24:1 (nervonic acid), 
TOA (technical oleic acid), LCFAs (hydrolyzed food-grade canola oil), tr (traces), - (not detected), NS 
(not specified). 
 
Strain Carbon 
source 
% 
PHA 
Monomer composition (% of molar PHA) Ref. 
C6 C8 C10 C12 C12:1 C14 C14:1 
P. putida 
Bet001 
C16 65.3 4.1 36.9 34.8 18 - 6.3 - (Gumel et 
al., 2012) 
C18:1 68.9 5 31.8 24.1 22.9 - 14.1 - 
P. putida C18:1 25-
35 
4.4 33.5 32.2 14.4 - - 15.5 (Eggink et 
al., 1992) 
P. putida 
KT2442 
C18:1 31.9 5.1 45.2 33.1 12.7 - 3.9 tr (de Waard 
et al., 1993) 
P. 
aeruginosa 
C18 5.4 0.8 65.7 24.7 8.1 - 0.7 - (Impallome
ni et al., 
2011) 
 
C18:1 15 4 55 27 8 - - 6 
C22:1 9.3 3 43 36 10 - - 8 
C24:1 10 4 28 43 14 - - 11 
P. 
guezennei 
C18:1 NS 2 37.7 35.6 11 - 1.9 13.8 (Simon-
Colin et al., 
2012) 
P. putida 
mt2 
C18:1 13.5 10 45.3 25.9 9.2 2.3 - 8.2 (Fontaine 
et al., 2017) 
P. putida 
LS46 
LCFAs 38.3 5.4 41.4 26.7 9.1 3.6 9.3 8.6 (Blunt et 
al., 2018) 
P. 
aeruginosa 
42A2 
TOA 56.6 - 14.5 40.2 32.8 4.2 - 8.2 (Fernández 
et al., 2005) 
P. 
aeruginosa 
C18:1 22 4.9 18.3 36.2 8.7 2 0.5 2.7 (Marsudi et 
al., 2008) 
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One interesting finding is the fact that P. putida KT2440 FadBA strain produced very little 
amounts of PHA in rich medium using long-chain fatty acids as substrates while medium-chain 
ones (like sodium octanoate or 10-undecenoic acid) conduct to the production of even higher 
amounts of polymer than the wild type what has been previously reported (Ouyang et al., 
2007). This could be attributed to the PHA synthase affinity for medium chain precursors or 
other regulatory aspects (Rehm, 2003). The genes of the β-oxidation pathway would be only 
active in minimal medium due to the absence of other carbon sources to sustain the growth 
making possible to obtain PHA due to the oxidation of long-chain precursors to medium-chain 
ones. The same strain growing in rich medium plus medium-chain substrates would lead to 
the accumulation of medium-chain intermediates inside the cell that could be channelled to the 
PHA cycle. 
The presence of double bonds in PHA was firstly described by Lageveen and 
collaborators obtained by synthesis de novo using glucose as carbon source (Lageveen et al., 
1988). Double bonds have been exploited for the production of tailor-made materials through 
post biosynthetic chemical modifications (Raza et al., 2018). The use of an unsaturated 
precursor should be expected to lead to the appearance of shorter unsaturated monomers 
through their processing by the β-oxidation. This occurs when 10-undecenoic acid is employed 
in the wild type strain, where similar proportions of C9:1 and C11:1 are obtained. Conversely, 
oleate conducted to the presence of C14:1 and saturated shorter monomers in the final polymer. 
These results match with those described in the literature (Table 12). Other studies explore 
the use of precursors that contain linoleic or linolenic fatty acids (like sunflower oil with 50 % 
of linoleic acid), obtaining C14:2 and C14:3 monomers respectively in the final polymer that would 
originate from two cycles of the β-oxidation of these substrates (de Waard et al., 1993; 
Fernández et al., 2005; Impallomeni et al., 2011). Shorter unsaturated monomers, C8:1 and 
C10:1, are only obtained when linolenic acid is used as carbon source likely due to specific 
enzymes such as trans-enoyl-CoA isomerase and trienoyl-CoA-reductase to remove the 
double bonds (de Waard et al., 1993; Fontaine et al., 2017). When longer precursors like erucic 
or nervonic  acids (C22:1 and C24:1) are employed as carbon sources, the composition is quite 
similar to that of oleic acid (C18:1) due to the PHA synthase exclusive activity for medium-chain 
substrates (Impallomeni et al., 2011). The β-oxidation weakened strain shows an interesting 
final monomer composition when oleate is used as carbon source, with twice double bonds 
and considerable higher proportions of C14 and C12 than the wild type strain. When 10-
undecenoic acid is employed, a near homopolymer of C11:1 is obtained (96 %). This can be 
attributed to the reduced activity of the β-oxidation pathway that conducts to the accumulation 
of the C11:1 precursor, substrate of the PHA synthase. A previous study developed in our 
laboratory tested this substrate in a mutant in the fadB gene of P. putida KT2442, observing a 
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slightly higher amount of PHA and higher proportion of longer monomers than the wild type at 
the beginning of the cultures (Escapa et al., 2011). Conversely, when both fadB and fadA 
genes were deleted in P. putida KT2440 this pattern was observed in the different growth 
phases. Feeding this strain with waste and plant oils is expected to lead to polymers with higher 
proportion of longer and unsaturated monomers varying the final properties and allowing the 
incorporation of chemical modifications that enhance the applicability of these materials.  
The co-metabolic strategies through the addition of sodium octanoate had not a 
significant impact in the final PHA yields. However, despite the low concentrations of this 
compound, a considerable increment of C8 monomer in the final PHA is observed in the P. 
putida KT2440 FadBA strain. This can be explained by the fact that this strain did not use 
octanoate for grow which favored the accumulation of this intermediate. The great affinity of 
PHA synthase for this monomer would increase its ratio in the final polymer. The use of non-
related precursors like glucose follows the same pattern in all the strains, confirming the 
specific effect of the mutations on the β-oxidation pathway.  
P(3HB) was the first PHA identified (Lemoigne, 1926) being the most widely studied and 
characterized member of the PHA family. P(3HB) have received commercial interest due to 
the efficient large-scale production and the biocompatibility, so it has been exploited for many 
purposes ranging from packaging to biomedical applications. Some examples include their use 
as films in bags and bottles, tissue engineering, drug delivery, bio-implant patches, agricultural 
foils and fibers in textiles among others (Anjum et al., 2016). Here we demonstrated the 
efficient production of P(3HB) polymer in a strain lacking the pha cluster for mcl-PHA 
production. Nevertheless, P(3HB) holds a high melting temperature and brittle and stiff 
properties that make difficult its processability. A good way to address this problem is blending 
it with other polymers like the mcl-PHA ones, that have lower melting temperatures and 
elastomeric properties that may improve processability. Blending is a simple approach to 
obtain enhanced polymeric materials (Li et al., 2016). PHA properties can be modified by 
blending different types of PHA. As explained in the Introduction, following this approach, 
improved thermal and mechanical properties can be achieved thus expanding current 
applications. In this sense, increase Young’s modulus, tensile strength, thermal stability, 
tailorable biodegradability and increase biocompatibility were obtained for P(3HB)/P(3HO) 
blends comparing with P(3HO) films (Basnett et al., 2013).  To avoid the costs related to the 
production and extraction of the two polymers independently, in this work we have tried to 
produce them at the same time in the model bacterium P. putida KT2440. This has been 
successfully achieved by introducing the genes for the production of P(3HB) from C. necator, 
achieving a high yield (1.41 g/L) and a similar proportions of P(3HB) and P(3HO-co-3HHx) in 
the final polymer. 
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As exposed in the Introduction, the length of the side chain, the presence of functional 
groups and the structure of the polymer influence the properties of the polymer. The results 
shown here demonstrate the effect of the monomer composition on the Tm values obtained. 
These values are related with the crystalline state of the polymer. In this sense, novel PHA 
with higher melting temperature values were obtained which make them interesting in the food 
industry for blending with other polymers.  
As a proof of concept, the post-funcionalization of P(3HO-co-3HU) was carried out by 
adding fluorescent probes to the unsaturated groups though chemical modifications. The ability 
to regulate the size of the lateral chain and the percentage of unsaturated groups leads to the 
potential to choose the type of polymer for postfuncionalization strategies. In this chapter, the 
P(3HO-co-3HU) polymer was chemically modified but this approach can be extrapolated to 
other polymers with the desired properties. The efficiency of functionalization is similar to the 
percentage of unsaturated groups in the lateral chains of the polymer (around 25 %). Despite 
the PHOU nanoparticles obtained showed an aggregated pattern, this can be solved by 
optimizing the formation method. Nevertheless, these results could be considered as 
promising ones since fluorescence is maintained after nanoparticles production. Covalently 
modified fluorescent polymers can be employed for many interesting applications such as 
bioimaging in drug targeting and delivery. 
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Conclusions 
1. Phasin PhaF and its N-terminal domain, BioF, adsorb efficiently to different 
hydrophobic-hydrophilic interfaces reducing the surface tension of water similarly 
to other surface-active proteins. Both proteins have affinity for various 
phospholipid species, interacting more strongly with PG. 
2. Various modules based on the BioF domain maintain the affinity for the PHA 
granule supporting a conformation-dependent interaction between this protein 
and the polymer, making possible to design a simplified tag for PHA 
functionalization, called MinP. 
3. MinP tag showed an efficient binding to the PHA granule, producing high 
functionalization and stability ratios. These properties make MinP tag 
appropiated for the functionalization of PHA materials. 
4. PHA nanoparticles have been demonstrated to have negligible effects on 
pulmonary surfactant biophysical properties, expanding the potential applicability 
of these devices in lung therapy. 
5. In vivo functionalization of PHA granules with pulmonary surfactant proteins has 
been demonstrated to be an efficient approach for the production of therapeuthic 
nanoparticles.  
6. A panel of PHA varying in monomer composition has been generated by 
manipulating PHA related metabolic pathways such as the β-oxidation. Some of 
the polymers obtained showed improved thermal properties. 
7. The chemical postfunctionalization of PHA carrying double bonds in their lateral 
chains with fluorescent groups leaded to a novel fluorescent polymer. 
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Conclusiones 
1. La fasina PhaF y su dominio N-terminal, BioF, se adsorben eficientemente a 
diferentes interfases hidrofóbico-hidrofílicas reduciendo la tension superficial del 
agua de forma similar a otras proteínas con actividad interfacial. Ambas 
proteínas tienen afinidad por varias especies de fosfolípidos, interaccionando 
estrechamente con PG.  
2. Varios módulos basados en el dominio BioF mantienen la afinidad por el gránulo 
de PHA, lo que apoya una interacción dependiente de conformación entre esta 
proteína y el polímero, haciendo posible el diseño de un tag simplificado para la 
funcionalización de PHA, denominado MinP.  
3. El tag MinP ha mostrado una unión eficiente al gránulo de PHA, con una elevada 
tasa de funcionalización y estabilidad. Estas propiedades hacen al tag MinP 
apropiado para la funcionalización de materiales basados en PHA.  
4. Las nanopartículas de PHA tuvieron efectos despreciables en las propiedades 
biofísicas del surfactante pulmonar, expandiendo así la potencial aplicabilidad de 
estos dispositivos en terapia pulmonar. 
5. La funcionalización in vivo de gránulos de PHA con proteínas del surfactante 
pulmonar se ha revelado como una aproximación eficiente para la producción de 
nanopartículas terapéuticas.  
6. Un panel de PHA con composición monomérica variable ha sido generado 
mediante la manipulación de las rutas metabólicas relacionadas con el PHA 
como la β-oxidación. Algunos de estos polímeros presentan propiedades 
térmicas mejoradas.  
7. La postfuncionalización química de PHA que contienen dobles enlaces en sus 
cadenas laterals con grupos fluorescentes ha conducido a la formación de un 
nuevo polímero fluorescente.  
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ANNEX 1 
 
Figure 1. Nucleotide sequence of the phaC1 gene with modified nucleotides to avoid the 
specified restriction sites shown in Figure 14. Bold type nucleotides indicate the changes performed.
 
>PhaC1_mod
ATGAGTAACAAGAACAACGATGAGCTACAGCGGCAGGCCTCGGAAAACACCCTGGGGCTG
AACCCGGTCATCGGCATCCGCCGCAAGGACCTGTTGAGCAGCGCACGCACCGTGCTGCGC
CAGGCCGTGCGCCAACCGCTGCACAGCGCCAAGCATGTGGCTCACTTTGGCCTGGAGCTG
AAGAACGTGTTGCTGGGCAAATCCAGCCTGGCCCCGGACAGCGACGACCGTCGCTTCAAT
GACCCGGCCTGGAGCAACAACCCGCTGTACCGCCGCTACCTGCAAACCTACCTGGCCTGG
CGCAAGGAGCTGCAAGACTGGGTGAGCAGCAGCGACCTGTCCCCCCAGGACATCAGCCGC
GGCCAGTTCGTCATCAACCTGATGACCGAGGCCATGGCGCCGACCAATACCCTGTCCAAC
CCGGCTGCGGTCAAACGCTTCTTCGAAACCGGCGGCAAGAGCCTGCTCGATGGCCTGTCC
AACCTGGCCAAGGACATGGTCAACAACGGCGGTATGCCCAGCCAGGTGAACATGGATGCC
TTCGAAGTGGGCAAGAACCTGGGCACCAGCGAAGGCGCGGTGGTGTACCGCAACGATGTG
CTGGAACTGATCCAGTACAGCCCCATCACCGAGCAGGTGCACGCCCGTCCGCTGCTGGTG
GTGCCACCGCAGATCAACAAGTTCTACGTGTTCGACCTCAGCCCGGAAAAGAGCCTGGCG
CGCTTCTGCCTGCGCTCGCAGCAGCAGACCTTCATCATCAGCTGGCGCAACCCGACCAAG
GCCCAGCGTGAATGGGGCCTGTCCACCTACATCGATGCGCTGAAAGAAGCCGTCGACGCG
GTGCTGTCGATTACCGGCAGCAAGGACCTGAACATGCTCGGCGCCTGCTCCGGTGGCATC
ACTTGTACCGCACTGGTGGGCCACTATGCCGCCATTGGCGAGAACAAGGTCAACGCCCTG
ACCCTGCTGGTCAGCGTGCTGGACACCACCATGGACAACCAGGTTGCTTTGTTTGTCGAC
GAGCAGACCTTGGAGGCCGCCAAGCGCCACTCCTATCAGGCGGGCGTGCTGGAAGGCAGC
GAAATGGCCAAGGTGTTCGCCTGGATGCGCCCCAACGACCTGATCTGGAACTACTGGGTA
AACAACTACCTGCTCGGCAATGAGCCCCCCGTGTTCGACATCCTGTTCTGGAACAACGAC
ACCACGCGCCTGCCGGCCGCCTTCCACGGCGACCTGATCGAAATGTTCAAGAGCAACCCG
CTGACCCGCCCCGACGCCCTGGAAGTGTGCGGCACCGCGATCGACCTGAAACAGGTCAAA
TGCGACATCTACAGCCTCGCCGGCACCAACGACCACATCACCCCCTGGCCGTCATGCTAC
CGCTCGGCACATCTGTTCGGCGGCAAGATCGAATTCGTACTGTCCAACAGCGGGCATATC
CAGAGCATCCTCAACCCGCCGGGCAACCCGAAGGCACGTTTCATGACCGGTGCCGATCGC
CCGGGTGACCCGGTGGCCTGGCAGGAAAATGCCATCAAACATGCAGACTCCTGGTGGTTG
CACTGGCAGAGTTGGCTGGGCGAGCGTGCCGGCGCGCTGAAAAAGGCACCGACCCGCCTG
GGCAACCGTACCTATGCCGCCGGCGAAGCCTCCCCAGGCACCTACGTTCACGAGCGTTGA
